• Home
  • About Us
  • Health Insurance Companies

Health Plan News

Timely Health Plan News and Commmentary.

Health Plan News
Home Archives for Medical And Healthcare

Company Nurse Expands Its Injury Hotline for Workers’ Compensation

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: Company Nurse

The Expanded Nurse Call Center Will Address Growing Number of Public and Private Employers Who Want to Make the “Right Call” for Their Injured Workers

SCOTTSDALE, AZ–(Marketwire – December 13, 2010) – In striving to help a growing number of public and private employers control workers’ compensation costs and foster occupational health and safety, Company Nurse, the premier nurse hotline for workplace injuries, today announced that it has expanded its Scottsdale-based nurse triage call center.

When a workplace injury occurs, client employees and supervisors call Company Nurse to report injuries and to speak with a triage nurse. Unlike nurse case managers, triage nurses get involved at the front end of the claims process, essentially on the day of injury — which is the earliest, most critical point at which to influence medical care, claims costs, return-to-work (RTW) outcomes, and employee satisfaction. Many organizations view nurse injury triage as a vital part of their corporate wellness, employee wellness, and employee health programs.

“Our nurses assess injuries over the phone and refer employees to the most appropriate level of care — whether it’s an urgent care facility, occupational clinic, or simple first aid,” said Paul Binsfeld, CEO of Company Nurse. “As a result, our Injury Hotline facilitates immediate, critical medical decisions that positively impact an employee’s medical care, as well as overall claims’ costs and outcomes.”

The expanded Scottsdale-based call center works in sync with Company Nurse’s second call center in Tennessee. Due to growing nationwide demand for nurse injury triage for workers’ compensation, Company Nurse has grown 200 percent over the last four years and has recently moved into office space double its previous size to accommodate growing call center operations.

“During today’s difficult economy, employers need to minimize the financial impact of rising medical and indemnity costs on their workers’ compensation programs and bottom lines,” said Binsfeld. “Our program provides an effective solution to today’s most pressing workers’ compensation challenges: injuries are often reported late, sometimes five to 10 days after an incident has occurred; supervisors frequently err on the side of caution, sending employees, even those with minor injuries, to the ER for care; and many organizations are not optimally leveraging cost-effective preferred provider networks.”

Company Nurse’s Injury Hotline offers employers a proactive and structured response to each and every workplace injuries — 24 hours a day, 7 days a week. Triage nurses are highly compassionate and listen closely to each employee’s unique medical needs. Recognizing that organizations have specific workers’ compensation requirements, Company Nurse can customize its injury response and workflow to meet the client’s occupational health and safety needs.

Carol S. Sterling is the Human Resources Manager of the Boys & Girls Clubs of Metropolitan Phoenix. As an early adopter of the Company Nurse program, her organization experienced several key benefits. “First, we receive instant notification of injuries, so we can immediately file our first report of injury forms,” said Sterling. “Second, Company Nurse is extremely flexible. We were able to include our local network of preferred providers in their referral process. Third, Company Nurse helps to control medical expenses, as triage nurses often refer injured workers to urgent care clinics, rather than the ER, which saves costs and still ensures quality care. Fourth, supervisors experience ‘peace of mind’ in knowing injured employees are immediately assessed and referred for appropriate treatment, and we also experience smooth processing of claims and medical bills among the provider, insurance company, and employer.”

Company Nurse’s Injury Hotline delivers proven value. By providing injured workers with first aid and self-care guidelines, 20 to 40 percent of incoming calls are “report only” incidents and do not result in compensable claims. With appropriate care and optimal injury management, employers reduce unnecessary ER visits by as much as 300 percent. By integrating RTW coordination, many employers have reduced lost time and temporary labor costs. And with prompt, open communication, injured employees have an overwhelmingly positive experience, resulting in reduced litigation. Due to these benefits, many clients have experienced as much as a 200 percent return on investment within the first year of program implementation. These benefits have driven Company Nurse’s continued success and growth in the workers’ compensation market.

About Company Nurse
The Company Nurse Injury Hotline enables organizations to make the “Right Call” for workplace injuries. As an independent facility, our triage nurses are compassionate and objective when assessing employee injuries and medical needs. Our injury-triage process is founded on three important elements for workers’ compensation success: 1) Right Time — we respond on the Day of Injury, the earliest point at which to influence costs, outcomes, and employee satisfaction; 2) Right Care — our nurses refer employees to an appropriate level of care, whether ER, clinic or first aid; 3) Right Results — clients reap optimal savings and a return on investment, while employees benefit from a prompt, compassionate response to their workplace injuries. For more information, go to www.companynurse.com or call (888) 817-9282.

Media Contact:
Tammy Delatorre
661-775-0550

Filed Under: Facilities And Providers

Metropolitan Anesthesia Consultants Appoint Amanda O’Neal, FACHE as Chief Operating Officer

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: Metropolitan Anesthesia Consultants

Healthcare Executive to Lead Operations and Business Development at Leading Physician-Only Anesthesia Group

DALLAS, TX–(Marketwire – December 13, 2010) – Metropolitan Anesthesia Consultants (www.metroanesthesia.com), one of the largest physician-only anesthesia groups in North Texas, today announced that is has appointed Amanda O’Neal, FACHE as its Chief Operating Officer.

O’Neal will oversee business development, operations, and process improvement at the group, which has nearly 60 member physicians. Metro Anesthesia services a variety of major hospitals and hospital systems in the area, including HCA, Tenet and Baylor.

“We are pleased to have Amanda join our management team,” said Norman Rice, MD, Chairman of Metro Anesthesia. “She is a distinguished healthcare executive and active member of the community. She will help us further our mission of providing the highest quality healthcare possible.” 

O’Neal has a wealth of experience spanning physician recruitment, physician sales, marketing, corporate wellness, business planning, strategic development and more. She was previously the president and founder of Coppell-based The Brummitt Group, a boutique healthcare consulting firm. Prior to that, she held positions at Trinity Healthcare Services and HCA, Inc. O’Neal has a bachelor’s degree in business administration from Stephen F. Austin State University and a master’s degree in health administration from the University of Southern California.

O’Neal is also a Fellow of the American College of Healthcare Executives, the nation’s leading professional society for healthcare leaders. Only 7,500 healthcare executives hold this elite distinction nationwide. O’Neal is also active in her community, having recently been named chairperson of Irving Healthcare Foundation’s TexasFest gala, scheduled for next spring.

“Metro Anesthesia is one of the top physician-only anesthesia groups in the country in terms of recruiting the best doctors and providing the highest quality healthcare possible,” O’Neal said. “I’m thrilled to join their team.”

About Metropolitan Anesthesia Consultants
With nearly 60 physicians, Metropolitan Anesthesia Consultants is one of the largest physician-only anesthesia groups in North Texas. The organization prides itself on an unprecedented commitment to quality, excellence, and service. For more information, please visit http://www.metroanesthesia.com/.

Press Contact:
Erik Bratt
Defakto Group
858-737-3200
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Radient Pharmaceuticals Signs Full Service Distribution Agreement With Naroo Ditech Inc. in Korea: Minimum Order Commitment of 3,352 Onko-Sure(R) Test…

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: Radient Pharmaceuticals Corporation

TUSTIN, CA–(Marketwire – December 13, 2010) – Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into a five-year full-service distribution agreement with Naroo Ditech Inc. to expand the Company’s Onko-Sure® IVD cancer test throughout the Korean healthcare market.

Under the terms of the agreement, Naroo Ditech has committed to purchase a minimum of 3,352 Onko-Sure® test kits over the duration of the partnership. Naroo Ditech will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure® in diagnostic centers and clinical labs throughout the Korean market.  Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure® IVD cancer test at relevant healthcare conferences and events; incorporating relevant product information on the Naroo corporate website. Additionally, Naroo Ditech will provide a dedicated customer service team to respond to customer inquiries and technical questions.

RPC’s Chairman and CEO Douglas MacLellan commented on today’s news, stating, “We are extremely pleased to have finalized our sales, marketing and distribution partnership with Naroo and anticipate this agreement will significantly expand the commercialization of Onko-Sure® in the Korean market. One of Naroo’s key strategies is to market Onko-Sure® as a screening test for industrial workers at Korea’s largest manufacturers, such as Hyundai. This latest agreement adds to our expanding list of global distributors, through which RPC is working to grow product sales and revenues.”

Onko-Sure® is a simple, noninvasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.radient-pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel: ) 206.310.5323

Click here to see all recent news from this company

Filed Under: Facilities And Providers

MMRGlobal Names Sunil Singhal Executive Vice President and Adds Two Members to Board of Advisors

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: MMRGlobal, Inc.

LOS ANGELES, CA–(Marketwire – December 13, 2010) –  MMRGlobal, Inc. (OTCBB: MMRF) (“MMR”) today announced that Sunil Singhil has been named Executive Vice President and a member of the Executive Committee, succeeding Rich Teich, who will focus on the sales, marketing and installation support for MMRPro and MMRPatientView, the Company’s professional health IT products for physicians, small hospitals and healthcare professionals. Mr. Singhal was introduced to the Company by Nihilent Technologies, where he was Co-founder and served as Chief Operating Officer of North America. In addition, Michael J. Finley, Vice President, Worldwide Carrier Relations at Qualcomm, and John R. Seitz, CEO of Spalding Surgical Center of Beverly Hills, have agreed to join MMRGlobal’s Board of Advisors. 

Robert H. Lorsch, MMRGlobal Chairman and Chief Executive Officer, said, “Since September of this year, Sunil has been working alongside Rich and I overseeing the integration and development of MMRGlobal’s MyMedicalRecords.com Personal Health Record, the MyEsafeDepositBox.com online vault, and the MMRPro suite of professional products and services. In his new position as Executive Vice President, Sunil will also work with me and Ingrid Safranek, MMR’s Chief Financial Officer, on the day-to-day management of the Company.”

Mike Finley, who Lorsch has known for nearly 18 years since he was a President of Verizon Wireless, has been advising the Company since its initial meetings with Sprint Nextel in Kansas City, where he was President of the West Region and Senior Vice President of Sprint Corporation. A widely respected executive in the telecommunications and wireless industry, necessary to the MMR operating system and MMRGlobal’s future growth in wireless, Mr. Finley’s success in selling wireless technologies to consumers is a timely addition as the Company goes deeper into mobile health opportunities for MyMedicalRecords and MMRPro. With the addition of John Seitz to the Board of Advisors, management has the expertise of a recognized leader in the Ambulatory Surgical Center industry. Mr. Seitz heads one of the most advanced surgical centers in the U.S. and will advise on the Company’s strategy for sales of MMRPro into surgery centers and other healthcare specialty groups.

In addition to the new appointments, MMRGlobal has increased its presence at Associated Television International’s headquarter building in Los Angeles, adding an additional 3,000 sq. ft. for sales training, outbound telesales, and a videoconferencing center.

Management

Sunil Singhal: Mr. Singhal, 55, has over 25 years experience in the IT products and services industry where he is recognized for strategically implementing innovative technologies. He has expertise in all facets of the IT products and services business, including executive management, information strategy planning, cross-border operations, business development, sales and marketing, R&D, project management, and mergers and acquisitions. From 2005 until 2010, he was head of North American Sales in the Energy, Resources, and Utilities industry for Tata Consultancy Services (TCS). Prior to that, from 2001 to 2005, he was Co-founder and Chief Operating Officer, North America of Nihilent Technologies, which is MMRGlobal’s technology partner.

Mr. Singhal started his IT services career with Tata Consultancy Services in 1979 and was involved in products and tools development, project management, and business development until 1991. From 1991 to 2001, he held a series of senior technical, business development and executive management positions with entrepreneurial companies. These included International Informatics Solutions (now Xansa) as Technical Director and Member of the Board; IMRglobal Corp. (now CGI, Inc.) as Vice President of Southwest Region and Vice President of Northeast Region; and Hexaware Technologies, Inc. as Senior Vice President for Business Development. Throughout his career, Mr. Singhal has established long-term business relationships with clients in North America, the United Kingdom, Europe, India and Singapore.

Mr. Singhal holds a Bachelor’s degree in Electronics and Communication Engineering from the University of Roorkee (now IIT, Roorkee) and a Masters degree in Digital Electronics from NUFFIC/PII, Eindhoven in the Netherlands.

Board of Advisors

Mike Finley: Prior to his current position as Vice President, Worldwide Carrier Relations for Qualcomm, Mr. Finley was President of the West Region for Sprint Nextel from 2006 to 2008 and a Senior Vice President of Sprint Corporation. He joined Nextel in 2002 as Area Vice President of Southern California and was promoted to Senior Vice President of General Business for the U.S. following the Sprint Nextel merger. Before joining Nextel, he was a Senior Vice President of Wingcast, a JV between Ford Motor Company and Qualcomm which developed telematic products for Ford vehicles. From 1993 to 2001, Mr. Finley served as President of Verizon Wireless in Southern California, Vice President and General Manager in Sacramento and was Vice President of Sales in Ohio for Airtouch Cellular. Prior to joining Airtouch, he held positions with Cellular One and McCaw Cellular. He began his career in communications in 1985 as a Co-founder of Celluland, a national franchise which created an alternative distribution approach in advance of consumer marketing of wireless products. 

John Seitz: Mr. Seitz is Chief Executive Officer of Ambulatory Surgical Group (ASG), an Ambulatory Surgical Center (ASC) development and management company headquartered in El Segundo, California. In his leadership role, he oversees business development and operational and financial management of all ASG surgery centers, and his financial management skills are widely sought throughout the industry. For over 25 years, Mr. Seitz has focused on healthcare, gaining an extensive network of contacts and earning the respect of physicians and industry executives as a developer and manager of ASC projects. Prior to Ambulatory Surgical Group, he has been a founder and either the CEO or president of three successful start-up companies in the healthcare industry. Most recently, he was one of the founders and President of Surgem, LLC, where he was responsible for building the ASC company from start-up to success in less than three years. During his time at Surgem, he recruited the management team, directed the development and operation of eight ASC projects and was responsible for the acquisition and turnaround of an underperforming center. Prior to Surgem, he was founder and CEO of Cornerstone Physicians, a nationally recognized medical practice management company.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (MMR), provides secure and easy-to-use online Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. MMRGlobal’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” “help” and “continue,” or the negative of such terms and other comparable terminology. MMRGlobal, Inc. disclaims any intent or obligation to revise or update any forward-looking statements. These forward-looking statements are based on MMRGlobal, Inc.’s reasonable expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, and such other risks and uncertainties as detailed from time to time in MMRGlobal, Inc.’s public filings with the U.S. Securities and Exchange Commission.

CONTACT:
Bobbie Volman
MMRGlobal, Inc.
(310) 476-7002, Ext. 7015
[email protected]

Michael Selsman
Public Communications Co.
(310) 553-5732
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Zweena(R) Revolutionizes Personal Health Records With New Internet Service for Individuals and Their Families

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: Zweena

Partnered With Microsoft HealthVault®, Zweena Eliminates the Complexity of Creating and Managing a PHR for Use in Self-Care, Family Care, and Protection Against Medical Errors

SKILLMAN, NJ–(Marketwire – December 13, 2010) – Zweena® today launched its revolutionary new Personal Health Record (PHR) web service, featuring a proven proprietary platform that eliminates the complexity of creating and managing an online health record. Partnered with Microsoft HealthVault®, Zweena enables consumers to create and maintain a personally controlled patient health record for meaningful use in self-care, care of family members, and to share medical records directly with healthcare providers, via the Internet. Zweena’s innovative platform collects medical records on behalf of individuals, creates a PHR based on the Continuous Care Record (CCR) guidelines outlined by the American Academy of Family Practice, then stores both scanned and discreet data within the individual’s own secure Personal Health Community (PHC) for sharing with family members, and directly with providers.

“Eighty-six percent of Americans or higher say that PHRs could help them avoid duplicated tests, keep doctors informed, check the accuracy of medical records, and track personal health expenses, yet only seven percent use PHRs today, due to the complexity in creating and maintaining a PHR with existing services,” said John Phelan, CEO of Zweena. “Recognizing the urgency and need for consumers to have accurate and current PHRs, Zweena developed a revolutionary electronic health record system that makes personal digital health records easy to set up, keep current, and share in a secure network for use in self-care and care of family members.”

About Zweena
Zweena®, taken from the Moroccan name meaning “beautiful,” connects individuals and their family members to the medical community of doctors and providers they rely on to manage and maintain their health. Zweena powers the leading Internet-based platform for creating and managing a Personal Health Record (PHR). Partnered with Microsoft HealthVault®, Zweena transforms paper medical records into scanned and organized discreet data files, eliminating the complexity of creating and managing a PHR on one’s own. The Zweena Personal Health Record is accurate, current, and can be used in self-care, the care of family members, and shared with healthcare providers via an individual’s secure Personal Health Community (PHC), anywhere in the world. For information on Zweena, visit: www.zweenahealth.com.

Media Contacts:
Mark Hall
EGOEAST Inc.
Email Contact
609-477-3475

Click here to see all recent news from this company

Filed Under: Facilities And Providers

DentalPlans.com Launches Blue Cross and Blue Shield of Florida FamilyBlue Discount Plan

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: DentalPlans.com

Leading Dental Plan and Healthcare Provider to Offer Savings on Dental Care and More

PLANTATION, FL–(Marketwire – December 13, 2010) – DentalPlans.com, the definitive source of discount dental plans in the United States, continues to grow as they announce the addition of the Blue Cross and Blue Shield of Florida FamilyBlue Discount Plan. The plan joins the already extensive list of 30+ affordable regional and national dental plans on DentalPlans.com. 

The Blue Cross and Blue Shield of Florida FamilyBlue Discount Plan grants members access to a network of providers across the state of Florida, each agreeing to offer their dental services at a discount of 10% to 50%. Plan members will find sizeable savings on everything from cleanings and checkups, to root canals, braces, crowns and some cosmetic procedures. For the first time, individuals and families can join the FamilyBlue Discount Plan for an entire year on DentalPlans.com and receive 3 additional months of membership for free. These turnkey plans start at $134.95 a year for individuals and $179.95 a year for adults.

“Blue Cross and Blue Shield of Florida is one of the most trusted and recognizable healthcare providers in the country,” says Buddy Johnson, CEO of DentalPlans.com. “We’re excited to announce this addition to our diverse offering of discount dental plans, so we can make dental care more affordable and accessible to people throughout the state of Florida.”

The Blue Cross and Blue Shield of Florida FamilyBlue Discount Plan does not have health restrictions or annual limits, and can be used as often as needed. In addition to dental care, the plan also provides discounts on other health services such as vision care, hearing care, diabetic supplies, chiropractic services and prescription drugs. A 24-Hour NurseLine and vitamins (including beauty, wellness and pet products) are also offered at a discount for the convenience of its members.

Interviews with DentalPlans.com representatives and network practitioners are available. For editorial inquiries, please contact Kelly Downey of Shamin Abas Public Relations at 561.366.1226 or [email protected].

About DentalPlans.com (www.DentalPlans.com)

DentalPlans.com is dedicated to improving oral health nationwide by making quality dental care affordable and accessible to everyone. DentalPlans.com proudly offers the freedom to choose from an extensive selection of discount dental plans designed to save members money on their dental care needs. With more than 40 years of experience in the dental industry, their devoted team quickly transformed DentalPlans.com into a trusted industry leader and the largest online provider of discount dental plans. Since 1999, DentalPlans.com has offered great value and convenience with an extensive choice of money-saving discount dental plans in one user-friendly website.

MEDIA CONTACT:
Kelly Downey
Shamin Abas Public Relations
561.366.1226

Click here to see all recent news from this company

Filed Under: Facilities And Providers

FONAR UPRIGHT MRI Customer Wins Jury Decision in Federal Court for Antitrust Lawsuit Versus CareCore National

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: FONAR Corporation

MELVILLE, NY–(Marketwire – December 13, 2010) – FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, announced today that a provider of outpatient diagnostic services (a FONAR customer) and several Stand-Up MRI diagnostic imaging professional corporations (PCs) received a jury verdict in their favor in an anti-trust lawsuit against CareCore National, LLC, a radiology benefits management (RBM) company (www.carecorenational.com).

This antitrust lawsuit involved CareCore National’s exclusion of the plaintiffs, all of them providers of MRI services using Stand-Up MRI scanners (FONAR UPRIGHT® Multi-Position™ MRIs), from utilization by its member subscribers. CareCore Radiology, a division of CareCore National, covers more than 30 million member subscribers in all 50 states. The diagnostic service provider and the PCs were represented by Constantine Cannon LLP, New York, NY, (www.constantinecannon.com). 

After more than a two-week trial, the verdict was reached November 30, 2010 in the U.S. District Court for the Eastern District of New York. The case is Stand-Up MRI v. CareCore National, E.D.N.Y. Case No: 08 Civ. 2954 (LDW) (ETB). The eight members of the jury were unanimous in their decision and awarded over $11 million in damages to the diagnostic service provider and the PCs in the case, which are to be trebled by law. The total judgment with costs and attorney fees is expected to be close to $40 million.

In a press release, (http://www.prnewswire.com/news-releases/constantine-cannon-attorneys-win-important-healthcare-antitrust-jury-trial-against-carecore-national-llc-111128319.html) lead Constantine Cannon trial attorney Matthew Cantor said: “This verdict is not just important for my clients, but for patients everywhere. The evidence in this case showed that even CareCore considered the Upright MRI to be medically necessary and that, nonetheless, CareCore and its owners denied patients the ability to benefit from these important diagnostic procedures. The actions of benefits managers (RBMs) that are owned and controlled by physicians, like CareCore, must be scrutinized to ensure that patient welfare is not compromised. Constantine Cannon expects that the defendants will attempt to overturn the jury award either in post-trial motion practice or on appeal. If that occurs, Constantine Cannon will vigorously defend the decision of the jury.”

“The jury found that CareCore, in league with New York-area radiologists and radiology practices that owned and/or governed CareCore, conspired to unreasonably restrain trade in the market for commercially-insured outpatient radiology procedures. The jury also found that these restraints harmed the plaintiffs — several New York radiology practices and their medical management company — that offer unique and medically necessary Upright MRI services. The Upright MRI is the only MRI that can scan patients in the weight-bearing positions that patients actually feel their pain. By doing so, Upright MRIs diagnose patient ailments, including those related to the spine, that no other MRI can,” said Cantor.

Raymond Damadian, president and founder of FONAR said, “We are pleased that the Federal Court and Jury understands the medical necessity of the FONAR UPRIGHT® Multi-Position™ MRI aka STAND-UP® MRI. This is important for FONAR, its customers, future customers and particularly the patients who need the UPRIGHT® MRI so they can be correctly diagnosed and not be given the wrong treatment which often involves surgery. We expect this to help those patients across our nation who have been previously denied these critical examinations by the RBMs.”

“FONAR’s UPRIGHT® MR technology is vital to patient needs nationwide,” said Dr. Damadian. “Back pain is the second most common reason for visiting the doctor’s office after the common cold. Close to one million spine surgeries are performed each year, but the outcomes are not good with a failure rate that varies from 10% to 40% depending on the reported study (1). Alf Nachemson, MD refers to the saddest group of these patients, those who have undergone 4, 5, or 6 spine surgeries as “multiply operated surgical cripples” (2). The surgical failure is commonly the result of operating on the wrong spinal segment (i.e. not the one responsible for the patient’s pain). This occurs because the origin of the pain is often attributed to the wrong degenerative change in the spine when the patient is imaged on a recumbent-only MRI. Degenerative changes in the adult spine are frequently multiple in number. The suspected pain generating anatomy is conventionally identified from recumbent (conventional) MRI images while the patient’s pain often occurs only when the patient is upright and when the pathology generating it is visible only when the patient is upright and fully weight-loaded.”

Dr. Damadian continued, “The FONAR UPRIGHT® Multi-Position™ MRI enables the patient to place himself in the position that generates his pain so that an MRI picture can be taken in the same position that generated the patient’s pain. Correctly identifying the pain generating pathology markedly improves patient surgical outcomes. In addition, it enables the surgeon to see ALL the pathology he has to address, not just the single position non-weight-bearing image provided by the conventional MRI. This enables the surgeon to see the full extent to which the disk herniation of his patient increases when he/she flexes or extends, or the extent to which the patient’s vertebra is sliding back and forth with body position and generating pain. Approximately 1 million spine surgeries are performed in the U.S. each year and technology to improve the surgical outcomes for these patients is a serious need.”

“In addition, there are a wide range of other needs that patients have for FONAR’s UPRIGHT® Multi-Position™ MR imaging technology,” said Dr. Damadian. “Patients who have been hospitalized, for example, with congestive heart failure, cannot lie down. In the absence of UPRIGHT ® MRI these patients are unable to receive MRI examinations when they are needed.”

“Patients with scoliosis, which most commonly arises for the first time in young adolescent girls, have been reported by the National Cancer Institute (3) to experience a 70% higher incidence of breast cancer as adults than the non-scoliotic population. The increased incidence is attributed to the multiple annual chest x-rays (2-3 times per year) needed to monitor the child’s scoliosis until adulthood in order to assure satisfactory treatment.” Dr. Damadian added, “the FONAR UPRIGHT® MRI provides the same necessary vertebral angle (“Cobb angle”) measurements as the x-ray (plus the needed measurements of vertebra rotation not supplied by x-ray), thereby avoiding the annual radiations of the x-ray procedure and eliminating the danger of subsequent adult breast cancer.”

“Women patients, for example, as a result of the inherent trauma of childbirth to their pelvic floor anatomy, will commonly suffer the consequences of PFD (pelvic floor dystrophy) later in life. The symptoms of PFD are cystic prolapse (“falling urinary bladder”) and its chronic cystitis symptoms of urinary frequency, burning on urination, fever, and if unaddressed, chronic kidney inflammation (pyclonephritis). The patient must be upright to see it. It commonly returns to its normal position when the patient is recumbent and therefore is not diagnosed by the patient’s physician who examines her in the recumbent position. It affects 10 million women. The UPRIGHT® MRI readily visualizes the fallen bladder when these patients are upright, so that the surgeon has full image visualization of the anatomy that has to be repaired.

“Another serious present need for the FONAR UPRIGHT® Multi-Position™ MRI is the rising body of patients who are sustaining dislocations of the cervical spine from automobile collision whiplash injuries of the head and neck. The UPRIGHT® MRI is needed to assess the extent to which the brain has been dislocated [descent of the tonsils of the cerebellum] into the opening in the bottom of the skull (foramen magnum). This critical assessment of the extent of brain herniation into the opening at the base of the skull (cerebellar tonsil ectopia, or CTE) can only be determined with the patient in the upright position so that the surgical repair of this herniation and the patient’s “drop attacks” can be eliminated. (4)”

(1) The Failed Spine, M. Szpalski and R. Gunzburg, eds., Lippincott Williams & Wilkins, 2005, p. 123.
(2) Alf L. Nachemson, MD, “The Lumbar Spine An Orthopaedic Challenge”, Spine, Vol. 1, Number 1, March 1976, p. 65.
(3) National Cancer Institute, “Scientists Find Link Between Pre-1970’s Diagnostic X-rays for Scoliosis and Breast Cancer Mortality,” www.cancer.gov, 8/15/2000. “Breast Cancer Mortality  After Diagnostic Radiography: Findings from the U.S. Scoliosis Cohort Study”, Michele Morin Doody, et al., Spine, Aug. 15, 2000, Vol. 25, No. 16.
(4) Michael D. Freeman, et al., Brain Injury, July 2010:24(7-8):988-994.

About Constantine Cannon LLP

Constantine Cannon LLP represented the plaintiffs in the case. They have deep expertise in practice areas that include antitrust and complex commercial litigation, government relations, employment matters, securities and e-discovery. With offices in New York, NY and Washington, DC, the firm’s antitrust practice is among the largest in the nation, with more than 30 attorneys representing both plaintiffs and defendants in complex antitrust litigation.

For investor and other information visit: www.fonar.com.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™, True Flow™, The Proof is in the Picture™, Spondylography™ Spondylometry™ and Upright Radiology™ are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company’s financial results may be found in the company’s filings with the Securities and Exchange Commission.

Filed Under: Facilities And Providers

Medistem Co-Authors Scientific Publication Detecting Neurodegeneration Before Symptoms Develop

Posted on December 13, 2010 Written by Annalyn Frame

SOURCE: Medistem Inc.

MRI Study in Sheep Shows Changes in Brain Structures Associated With Scrapie Infection

SAN DIEGO, CA–(Marketwire – December 13, 2010) – Medistem Inc. (PINKSHEETS: MEDS) reported today peer-reviewed publication of a research project using MRI to assess brain changes in sheep infected with scrapie (sheep form of Mad Cow Disease) before symptoms of the fatal brain disease appear. 

The study, whose senior author was Dr. Joel Stutman and funded by the Louis and Lena Minkoff Foundation, compared 37 sheep that were positive for the infectious protein associated with scrapie, called PrPSc, to 80 sheep that had no evidence of the disease-causing protein. It was found that all sheep possessing the protein, whether symptomatic or non-symptomatic, exhibited a unique change in the anatomy of the brain as detected by MRI. Specifically, a greater ventricle to cerebrum area ratio was found in MRI images of infected sheep compared to healthy sheep.

“We are extremely grateful to Dr. Stutman and his team for allowing us to collaborate on this important project which integrated computer-based image analysis techniques with molecular diagnostics to demonstrate a very important finding: that in sheep with scrapie specific MRI changes can be indicative of neurodegeneration before symptoms appear,” said Vladimir Bogin, MD, Chairman and President of Medistem. “One of the major findings in the published stem cell clinical trials has been that some patients respond extremely well, while others do not. Medistem believes that development of disease-assessing techniques such as the one reported, will allow for better selection of patients that would respond to stem cell-based interventions.”

Medistem has filed an IND with the FDA for human trials of its universal donor stem cell, the Endometrial Regenerative Cell (ERC). The first product in development is a treatment for critical limb ischemia, a condition that causes approximately 150,000 amputations per year in the US. Published research demonstrates that Endometrial Regenerative Cells can generate lung, liver, pancreas, bone, muscle, heart, fat, and brain tissue, thus the company is currently exploring other disease indications. 

“Medistem collaborators have already used Endometrial Regenerative Cells in the treatment of patients with multiple sclerosis, a neurodegenerative condition which creates similar brain alterations as seen in the current study,” said Thomas Ichim, CEO of Medistem and co-author of the publication. “The reason for our participation in the sheep scrapie project is to be at the cutting edge of imaging studies in the neurosciences. This, in our opinion, allows us to: a) Select better inclusion/exclusion criteria for our future multiple sclerosis studies; and b) Objectively analyze effects of our intervention in humans.”

Endometrial Regenerative Cells are currently available for sale as a research reagent through General Biotechnology LLC at http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

The study, entitled “Generalized cerebral atrophy seen on MRI in a naturally exposed animal model for Creutzfeldt-Jakob disease” can be found online at http://www.translational-medicine.com/content/pdf/1479-5876-8-125.pdf.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem’s collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact:
Vladimir Bogin, MD
Chairman of the Board
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego
CA 92122
858 349 3617
858 642 0027
www.medisteminc.com

id=”nav_links”>

Filed Under: Medical And Healthcare

Assisted Living Concepts, Inc. Reports the Completion of Restructuring at Scotia Investments Limited

Posted on December 10, 2010 Written by Annalyn Frame

SOURCE: Assisted Living Concepts, Inc.

MENOMONEE FALLS, WI–(Marketwire – December 10, 2010) – Assisted Living Concepts, Inc. (NYSE: ALC) reported that the previously announced reorganization of its largest shareholder, Scotia Investments Limited, has been completed and that the shares of Class A and Class B Common Stock of Assisted Living Concepts, Inc. previously held by Scotia Investments Limited and its subsidiaries have been transferred to a former affiliate of Scotia Investments, Thornridge Holdings Limited. Thornridge, a privately-held limited company existing under the laws of Nova Scotia with its head office in Bedford, Nova Scotia, is wholly owned by private holding companies owned by members of the extended family of Jean Hennigar, a daughter of the late R.A. Jodrey, including her son David J. Hennigar, who is chairman of Assisted Living Concepts, Inc.’s Board of Directors. Prior to the reorganization, Scotia Investments Limited was also owned by members of the R.A. Jodrey family.

On December 6, 2010, Thornridge filed a statement on Schedule 13D with the United States Securities and Exchange Commission reporting that on November 5, 2010 Blomidon Investments Limited, the ultimate parent of Scotia Investments Limited, and three holding companies of Blomidon that owned all of the common shares of Blomidon, including Thornridge, completed a reorganization pursuant to which, among other things, Thornridge acquired all of the shares of Class A Common Stock and Class B Common Stock of Assisted Living Concepts, Inc. previously owned directly or indirectly by Scotia Investments Limited.

“We are pleased that the restructuring of Scotia Investments has resulted in the continued ownership commitment by the Hennigar family,” commented Laurie Bebo, President and Chief Executive Officer. “Based upon their past commitment and their recent Schedule 13D filing, we believe this restructuring of Scotia will have no material impact on ALC and reinforces the support for ALC’s strategic direction.”

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,305 units in 20 states. ALC’s senior living residences typically consist of 40 to 60 units and offer residents a supportive, home-like setting and assistance with the activities of daily living. ALC employs approximately 4,100 people.

Forward-looking Statements

Statements contained in this release other than statements of historical fact, including statements regarding anticipated financial performance, business strategy and management’s plans and objectives for future operations, including management’s expectations about improving occupancy and private pay mix, are forward-looking statements. Forward-looking statements generally include words such as “expect,” “project,” “point toward,” “intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,” “strategy” or “objective.” Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. In addition to the risks and uncertainties referred to in the release, other risks and uncertainties are contained in ALC’s filings with United States Securities and Exchange Commission and include, but are not limited to, the following: changes in the health care industry in general and the senior housing industry in particular because of governmental and economic influences; changes in general economic conditions, including changes in housing markets, unemployment rates and the availability of credit at reasonable rates; changes in regulations governing the industry and ALC’s compliance with such regulations; changes in government funding levels for health care services; resident care litigation, including exposure for punitive damage claims and increased insurance costs, and other claims asserted against ALC; ALC’s ability to maintain and increase census levels; ALC’s ability to attract and retain qualified personnel; the availability and terms of capital to fund acquisitions and ALC’s capital expenditures; changes in competition; and demographic changes. Given these risks and uncertainties, readers are cautioned not to place undue reliance on ALC’s forward-looking statements. All forward-looking statements contained in this report are necessarily estimates reflecting the best judgment of the party making such statements based upon current information. ALC assumes no obligation to update any forward-looking statement.

Filed Under: Medical And Healthcare

American Diabetes Association Applauds Two-Year Re-Authorization of Special Diabetes Program

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: American Diabetes Association

ALEXANDRIA, VA–(Marketwire – December 9, 2010) – The American Diabetes Association®, the nation’s leading voluntary health organization in the fight to Stop Diabetes®, praises Congress for reauthorizing the Special Diabetes Program. The renewal, which was part of the Medicare and Medicaid Extenders Act of 2010, will ensure the Special Diabetes Program for Indians (SDPI) and the Special Diabetes Programs for Type 1 Diabetes (SDP-Type1) continue through September 2013. The measure will provide $150 million in funding per year to each program. Nearly 24 million Americans are living with diabetes and another 57 million have prediabetes. Recently, the Centers for Disease Control and Prevention (CDC) released a report stating that if current trends continue, one in three Americans will have diabetes by the year 2050. Diabetes is among the leading causes of death by disease in the United States. It is a leading cause of heart disease, stroke, blindness, kidney disease, and amputation.

SDPI provides prevention, education and treatment programs in Native American communities. American Indians and Alaska Natives have the highest age-adjusted prevalence of diabetes among all U.S. racial and ethnic groups, where diabetes is four to eight times more common than in the general population. Studies have demonstrated that SDPI’s prevention and treatment efforts have contributed to significant reductions in diabetes complications in these targeted populations.

“We applaud the extension of the Special Diabetes Programs,” said Gale Marshall, Chair, American Diabetes Association’s Awakening the Spirit Native American initiative. “The Special Diabetes Program for Indians provides for more than 450 community-directed programs, allowing local tribes and health programs to set priorities that meet their needs, including prevention activities or treatment. Because of these education and treatment programs, the American Indian and Alaskan Native communities have stories of hope and progress in facing the battle against diabetes.” 

The Special Diabetes Programs for Type 1 Diabetes provides funding for groundbreaking type 1 diabetes research. Clinical research supported by this program has demonstrated tangible results — from delaying the full onset of type 1 diabetes in newly diagnosed patients to gaining insight on the underlying causes of diabetes and halting or reversing costly complications such as diabetic eye disease.

“The Special Diabetes Programs for Type 1 Diabetes is a vital federal effort that is bringing us closer to a cure for this epidemic,” said Janel Wright, National Chair, Advocacy Committee, American Diabetes Association. “This cost-effective program provides crucial funding for research and results in real advances for people living with type 1 diabetes.”

About The American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Contact:
Lauren Gleason
(703) 549-1500 Ext. 2622
[email protected]

id=”nav_links”>

Filed Under: Facilities And Providers

Fresh Start Private Naltrexone Implant Procedure Shows Excellent Potential for Reduction in Alcoholism

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Fresh Start Private Management Inc.

Naltrexone Reduces the Number of Occasions During Which a Person Is Likely to Drink

LOS ANGELES, CA–(Marketwire – December 9, 2010) – Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, provided data today showing that Naltrexone is effective in the treatment of alcoholism.

According to published results in the Oxford Journals, research indicated that “Naltrexone is superior to placebo. Subjects treated with Naltrexone experience significantly fewer episodes of relapse, and significantly more remain abstinent when compared to placebo-treated subjects {risk difference of relapse rates = -14% [95% confidence interval (CI): -23%, -5%]; and risk difference of abstinence rates = 10% (95% CI: 4%, 16%)} after 12 weeks of treatment. The Naltrexone-treated subjects also consume significantly less alcohol over the study period than do placebo-treated subjects.” See http://alcalc.oxfordjournals.org/content/36/6/544.full for the complete results of the study.

A study by Joseph R. Volpicelli, MD, PhD; Arthur I. Alterman, PhD; Motoi Hayashida, MD, ScD; Charles P. O’Brien, MD, PhD, yielded other significant findings as follows:

“Seventy male alcohol-dependent patients participated in a 12-week, double-blind, placebo-controlled trial of Naltrexone hydrochloride (50 mg/d) as an adjunct to treatment following alcohol detoxification. Subjects taking Naltrexone reported significantly less alcohol craving and days in which any alcohol was consumed. During the 12-week study, only 23% of the Naltrexone-treated subjects met the criteria for a relapse, whereas 54.3% of the placebo-treated subjects relapsed. The primary effect of Naltrexone was seen in patients who drank any alcohol while attending outpatient treatment. Nineteen (95%) of the 20 placebo-treated patients relapsed after they sampled alcohol, while only eight (50%) of 16 Naltrexone-treated patients exposed to alcohol met relapse criteria. These results suggest that Naltrexone may be a safe and effective adjunct to treatment in alcohol-dependent subjects, particularly in preventing alcohol relapse.”

Fresh Start Private (FSP) is the only alcohol treatment program to offer a single-administration, licensed long-acting, Naltrexone implant procedure. Naltrexone has been approved for use by the FDA within the United States for the treatment of alcohol.

Trained medical doctors insert a specially formulated, biodegradable Naltrexone implant just beneath the skin below the patient’s lower abdominal area. The procedure is rapid and requires only local anaesthetic.

FSPs revolutionary procedure works instantly to block the receptors in the brain that crave alcohol. This one-time treatment is affordable and so fast a patient can be back to work the very next day, free from the physical cravings for alcohol.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has licensed a highly effective treatment delivers target therapeutic levels of Naltrexone that significantly reduce patients’ cravings for alcohol. Please visit www.freshstartprivate.com

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission.

Contact
Tom Kennedy
Phone: 949.209.8964
Email Contact

Filed Under: Facilities And Providers

The Children’s Medical Center of Dayton Partners With Medicity for Health Information Exchange in Ohio’s Miami Valley

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Medicity

Bidirectional Exchange Will Connect Hospital Systems, Physician EHRs and Allied Care Providers to Improve Care Delivery

SALT LAKE CITY, UT–(Marketwire – December 9, 2010) –  The Children’s Medical Center of Dayton (Dayton Children’s), a not-for-profit, freestanding children’s hospital serving 20 counties in Ohio and Eastern Indiana, has selected Medicity to power bidirectional health information exchange (HIE) between the medical center, affiliated physicians and other partners in its healthcare community.

Dayton Children’s will implement Medicity’s Novo Grid infrastructure — patented technology for connecting care teams and integrating with electronic health records (EHRs) — to distribute results, reports, and face sheets from the hospital’s Epic clinical systems and McKesson registration systems to community providers. The same Grid infrastructure will power laboratory and radiology orders back to the hospital.

“Our partnership with Medicity enables us to meet the HIE needs of Dayton providers while addressing our hospital’s unique business objectives,” said Beth Fredette, Dayton Children’s CIO. “By sponsoring the secure flow of health information in our community, we aim to improve clinical workflow, enhance patient care and improve affinity with our affiliated physicians by supporting their efforts to achieve meaningful use requirements.”

“The Grid enables secure electronic exchange regardless of which EHR a physician practice has adopted or whether the practice is paper-based,” said Kipp Lassetter, MD, Medicity CEO, “which means that Dayton Children’s now has a single solution that adapts to a wide variety of practice needs. Significantly, the Grid also provides the flexibility and control for the hospital to connect with state and regional HIE initiatives as they come along.”

About The Children’s Medical Center of Dayton
The Children’s Medical Center of Dayton is the region’s only medical facility dedicated to children. Consistently recognized as one of the country’s best pediatric hospitals, Dayton Children’s provides medical treatment, advice and information for children and families from 20 Ohio counties and eastern Indiana. Dayton Children’s accreditation by the Joint Commission on Accreditation of Healthcare Organizations ensures the regions’ infants, children and teens receive excellent pediatric care. For more children’s health and safety information, visit our web site at www.childrensdayton.org.

About Medicity
Medicity, the industry standard for health information exchange (HIE), is the leading innovator and largest provider of HIE technology — with more than 700 hospitals and 250,000 physicians in its connected ecosystem. Medicity’s solutions empower hospitals, physicians and HIEs with secure access to and exchange of health information — improving the quality and efficiency of patient care locally, regionally and nationally. For more information, please visit us or follow us on Twitter.

Contact:
Amendola Communications for Medicity
Janet Cabibbo
480-664-8412 ext. 15
[email protected]

Moira Alter
Marketing Manager, Dayton Children’s
937-641-3618
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Marathon Health Engagement Rates Exceed Prediction for Health Improvement

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Marathon Health

BURLINGTON, VT–(Marketwire – December 9, 2010) – Marathon Health today announced that health program engagement rates achieved for Accellent, Inc exceeded prediction by 27%. Marathon Health achieved a 97% engagement rate of the target population identified in March 2009 as being at high risk for a chronic condition or who had an existing chronic condition. The Marathon Health definition of engagement is any person who has met with the nurse health coach and selected a risk- or condition-related goal to work on with health coaching as appropriate.

Accellent, a leading supplier of supply chain solutions to the medical device industry, offers its employees face-to-face health assessments and health risk reduction coaching at their 15 US locations. Marathon Health provides these services with traveling nurses who visit Accellent sites at regularly scheduled intervals. Marathon Health also provides onsite health services at three of Accellent’s sites.

“Achieving this rate of engagement with a distributed workforce can be attributed to several factors,” said Tricia McCall, Accellent Vice President of Human Resources. “We have strong program champions at the local level to coordinate the activities. We offer an incentive program to get people involved with the screenings and assessments. And through Marathon Health, we provide high-quality coaching and outreach programs. Together, these factors combine to create the level of involvement we are seeing. This effort is one more way we are staying true to our company vision of ‘Helping People Live Better Lives’.”

The focus on engaging individuals with health risk factors has played an important role in the -3% medical trend experience at Accellent.

“It is well documented that individuals with high risk factors, such as hypertension, smoking, and obesity, will consume healthcare resources at two — five times the rate of a healthy person,” said David Demers, MPH, director of strategic planning at Marathon Health. “And while the numbers speak volumes, the real success is found in the hundreds of individual stories of employees who have improved their health. That is what we are most proud of at Marathon Health.”

About Accellent
Accellent provides fully integrated outsourced manufacturing and engineering services to the medical device industry in the cardiology, endoscopy and orthopaedic markets. Accellent has broad capabilities in design and engineering services, precision component fabrication, finished device assembly and complete supply chain management solutions. These capabilities enhance our customers’ speed to market and their return on investment by allowing them to focus their internal resources more efficiently. For more information, please visit www.accellent.com .

About Marathon Health
Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

Contact:
Tracey Moran
802-857-0459
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

InoLife Technologies, Inc. Retains John O’Maley and Associates to Launch Aggressive Retail Sales & Marketing Program for Company’s DNA-Based…

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: InoLife Technologies Inc.

30 Years of Experience and 40-Plus Successful Product Launchings Greatly Contributed to the Decision

RALEIGH, NC–(Marketwire – December 9, 2010) – InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company, announced today that it has retained John O’Maley and Associates to manage its retail sales & marketing program and aggressively place the Company’s current and future DNA-based products into the consumer market.

John O’Maley and Associates (JOA) provide over 30 years of experience in successfully launching over 40 consumer products into nearly every trade channel of the market. This company has a long-standing and trusted reputation in the retail industry in providing world-class sales presentations on products that result in significant sales and brand awareness.

John O’Maley, President of JOA, contributes his success from his training in sales and marketing, advertising and business development at Proctor & Gamble. That experience has proven to be instrumental in generating outstanding results for his clients. JOA also uses a proven national broker network that consists of over 30 key senior account sales executives who were trained in fortune 500 companies. This ensures continuity and excellent national coverage. For more information on JOA visit www.omaley.com

InoLife has considered many companies to use for this important aspect for the success in placing its current and future DNA-Based products into the consumer market. Management feels that John O’Maley and Associates has the experience and proven success record to get the job done. We look forward to working with John’s company.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company’s control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

Filed Under: Facilities And Providers

Manchester Manor Health Care Center Distinguished With Highest Level National Award

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Manchester Manor Health Care Center

Achievement in Excellence Awarded for Exemplary Delivery of Quality Long Term Care

MANCHESTER, CT–(Marketwire – December 9, 2010) – Manchester Manor Health Care Center has been recognized as a 2010 recipient of the National Quality Award at the level of Gold – Excellence in Quality presented by the American Health Care Association/National Centers for Assisted Living (AHCA/NCAL), a Washington D.C. based trade organization with approximately 11,000 nursing facility members nationwide. Manchester Manor is the only 2010 recipient of this distinguished national award. Over the 15 years of the Quality Award program, only 4 companies, owning 10 facilities, have ever received an award at this level. The award was formally presented to Manchester Manor during AHCA’s 61st Annual Convention and Exposition, October 10-13, 2010 in Long Beach, CA.

“The staff and leadership of Manchester Manor Health Care Center have demonstrated that they can sustain a high level of performance across a broad spectrum of services, and have set themselves apart as a health care organization of the highest distinction,” stated Bruce Yarwood, President and CEO of AHCA. “We applaud this outstanding achievement that honors their commitment to a rigorous journey of continuous improvement.”

Implemented by AHCA/NCAL in 1996, the National Quality Award Program is based on the core values and criteria of the Malcolm Baldrige National Quality Award Program. It provides a pathway for providers of long term and post-acute care services to journey towards performance excellence. Applicants for the prestigious Gold – Excellence in Quality award demonstrate by approach, deployment and consistency of results that they are achieving high levels of performance in health care, customer satisfaction, market, workforce, process and leadership outcomes over time. At the Gold level, applicants must successfully address the Malcolm Baldrige Program’s Health Care Criteria for Performance Excellence. Gold applications are reviewed by teams of Master Examiners with extensive qualifications and special training to qualify as judges. A ten member Board of Overseers provides oversight of the award program.

“No one knows better than the staff at Manchester Manor that their quality journey never ends, but this award level is a significant achievement,” stated Bernie Dana, Chair, AHCA/NCAL National Quality Award Board of Overseers. “Clearly Manchester Manor is one of the very best long term care providers in the entire nation.”

Manchester Manor Health Care Center previously received the Silver – Achievement in Quality Award (2008) and the Bronze – Commitment to Quality Award (2007).

Contact:
Mary Ellen Gaudette
Administrator
Email Contact
385 West Center St.
Manchester, CT
Tel. 860-533-2532
Fax. 860-645-0841

Click here to see all recent news from this company

Filed Under: Facilities And Providers

What 2010 Planning Will Mean for Pharma and Biotech in 2011

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Cutting Edge Information

Top Research Topics in 2010 Point Spotlight on Where Companies Will Be Taking Action Next Year and Beyond, Says Management Consulting Firm Cutting Edge Information

RESEARCH TRIANGLE PARK, NC–(Marketwire – December 9, 2010) – As many companies put the finishing touches on their 2011 Action Plans, the pharmaceutical and biotechnology sectors are looking to create opportunities from the challenges of recent years.

Cutting Edge Information, Inc. analyzed what issues its clients have studied most closely in 2010 and the resulting decisions and strategies they are likely to implement in 2011. “The popularity of each topic shows the areas that companies consider most important as they enter 2011,” said Jason Richardson, president of Cutting Edge Information.

“These are the areas executives believe offer both challenges and opportunities that can provide competitive advantage if managed well in the next year.”

The lists below include both the subject areas identified by industry executives and the top project conducted by Cutting Edge Information (http://www.cuttingedgeinfo.com/) for that functional group.

Top 3 Medical Affairs Reports
#1 Thought Leader Fair-Market Value: Compensation Benchmarks and Procedures
#2 Medical Science Liaison Programs — The New MSL Profile: Internal Thought Leader, External Voice and Clinical Catalyst
#3 Pharmaceutical and Medical Device Regulatory Affairs

Top 3 Clinical Development Reports
#1 Benchmarking Drug Safety and Pharmacovigilance
#2 Streamlining Clinical Trials
#3 Clinical Trial Patient Recruitment

Top 3 Decision Support and Forecasting Reports
#1 Oncology Market Forecast to 2015
#2 Strategic Pharmaceutical Competitive Intelligence
#3 Diabetes Market Forecast to 2015

Top 3 Market Access Reports
#1 Health Economics and Outcomes Research
#2 Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform
#3 Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs

Top 3 Portfolio Planning and Business Development Challenges
#1 Lifecycle Management: Strategy, Selection and Execution
#2 Pharmaceutical and Biotechnology Business Development: Accelerating the Deal
#3 Pharmaceutical Alliance Management

Top 3 Marketing and Commercialization Reports
#1 Countering Generics and Biosimilar Threats
#2 Pharmaceutical Speaker Programs
#3 Driving Successful Pharmaceutical Brands

Cutting Edge Information will continue to analyze key trends emerging from 2010 and impacting 2011 and beyond. More detail and background about Cutting Edge Information is available through the pharmaceutical Twitter feed, the life sciences research and consulting LinkedIn page, and a set of complimentary newsletters providing new management analysis monthly.

For media inquiries, please contact
Stephanie Swanson
919-403-6583
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Surrex Announces Strategic Partnership With gloStream

Posted on December 9, 2010 Written by Annalyn Frame

SOURCE: Surrex EHR Solutions

EL SEGUNDO, CA–(Marketwire – December 9, 2010) –  Surrex EHR Solutions (www.surrex-ehr.com), a rapidly growing US based Healthcare IT Consulting firm, and gloStream (www.glostream.com), the world’s only provider of a Meaningful Use ready Electronic Health Records system (EHR) with MS Office built directly in, today announced the formation of a strategic partnership through which Surrex will perform sales, implementation and system integration of the gloStream platform for physician offices around the United States. 

Recognizing the need for a powerful, effective, and highly efficient EHR and Practice Management solution in small and medium sized medical offices, Surrex selected gloStream for their easy-to-use MS Office based technology, state of the art integration with Voice Recognition software, and top tier customer support. gloSuite, an integrated EHR and PM platform, allows Physicians to dictate directly into a patient’s Electronic Medical Record, ePrescribe, and perform other critical day to day tasks. Medical office staff can rapidly customize templates and documents, file insurance claims, interface with 3rd billing services, and much more.

“Our team evaluated dozens of meaningful use certified EHR platforms as we sought to identify viable Partners,” said Tristan Carey, President of Surrex EHR Solutions. “gloStream was one of a very small number of organizations that met our criteria for product quality, process management, solutions integration, pricing, and ongoing customer support. We’re very pleased to be one of the newest members of the gloStream Partner community.”

“We are proud and excited to welcome Surrex to the gloStream community,” said Brenda Hodge, gloStream’s Executive Vice President for Partners and Practices. “Their level of commitment to the gloStream Partner Program ensures that physicians all over the U.S. will have access to not only the best EMR and PM software, but also to an IT advisor that can implement and support entire networks and essential data.”

Both companies anticipate a highly successful partnership and look forward to serving the physician marketplace across the United States. 

Surrex EHR Solutions specializes in the selection, implementation, integration, and support of Electronic Medical Records (EMR / EHR) and Practice Management (PM) solutions. Contact Surrex at www.surrex-ehr.com, or by calling 1-877-4SURREX (877-478-7739).

gloStream provides doctors with certified, voice-enabled electronic medical record and practice management solutions delivered and supported through a nationwide community of local technology Partners. gloStream products are secure, easy-to-use applications and the only solutions on the market with Microsoft Office built right in. 

Contact:
Michael Junge
949-202-5839

Filed Under: Facilities And Providers

ALDA Pharmaceuticals Corp.: Private Placement

Posted on December 8, 2010 Written by Annalyn Frame

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 8, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company” or “ALDA”) announces that it is undertaking a non-brokered private placement of up 2,000,000 units of the Company (the “Units”) at a price of $0.10 per Unit for proceeds to the Company of up to $200,000. Each Unit will consist of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of 24 months from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.

Certain insiders of the Company have been selling common shares of ALDA through the facilities of the TSX Venture Exchange in connection with this private placement and will reinvest up to $175,000 of the proceeds in the private placement. Accordingly, insiders of ALDA will be subscribing for over 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101.

The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital purposes.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Filed Under: Medical And Healthcare

Marketwire Health/Fitness/Wellness Features Package Summary

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: Marketwire – Media Relations

CHICAGO, IL–(Marketwire – December 8, 2010) – Marketwire announces that the following releases were included in the Health/Fitness/Wellness Features Package. Below is the list of headlines included in the package.

EmpowHER Offers Resources to Help Women Manage Holiday Stress
http://www.marketwire.com/press-release/EmpowHER-1365614.html

Marketwire’s Media Relations Department serves the information needs of the media. As a liaison between the media and Marketwire clients, our Media Relations team utilizes a variety of means to ensure that journalists, analysts and online communities receive news and information on companies, industries and topics of interest in the formats and via the distribution mechanisms they desire. To that end, our Media Relations staff, located throughout North America, the UK and Asia, manages relationships with media around the world, specializing efforts across 140 vertical industries, traditional and specialty markets, and various media.

Filed Under: Medical And Healthcare

Global Health Care Market Is $5.5 Trillion and Growing Quickly, Says Plunkett Research

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: Plunkett Research, Ltd.

HOUSTON, TX–(Marketwire – December 8, 2010) –  Plunkett Research, Ltd. has released its newest market research and competitive analysis report, Plunkett’s Health Care Industry Almanac, 2011 edition, which identifies and analyzes major trends shaping the health care industry.

According to Jack W. Plunkett, CEO of Plunkett Research, Ltd., “While total health expenditures continue to grow in the U.S., health care is spreading rapidly in emerging nations like India and China.”

Major trends affecting the Health Care Industry analyzed in Plunkett’s report include:

  • Continued rise in health care costs.
  • Employers push health care costs onto employees.
  • Medicare and Medicaid spending continue to surge.
  • Health Care Reform Act of 2010 set to bring big changes.
  • Major drug patents expire while generic growth continues.
  • Quality of care and health care outcomes data become available online.
  • Obesity sparks government action.
  • Health care thrives offshore, medical tourism grows.
  • Disease management programs take root.
  • Health care industry to grow rapidly in China and India.

“Eventually, innovative health practices and technologies developed for lower-income nations will migrate to the U.S., helping to contain costs,” said Jack Plunkett.

A complete report with detailed industry trends and statistics analysis is provided in Plunkett’s Health Care Industry Almanac, 2011 edition. This informative reference book gives you the competitive intelligence you need, with a detailed industry overview, industry analysis and market research. Plus, thousands of contacts for business and industry leaders, industry associations and industry sites, as well as statistical tables, an industry glossary and thorough indexes — everything you need all in one value-priced, easy-to-use package.

A complimentary video of Plunkett discussing these trends is now available on the Plunkett Research website, as well as YouTube, and an Introduction to the Health Care Industry can be viewed at Plunkett’s website. 

About Plunkett Research, Ltd.
Plunkett Research is a leading provider of industry trends analysis and market research. Our reports and data services are used by the world’s top corporations, consultants, universities, libraries and government agencies. Plunkett’s products save time and effort when you need competitive intelligence, market research or marketing data. For more from Plunkett Research, become a Fan on Facebook and subscribe to our YouTube channel.

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Accuracy Most Important for DNA Sequencer Users: Kalorama Survey

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: Kalorama Information

NEW YORK, NY–(Marketwire – December 8, 2010) – Labs using DNA sequencers are more concerned with accuracy than cost in future purchases, according to a survey conducted by Kalorama Information. The healthcare market research publisher reported the survey findings in its recent report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems).”

“A significant number of respondents chose accuracy over cost, ease-of-use or speed,” said Justin Saeks, Kalorama Information’s biotech analyst and author of the report. “This was true both for labs using first-gen or next-gen systems.”

The Kalorama Information survey of 120 laboratories using next-gen and capillary systems was carried out from July to September of 2010, with the majority in the latter portion. About 70% of the labs were academic; the remainders were hospital, government or independent labs. 70% of the hospitals were in North America, 12% in Europe and 18% in ROW. The bulk of respondents were core labs with more than a third doing contract work. Respondents were asked for the most important criteria in considering a new sequencer purchase. Accuracy rated highest for 78.8% of respondents. Cost per sample run was also important, rating second as a criterion with 63.6% of respondents. 

Kalorama Information found that the preference for accuracy occurred regardless of whether the survey respondent used a 454, SOLID, Illumina or Capillary System. Saeks, who has been analyzing sequencer markets for the past decade, was not surprised at the ranking of accuracy over other qualities in purchasing new sequencers.

“One of the things we heard from respondents was that accuracy is proportionately more important because in sequencing the margin of error is low,” said Saeks. “Even a .01% error rate adds up to a lot. And accuracy drives other areas — a clean sequence, for instance, will enable software algorithms to work well.”

Kalorama Information has been covering developments in the DNA sequencing markets since 2007. More information on this report, “DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems),” can be found at: http://www.kaloramainformation.com/redirect.asp?progid=80130&productid=2657156.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

KBM Group Acquires Marketing Direct, Inc.; Announces Launch of KBM Group Health Business Unit

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: KBM Group

Results in Broader, Deeper Healthcare Expertise, Including Creative Campaign Development and Execution

RICHARDSON, TX–(Marketwire – December 8, 2010) – KBM Group, the global leader in knowledge-based marketing solutions, has agreed to acquire Marketing Direct, Inc. (MDI), the leading provider of agency services to the healthcare industry. MDI is an integrated marketing services company with expertise in strategy, design and execution of marketing campaigns, from go-to-market strategies and sales-lead conversion to media placement, primarily for the healthcare industry. The acquisition strengthens and broadens KBM Group’s existing products and services for the healthcare market, augmenting the company’s core capabilities with a wide array of agency services such as creative and media placement, including digital media channels. Based in St. Louis, MO, MDI is a privately held company. Financial terms of the deal are not being disclosed, and the acquisition is subject to regulatory and shareholder approvals.

Founded in 1997, MDI has been ranked one of America’s fastest-growing private companies by Inc. Magazine in its annual Inc. 5000 survey for 2008, 2009 and 2010. The company’s growth has been driven by providing direct and interactive marketing services primarily to the healthcare industry, but the company has experience in retail and financial services as well. MDI’s capabilities span marketing services end-to-end, including: consulting services, developing and optimizing direct market channels, facilitating the sales process through sales force automation, determining the best mix of online and offline media, performing analytics and testing to ensure results, developing creative campaigns from messages to branding, optimizing websites and online strategies, and media placement and execution. Providing these multichannel marketing services to targeted industries has given MDI industry-specific expertise that has allowed it to help its clients acquire millions of customers and engage them to improve healthcare outcomes.

With the combined strength of the acquisition, KBM Group is also officially announcing the launch of KBM Group: Health Services, a new business practice focused on improving how companies across the healthcare continuum engage with consumers and healthcare professionals. KBM Group: Health Services will immediately intensify its focus on helping organizations within the healthcare ecosystem create more meaningful engagements with consumers for the ultimate goal of improving healthcare outcomes while reducing the overall cost of healthcare services. Dennis Barnes, Jr., President & CEO of MDI, will become President, KBM Group: Health Services. The new unit will remain part of Enterprise Services within KBM Group.

“While KBM Group and MDI have been recognized and established leaders within healthcare for several years now, current and impending changes to healthcare require a more holistic approach to multi-channel engagement if we are to substantially reduce costs while improving outcomes,” says Dennis Kooker, KBM Group’s President & COO for Enterprise Services. “Combining KBM Group’s industry standards for data, analytics, and database services delivered through its Consumer Healthcare Engagement Platform (CHEP) with MDI’s expertise in blending creative content and program design with analytics was an obvious combination. MDI has also invested heavily within innovative digital channels that mark the future of consumer engagement. The fundamental beliefs of our organizations and how to serve the healthcare ecosystem are very much aligned.”

Dennis Barnes, President & CEO of MDI, says, “We look forward to contributing our successful record of growth and healthcare expertise to KBM Group, and to integrating our capabilities with KBM Group’s superb data and analytics capability. As an agency specializing in healthcare, we are impressed with the level of healthcare subject matter expertise and the vision that KBM Group has created for the healthcare ecosystem. I am thrilled to have the opportunity to lead an organization with the combined resources and capabilities that KBM Group Health will possess; not to mention how exciting it is to be able to prove our more fundamental goal of driving down the cost of healthcare in this country without needing to make villains out of the healthcare providers.” 

New York-based mergers & acquisition firm AdMedia Partners acted as exclusive financial advisor to MDI in the transaction (www.admediapartners.com). For information about MDI and its transition to KBM Group: Health Services, go to www.marketingdirect.com.

About KBM Group
KBM Group is the global leader in knowledge-based marketing solutions. Expert in both digital and traditional direct marketing, KBM Group helps companies manage, analyze and optimize marketing data to engage more effectively with their customers and prospects. KBM Group’s integrated, world-class solutions include strategic consulting, digital services, database services, analytics, marketing management, response services, data and marketing outsourcing. The company has 16 offices in nine countries serving global, enterprise and B2B2C-focused companies. KBM Group’s parent company, Wunderman is part of Young & Rubicam Brands and a member of WPP (NASDAQ: WPPGY). www.kbmg.com.

Contact:
Barbara Palmer
(Tel) +1 212 941 3367
(Mob) +1 917 405 8252
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

incentaHEALTH Finds Better Way to Fight Employee Obesity While Reducing Employer Health Care Costs

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: incentaHEALTH

Workplace Kiosks Screen and Measure Employee Health, Emails Motivate Increased Participation and Success Is Met by Cash Rewards

DENVER, CO–(Marketwire – December 8, 2010) – Like the scale in the doctor’s office, the numbers can be daunting. Similarly, the statistics that reveal an increasingly overweight America — 67 percent and rising — are sending shivers down the spine of this nation’s health care system, especially in corporate America where the costs of keeping employees healthy are threatening both the bottom line and the country’s economic future.

Today it costs employers an estimated $13,000 annually to provide premium health care benefits for a typical employee and his or her dependents, and that figure has gone up 10 percent each year for the past decade. Of that annual amount, almost $10,000 is paid by the employer. 

In an attempt to stem the tide, Denver-based incentaHEALTH has focused on one of the biggest drivers of health care costs: obesity. Overweight and obese employees incur over $1,500 in additional costs for the employer each year. In response, incentaHEALTH has developed a unique program that pays employees and their families to lose weight, stay healthy and remain productive. Blending technology, ingenuity, medical expertise, and employer resources, it is designed to encourage greater participation by employees in typical company health plans.

According to Todd McGuire, Chief Technology Officer, who co-founded the company in 2002 with CEO Jack Rule, the idea for incentaHEALTH was developed after discovering that among the most pressing issues facing the business world at the time were runaway health care costs and obesity.

“In 2002 we weren’t happy with the wellness programs used by the rest of the industry, so we created our own,” McGuire said. “Our technology authenticates health outcomes instead of relying on people to self-report. Since we are paying cash incentives, you don’t want somebody to send a friend down to weigh in for them.”

The centerpiece of the incentaHEALTH system is the patented HEALTHspot kiosk which, when strategically placed throughout a company’s facilities, provides:

  • Automated biometric measurements of weight, blood pressure and body mass index (BMI) using authenticated measurements (not self-reported)
  • Instant feedback to participants and program administrators
  • 24-hour, low cost operation and remote maintenance
  • Enhanced privacy
  • Full-body digital imaging to keep track of participant progress and create a visual progress report
  • Complete and accurate electronic records for both employee and employer

Supporting the kiosks, the program uses a variety of communication tools to reach all employees and motivate them to participate. Says McGuire, “Behavior change is a daily battle. It won’t occur with an occasional newsletter. A better approach is a daily coaching plan using emails and text messages that shows employees and their dependents exactly how to eat and exercise.” The program incorporates onsite kickoff sessions and printed support materials to reach employees without email access.

“The national view of health and wellness has matured significantly since we started our business,” said McGuire. “After extensive research of the problem and conducting surveys of the workforce, the wellness industry has found that people are inactive, overweight, have high blood pressure and are not eating properly. Employers are now demanding programs that result in real behavioral changes to tackle these issues.”

“Historically, employers have offered $50 to employees just to sign up for a wellness program, whether they used it or not,” he added. “What we do is shift from an incentive for participating to an incentive for measured performance. For example, if an employee signs up for our program and achieves a 15 percent weight loss, they will get paid, in actual dollars on a brightly colored check, when they weigh in at the HEALTHspot kiosk every 90 days.” The program pays incentives ranging from $15 to $150 per quarter to all employees based on the amount of weight they lose, so every level of success is rewarded.

So far, the incentaHEALTH approach to corporate wellness is working. Organizations across the globe are signing up — companies like Jackson National Life Insurance Co., Virginia Tech, Kaiser Permanente, Long Beach Memorial Medical Center, Accident Fund Insurance Company of America, U.S. Department of Health and Human Services, and others that are concerned about their employees’ health.

“incentaHEALTH has become an integral part of our overall wellness program, which helps our associates make healthier lifestyle choices,” said Cheng Hsu, benefits manager at Jackson National.

And users are noticing a big difference in their health.

“I’ve lost 70 pounds on this program. I am now eating healthy, watching my portion sizes and exercising,” said one employee participant. “It was a true godsend.”

About incentaHEALTH
incentaHEALTH is an innovative health care technology company based in Denver, Colorado. incentaHEALTH’s fully outsourced, employee weight management program is designed to help organizations reduce their health care costs by offering incentives to employees for improving their health. This is achieved by helping employees manage their weight through the use of interactive email coaching, workplace weigh-ins on private kiosks, and cash rewards for maintaining long term health improvements. For more information, visit www.incentahealth.com.

Media Contact:
Les Goldberg
Lages & Associates
(949) 453-8080
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Radient Pharmaceuticals Onko-Sure(R) In Vitro Diagnostic Cancer Test Potentially Effective as Veterinary Cancer Tumor Marker

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: Radient Pharmaceuticals Corporation

TUSTIN, CA–(Marketwire – December 8, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it has completed a pilot clinical study to measure the feasibility of using its Onko-Sure® in vitro diagnostic (IVD) cancer test kit as a veterinary tumor marker initially for cancer detection in domestic cats.

Preliminary data from the Onko-Sure® assay pilot study measuring domestic cat serum suggests RPC’s Onko-Sure® IVD cancer test may potentially detect cancer in domestic cats. In this pilot study, RPC ran samples from confirmed normal domestic cats and domestic cats with cancer. For cats with cancer, RPC ran a serum sample obtained first when the cats were cancer-free and another sample subsequently when the cats were confirmed with cancer. The relative levels of Onko-Sure® for the cats were compared using the Onko-Sure assay and showed a 2,853% increase in Onko-Sure levels versus the healthy sample. RPC is currently engaged in full clinical trial including 71 samples, which includes an antigen characterization that involves testing to identify direct evidence that RPC’s Onko-Sure® IVD cancer test kits are effective in cancer detection in domestic felines.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, “This development is anticipated to open the use of our Onko-Sure® assay as a veterinary cancer tool that could play an integral role in the screening and early detection of cancer for veterinary patients and further enhance RPC’s strong portfolio of novel oncology products. This is truly an exciting development for the Company and our valued shareholders.”

Onko?Sure is a simple, non?invasive, patent?pending and regulatory?approved IVD test for use as an aid in early detection of cancer. Onko?Sure enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko?Sure is approved by the US FDA for the monitoring of colorectal cancer, Health Canada as a lung cancer screen and cancer monitoring tool, and the European Union, Indian government, Korean government, and Taiwanese government as a cancer monitoring or cancer screening test. Onko?Sure test kits are currently sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam and in Chili for research use.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Appirio Selects RehabCare as Cloud Pioneer of the Year

Posted on December 8, 2010 Written by Annalyn Frame

SOURCE: Appirio

Healthcare Company, Its CIO and Vice President of Information Services Honored for Using Cloud and Mobile Technologies to Improve Patient Care and Transform an Industry

SAN FRANCISCO, CA–(Marketwire – December 8, 2010) – Salesforce.com Dreamforce Conference — Appirio has selected RehabCare as Cloud Pioneer of the Year, an annual award given by Appirio to companies and individuals that demonstrate leadership in cloud computing initiatives and a commitment to moving their business forward using public cloud platforms. 

RehabCare is a leading provider of physical rehabilitation program management services in more than 1,260 hospitals, skilled nursing facilities and other long-term care facilities in the U.S. They own and operate 35 hospitals, employ more than 18,000 people and report $1.6B in revenue. RehabCare’s commitment to using cloud-based and mobile platforms to improve patient care while growing their business and staying ahead of complex healthcare regulations stood out among more than a dozen nominated organizations.

“We view our technology investments as core to our company’s future and critical for patient care, and we think it can be a model for others in this industry,” said Dick Escue, CIO of RehabCare. “Using cloud computing, we can do things now that we wouldn’t have even thought possible two years ago. We see it as a huge differentiator for our company and the care we can provide.”

Over the past year, RehabCare has invested in building out an integrated technology platform that has dramatically improved their patient intake and referral process, the way they track, benchmark and improve rehabilitation procedures, and the way they report and communicate progress to Medicare, patients and their families. RehabCare has standardized on platforms, such as Salesforce, Force.com, Google Apps, and Google Health, and are in the process of developing a comprehensive cloud-based Electronic Medical Record platform that will begin rolling out next year. They’ve armed thousands of therapists with iPhones and iTouches and have been highlighted by Apple for their use of the iPad in healthcare.

Appirio’s Cloud Pioneer awards program was introduced earlier this year to recognize the champions and change agents among Appirio’s customers — those who recognize the unparalleled benefits of public cloud platforms and drive projects that are not only successful but truly impactful for their organization. Each Cloud Pioneer award winner is chosen by Appirio’s leadership team, based on nominations from the company’s delivery managers and cloud architects. Other 2010 Cloud Pioneer award winners include individuals at AIG Edison, Dolby Laboratories, DeVry University, Dunkin Brands, Japan Post Network and Perceptive Software. 

“The recipients of Appirio’s Cloud Pioneer award illustrate the potential of cloud computing to shape business strategy, accelerate innovation and drive competitive advantage,” said Chris Barbin, CEO of Appirio. “The executives and IT team at RehabCare who are applying cloud and mobile technologies throughout their business exemplify every one of these benefits. We are privileged to work with them and all of our Cloud Pioneers.”

Appirio’s 2010 Cloud Pioneers
Dick Escue and Jayson Chitwood (RehabCare), Tohru Futami (AIG Edison Life), Mary Ann Lusk and John Cunningham (DeVry University), Curtis Hodge and Scott Sullivan (Dolby Laboratories), Michael Wordell, Erik Astin, Greg O’Connor and Jon Cohen (Dunkin Brands), Neale Wooten (Perceptive Software), Yoshihiko Ohta (Japan Post Network)

About Appirio
Appirio (www.appirio.com) is a cloud solution provider offering products and professional services that help enterprises accelerate their adoption of cloud applications and platforms. Appirio’s innovation and expertise has been recognized by BusinessWeek as one of America’s Most Promising Startups and by AlwaysOn as 2010 On-Demand Company of the Year. Appirio has helped more than 180 leading enterprises implement, build and manage mission critical cloud solutions using salesforce.com, Google, Workday and Amazon. We are proud to serve a wide range of customers such as Avago, the City of Los Angeles, Diversey, Dunkin Brands, Flextronics, Japan Post Network, Ltd., IMS Health, Motorola, Qualcomm, RehabCare, Safety Kleen, Starbucks and VMware, as well as the 5,000 companies that use Appirio’s products to connect and extend cloud platforms. Founded in 2006, Appirio has offices in the U.S. and Japan, and is backed by Sequoia Capital and GGV Capital.

Media Contact:
Cara Foley
SHIFT Communications
Phone: 415-591-8416
Email: [email protected]

Filed Under: Medical And Healthcare

Health Options Worldwide Discusses the Rise of Domestic Medical Travel

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Health Options Worldwide

PRINCETON, NJ–(Marketwire – December 7, 2010) – More employers and insurance companies are providing domestic medical travel incentives such as waived deductibles; coinsurance plans and covered travel expenses if employees will simply travel within the United States for healthcare travel or to another region or city for medical care. “The savings are significant and therefore insurers and third party administrators are partnering with healthcare providers for new revenue sources, especially in these times of reduced revenues thanks to healthcare reform,” said David Goldstein, president of Health Options Worldwide (HOW), an online medical tourism agency that provides high-quality low-cost healthcare options domestically and internationally.

In fact, large employers are negotiating with American hospitals located in other states and encouraging employees to seek healthcare for major illnesses and surgeries in other regions of the country. “Employers are partnering with insurance companies and hospitals to save money on their employee health plans,” said Goldstein. “They are accomplishing this by negotiating single rate packages with high-quality hospitals in other states, to include all fees for medical services in a single treatment program.”

Employers who adopt “domestic medical travel” can reduce healthcare costs 20-40% simply by referring employees to American facilities with higher-quality care and lower negotiated prices than in their own hometown. Health industry analysts believe that medical tourism, and more specifically domestic medical travel, could improve overall quality of care and help drive down costs with national competition.

Healthcare savings in domestic medical travel programs are realized from lower prices, which are negotiated between the company and the out-of-state hospital. Reduced complications from procedures performed at these high-quality hospitals also help the bottom line. Follow-up care is handled at the local hospital and covered as part of the treatment program, under the company’s insurance plan.

“Domestic medical travel is not a new concept as employers and insurers have always referred patients to high-quality facilities elsewhere for complex procedures,” said Goldstein. As healthcare costs continue to rise nationwide, domestic medical travel is a way for major employees to control escalating costs and provide their employees with the best quality care.

Contact:

David Goldstein
President
Health Options Worldwide
Ph: 1-877-234-1345
www.healthoptionsworldwide.com

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Two Atlanta Business Leaders Appointed to Board of India-US Business Network

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Morley Research

ATLANTA, GA–(Marketwire – December 7, 2010) – Jane Green, PhD, president of Morley Research Consortium, and Donald Johnson, Chief Operations Officer of Opus Institutional Review Board, have been appointed to the India-US Business Network (IUSBN) Board of Directors.

In this capacity Dr. Green and Mr. Johnson will be integral to shaping the relationship between India and the United States as the two countries explore and develop mutually beneficial opportunities. The initial four areas of interest for the IUSBN are Biotech, Pharma, Diagnostic, Devices and Health Care; Cold Chain; Education; and Renewable Energy. 

The two Atlanta leaders, who both have extensive experience in clinical research, have been asked to sit on the Biotech Committee for the IUSBN. This committee is focused on matching companies from each country with counterparts in research and development.

“This is both an honor and an opportunity,” said Dr. Green. “By furthering cooperation with India, we achieve the ability to improve the level of research and development in the area of biotech in both countries. I believe this exchange of ideas and information can create exponential advances in developing products and technologies that will benefit the entire world.”

Dr. Green’s organization, the Morley Research Consortium, assists device and drug companies to achieve their research goals of bringing a new product to market through its contract research organization which additionally provides research compliance, total trial management, contracting, site identification and training.

“India is a world leader in technology innovations, and expects to achieve similar success in the biotech field,” said Mr. Johnson. “I am pleased to be able to play a role in helping reach that goal, while also strengthening and benefiting U.S. companies.”

Mr. Johnson manages Opus Institutional Review Board (IRB), the ethical overview organization mandated to review clinical research studies worldwide. Opus IRB has a board of directors consisting of the country’s top practicing physicians in a variety of clinical specialties and encompasses over 20 medical disciplines.

Mr. Johnson and Dr. Green are the first two board members of the IUSBN from the southern region of the U.S. and they are planning the initial Atlanta area meeting of the IUSBN in the first quarter 2011 for others interested in the organization.

Learn more about IUSBN at www.iusbn.org. 

Media Contact:
Lynn Hood
Email Contact
678-427-5040

Company Contact:
Jane Green
Email Contact
404-625-0036

Filed Under: Medical And Healthcare

SK&A Launches Web Video Series Featuring Customer Challenges and Solutions

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: SK & A, A Cegedim Company

IRVINE, CA–(Marketwire – December 7, 2010) – SK&A, A Cegedim Company, a leading provider of healthcare information solutions and research, today announced the launch of its new web video series, “My Data Dilemma.” The series will feature SK&A clients from industries such as pharmaceutical, biotechnology, healthcare consulting, medical device and others, discussing their specific marketing challenges and how they overcame them through effective targeting and use of SK&A’s healthcare data products.

Episode one of “My Data Dilemma” takes viewers inside a healthcare consulting company that was challenged with identifying and reaching all U.S. blood bank directors and maternity nurses to execute surveys in support of two campaigns. One of the company’s senior vice presidents identifies the challenge the organization faced, the strategy that was executed with SK&A’s help and the results the company received from the project.

“Video is a great medium to effectively deliver the value and insight of successful marketing strategies and tactics to our large base of clients and prospects, and I am excited the SK&A marketing department has provided an insightful and engaging series that will help our customers learn from one another,” said SK&A’s Dave Escalante, Vice President of Data and Information Solutions. “With healthcare marketing strategies changing so rapidly, we feel it is important to embrace our leadership position in this space, connect our community of users, and promote the exchange of ideas.”

SK&A’s commitment to creating a community within the healthcare marketing industry is reflected in its social media outreach efforts, which span across its blog, LinkedIn, Facebook, Twitter and YouTube. Users can find news articles, discussions and other resources available at SK&A. All of SK&A’s market insight reports, press releases and company announcements can be accessed through these social media channels. The web video series will be posted on SK&A’s website and YouTube, with access from all the social media web pages.

Coming soon in episode two, “My Data Dilemma” cameras visit the office of a global biotech company that was challenged with identifying all the U.S. hospitals that treat a specific disease. Tune in to see how they found a solution for their marketing research challenge.

To view episode one of “My Data Dilemma,” visit http://www.skainfo.com/video_series.php. 

About SK&A, A Cegedim Company:
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 800,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering.  

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com 

Contacts:

Jack SCHEMBER
SK&A, A Cegedim Company
Director of Marketing
Tel.: (+1) 949.255.1259
Email Contact

Aude BALLEYDIER
Cegedim
Media Relations
Tel.: +33 (0)1 49 09 68 81
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

miCARD(R) Partners With GWRRA: Provides Lifesaving Medical Card to Motorcycle Association

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: miCARD

Co-Branded Medical Information Card Gives Emergency Personnel Instant Access to GWRRA Members’ Critical Medical Information, 24/7, Worldwide

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – miCARD and Gold Wing Road Riders Association, the world’s largest social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles have partnered to provide GWRRA with a co-branded, medical information card that prepares association member/riders for an unanticipated medical emergency.

“One of the highest priorities at GWRRA is to ensure the health and safety of our 74,000+ members,” said Ed Price, Marketing Director at GWRRA. “We are pleased to join forces with miCARD to ensure our association riders are prepared for any kind of a medical event. No matter where our members go, we know that the lifesaving medical information on miCARD will be with them. I personally carry miCARD in my wallet all the time, as I travel extensively.”

Motorcycle Fatalities on the Rise
The National Highway Transportation Safety Administration projects more than 100,000 motorcycle injuries will occur this year alone. Even with the advent of statewide motorcycle safety campaigns to help automobile drivers become more aware of motorcyclists, fatalities continue to rise. Carrying medical information ensures that emergency personnel have the critical information they need to make lifesaving decisions should an accident occur.

miCARD is the only medical information card and online Personal Health Record(PHR) designed by an emergency physician. In less than one minute, miCARD gives medical personnel in the field a readable summary of a member’s vital medical information. This includes: current medical conditions, critical medications, emergency contacts, allergies and more. miCARD’s wallet card is further supported by an online PHR which stores additional member information such as: advance directives, physician contacts, EKG’s, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

“Critical decisions about your health are made in the first few minutes of your emergency care,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “If you are unconscious or incapacitated, medical personnel have no knowledge of your existing medical conditions, critical medications or other important details which could impact your care and save your life.”

miCARD is a low cost solution to the problem of emergency preparedness and care and can be created securely online in minutes. To ensure the health and safety of your association members or to enquire about co-branding opportunities with miCARD please visit www.micard.com/partners or contact us directly at (866)596.2956.

About miCARD
Headquartered in Scottsdale, AZ, miCARD is a physician designed, medical information card and online personal health record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information, 24/7 worldwide. miCARD is registered with the USPTO under patent & trademark protection. For more information about miCARD please visit www.micard.com or contact us at (866)596.2956.

About Gold Wing Road Riders Association
 Founded in 1977, The Gold Wing Road Riders Association (GWRRA) is the world’s largest single-marque social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles. Dedicated to our motto, Friends for Fun, Safety and Knowledge, GWRRA members enjoy the freedom of belonging to a not-for-profit, non-religious and non-political organization with more than 800 active chapters, serving nearly 80,000 U.S., Canadian and international members in 53 foreign countries.

Contact:
Media Relations
email: [email protected]
Phone: (866)596.2956

Filed Under: Medical And Healthcare

Over 35 Pharma, Biotech Leaders Headline iiBIG’s Pharma, Biotech Licensing & Partnering San Diego Summit

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: iiBIG

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG’s Pharma & Biotech Licensing & Partnering — scheduled for March 3-4, 2011 at the Doubletree Hotel San Diego Downtown in San Diego, CA — is designed to bring together EVPs, SVPs, Chief Business Officers, COOs and other Senior Management from Pharmaceutical and Biotech companies involved in licensing, business development and strategic alliances and partnerships. This educational and networking forum will provide insight and guidance to pharmaceutical licensing, business development and deal making executives from across the world — covering issues that will help pharmaceutical companies both large and small to structure the best deals, carefully monitor risks and, perhaps, find their next partner. Executives from across the country will gather together to exchange ideas and information. 

Key issues to be addressed include:

  • What are the best practice strategies in developing an effective win-win licensing deal?
  • Early versus Late Stage Partnering Opportunities
  • Role of Corporate Investors in Today’s Deals
  • The Evolving Business Model of Building a Biotech
  • What Uncertain Financial Markets Mean for Deal-Making
  • Maximizing Your Company Value Through Non-Traditional Alliances

Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology companies as they share their insights on the evolving state of the industry. Some key faculty speakers include:

  • Michael Shih, Senior Director, Business Development, Eisai Inc.

  • Dr. Robert Baughman, PharmD PhD, Vice President Experimental Pharmacology, MannKind Corporation

  • Linda A. Egger, PhD, CLP™, Senior Director, Scientific Liaison External Scientific Affairs – Diabetes and Obesity Licensing, Merck & Co.

  • Dr. Sameeh M. Salama, Senior Director, Business Development, NAEJA Pharmaceutical Inc.

  • Christoph Pittius, Ph. D., Executive Director, Business Development & Licensing, Novartis Oncology

  • Daisy Rivera-Muzzio, Senior Director EP Product Licensing, Portfolio Development, Pfizer

  • Allen Downs, Senior Executive Director, Licensing & Business Development, Purdue Pharma

  • Michael D. Step, Senior VP, Corporate Development, Santarus, Inc.

  • Gwen Melincoff, Senior Vice President of Business Development, Shire Pharmaceuticals

For complete information about this event visit: http://www.iibig.com/P1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. For more information, visit: http://www.iibig.com. 

Filed Under: Medical And Healthcare

Healthcare M&A Finance, Industry Leaders Head to iiBIG’s Nashville Forum, January 25-26, 2011

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: iiBIG

PORT WASHINGTON, NY–(Marketwire – December 7, 2010) – iiBIG returns to America’s Healthcare Silicon Valley to present the industry-leading Investment and M&A Opportunities in Healthcare, January 25-26, 2011, at the Nashville Convention Center in Nashville, Tennessee. In 2011, experts are predicting an increase in middle-market M&A deal flow in all sectors — however, healthcare will continue to lead all others. Now that financing is becoming easier to find, pent up demand for deals in the middle-markets, and especially in this sector, are expected to increase dramatically. At this conference, attendees will hear from and network with experts and insiders on the status of deal-making in the healthcare sector and how and where deals are getting done.

Executive Speaking Faculty Includes: Alvarez & Marsal; Bass, Berry & Sims PLC; Belmont Village Senior Living; Benesch, Friedlander, Coplan & Aronoff LLP; Bertram Capital Management LLC; Capella Health; Coker Capital Advisors; CredenceHealth; Cressey & Company LP; Diatherix Laboratories, Inc.; DOHI; Epsilon Securities, LLC; EpsteinBeckerGreen; GTCR Golder Rauner, LLC; Healthcare Finance Group, LLC; Healthcare Productivity Automation; IASIS Healthcare Corporation; Iora Health; MedSolutions; Nashville Health Care Council (NHCC); Oak Hill Capital Partners; Penn Medicine; PricewaterhouseCoopers; Raymond James & Associates; Regence Group (Blue Cross/Blue Shield Oregon and Utah); RehabCare Group, Inc.; Renal Advantage, Inc.; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; SunTrust Robinson Humphrey; Tenet Healthcare; and Vanguard Health Systems.

Conference Sponsors include: Bass, Berry & Sims PLC; EpsteinBeckerGreen (EBG); PricewaterhouseCoopers; SunTrust Robinson Humphrey; Alvarez & Marsal; Benesch; Healthcare Finance Group (HFG); Raymond James & Associates, Inc.; Coker Capital Advisors; Riordan, Lewis & Haden Equity Partners; Sonenshine Partners; and Whyte Hirschboeck Dudek S.C.

Register by December 31, 2010 and Save $200! Healthcare Providers: Register at $595
For more conference information and/or to register: http://www.iibig.com/F1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. We provide learning and networking settings for some of the business community’s BIGgest thinkers — those who occupy the highest levels in their companies and organizations. Our events focus on the most pressing and timely issues facing decision-makers in today’s global economy. For more information, visit: http://www.iibig.com. 

Filed Under: Medical And Healthcare

Adamis Pharmaceuticals Announces Phase 3 Meets Primary Endpoint

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Adamis Pharmaceuticals Corporation

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced the successful completion of a Phase 3 contraceptive trial of the company’s contraceptive gel product candidate named Savvy® (C31G). The study met its primary endpoint and was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), in the Contraceptive Clinical Trials Network at 14 sites in the United States. The results of the NICHD study are published in Obstetrics and Gynecology, v.116, pages 1265-1273, in December, 2010.

The Phase 3 trial was a randomized, double-masked, controlled comparator study to assess whether a gel containing the spermicide, C31G, was non-inferior to Conceptrol®, a commercially available product containing nonoxynol-9 (N-9). The clinical investigators found that C31G was not inferior in contraceptive efficacy to the comparator drug Conceptrol®. Thus, the study met its primary objective. Moreover, the gel was well-tolerated and had a high degree of acceptability in women who completed the study. No drug-related serious adverse events were observed with C31G. Drug-related side effects of C31G were generally mild and did not lead to discontinuation.

Currently, all spermicides commercially available in the U.S. contain the active ingredient N-9 in a carrier such as a gel, film, cream, foam, suppository, or tablet. N-9 has been reported in some studies to cause irritant and allergic reactions in some users. Although the Conceptrol® product was effective and well-tolerated in the NICHD comparative trial, there were a significantly lower number of drug-related events with the C31G gel and fewer women discontinued the study due to drug-related side effects. In an interview with Reuters Health, lead researcher Dr. Anne E. Burke of The John’s Hopkins School of Medicine stated, “There are concerns with nonoxynol-9, such as vaginal side effects and genital irritation for some users. It seems that C31G might offer improvements in those regards.” C31G does not contain nonoxynol-9 and, if commercialized, may offer a welcome alternative for women who seek a non-hormonal method of contraception. 

C31G previously was the subject of two Phase 3 clinical trials conducted in Africa, supported by Family Health International and the United States Agency for International Development, to determine whether C31G was safe and effective for reducing women’s risk of acquiring HIV infection. The external independent Data Monitoring Committee reviewing those trials concluded in 2005 and 2006 that, while there were no safety concerns based on the results of the studies to date, continuing the trials would not allow the effect of C31G on HIV acquisition to be determined because of a lower than expected rate of HIV seroconversion in the trials. The committee determined that continuation of the trials was not warranted due to a lack of statistical significance between C31G gel and the vehicle control in the interim data. Accordingly, the trials were discontinued.

Adamis estimates that the market for a product with the characteristics of C31G to be in the $500 million range. Dr. Dennis J. Carlo, President and CEO, stated, that “Since the product does not fit in the core business of the company, Adamis is currently evaluating various out-licensing opportunities. We are currently in discussions with multiple organizations that have a focus or business unit in the area of contraception.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has three wholly-owned subsidiaries: Cellegy Holdings, Inc.; Adamis Corporation; and Biosyn, Inc. Adamis Corporation has two wholly-owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Adamis Viral Therapies is focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s ability to successfully develop and market C31G assuming it is approved for marketing by the FDA and other regulatory authorities; regulatory issues or delays with the FDA; and the intellectual property protection that may be afforded by any patents or patent applications relating to C31G. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. These risks and uncertainties include, but are not limited to: whether C31G will be approved for marketing by the FDA and other regulatory authorities; whether the company will be able to obtain required funding to pursue activities relating to C31G; whether C31G is a commercially viable product and can be commercialized, manufactured, and marketed in a cost-effective manner; the extent of consumer demand for any such product; and whether any third party will be interested in entering into agreements relating to development and marketing of C31G. It is uncertain whether C31G will ever be commercialized or whether the company will ever realize revenues therefrom. Certain of these risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

Filed Under: Medical And Healthcare

ICare4autism to Create World’s First Global Autism Research and Education Center

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: ICare4autism

Mayor of Jerusalem Pledges Support in City Hall Ceremony

NEW YORK, NY and JERUSALEM–(Marketwire – December 7, 2010) – The International Center for Autism Research and Education (ICare4autism), a New York-based charity, announced plans to create the world’s first Global Autism Center on Mt. Scopus in Israel, dedicated to catalyzing breakthrough innovation in autism research and treatment. In a ceremony at Jerusalem‘s City Hall hosted by Mayor Nir Barkat, ICare4autism’s President Joshua Weinstein signed an agreement paving the way for ICare4autism to acquire the campus of Bezalel Academy of Art in 2013, and convert it into a center, housing:

  • State-of-the-art autism research facilities to serve as a platform for global collaboration.

  • The world’s first university-level school of autism studies, to raise therapeutic standards worldwide.

  • A model school, applying the latest research, technology and design to the needs of students across the Autistic Spectrum.

  • A foundation to support transformative global collaborations in autism education and treatment.

Joshua Weinstein said, “To tackle the global autism epidemic, we need a community of researchers, educators and advocates that reaches across borders. Our new Center will give us the ability to convene and empower that community.”

Said Dr. Eric Hollander, Chairman of ICare4autism’s Scientific Advisory Council, “The Center will drive the research needed to discover the etiology of autism, ultimately leading to better methods of detection and treatment.”

Said Mayor Barkat, “We welcome ICare4autism’s plan to create a Global Autism Center on Mt. Scopus, and we look forward to the breakthroughs in research that will emanate from its campus to benefit the entire world.”

About Joshua Weinstein, MBA and MA Ed
Mr. Weinstein is the Founder of ICare4autism, which encompasses Shema Kolainu – Hear our Voices School and Center for Children with Autism in New York City, and Tishma – ABA School and Center for Children with Autism in Jerusalem, Israel.

About Dr. Eric Hollander, MD
Dr. Hollander, Chairman of the Advisory Council of ICare4autism, is a renowned psychiatrist on the faculty of Montefiore Medical Center University Hospital of Albert Einstein College of Medicine, former Chair of Psychiatry at the Mt. Sinai School of Medicine and Director of the Seaver and Greater New York Autism Center of Excellence.

id=”nav_links”>

Filed Under: Medical And Healthcare

Radient Pharmaceuticals Announces Formation of New Subsidiary NuVax Therapeutics Inc.

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Radient Pharmaceuticals Corporation

TUSTIN, CA–(Marketwire – December 7, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) in partnership with Jaiva Technologies, today announced the formation of NuVax Therapeutics, Inc. (“NuVax”) — a wholly owned subsidiary of Radient Pharmaceuticals. The formation of NuVax Therapeutics is a strategic move on the part of RPC to enhance the Company’s Q2 2010 collaboration agreement with U.S.-based Jaiva Technologies — a biotechnology company focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products. 

NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilize RPC’s Combined Immunogene Therapy (“CIT”) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer. The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax under the leadership of Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia. Dr. Bhatia’s team will be responsible for engagement with clinical laboratories, hospitals and physicians in multiple international locations; conducting clinical trials for CIT technology; securing government approval for the use of CIT as a cancer therapy and vaccine throughout select markets; expansion and management of stage II clinical trials in multiple international locations including the U.S.; and full commercialization of CIT and all other in-licensed therapies in other select international markets. 

In 2001, RPC acquired CIT for approximately US$2 million in cash. The Company has since invested approximately US$1 million in additional capital for patent protection with a U.S. patent issued May 25, 2004. Developed by Dr. Lung-Ji Chang, CIT is a cancer therapy that works by simultaneously incorporating two genes directly into a patient’s tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang currently serves as a consultant to RPC for the continued development of CIT and other gene therapies.

According to RPC Chairman and CEO Mr. Douglas MacLellan, “The formation of NuVax Therapeutics provides a unique platform to significantly accelerate and expand our planned collaboration with Jaiva Technologies, specifically as it relates to the commercialization of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market. Simultaneously, it allows us to dedicate RPC resources to the continued worldwide commercialization of our Onko-Sure In Vitro Diagnostic cancer test. Together we anticipate success through both Companies to drive long-term growth and shareholder value.”

To support the growth and success of NuVax, RPC and Jaiva Technologies have established an internationally renowned executive and scientific team and board of directors that include RPC Chairman and CEO Mr. Douglas Maclellan, RPC COO and Chief Financial Officer Mr. Akio Ariura, Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia, RPC Board member Mr. Michael Boswell, Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at the University of Florida Gainesville, and Dr. Afsaneh Motamed-Khorasani, Director of Oncology at RPC.

New to the team is Dr. Donald P. Francis — Dr. Francis worked for CDC from 1971 to 1992: smallpox (assigned to WHO) in India, Bangladesh, Sudan and the former Yugoslavia, cholera in Nigeria, Ebola in Sudan, Assistant Director, Hepatitis Division, Assistant Director, Virology Division. From 1981 he worked on HIV/AIDS: Coordinator of Laboratory Activities (Atlanta), Consultant to State of California (Berkeley) and San Francisco Mayor’s office. His AIDS efforts were chronicled in And the Band Played On, by Randy Shilts. In 1993 he joined Genentech where his HIV vaccine work began. In 1995, Dr. Francis co-founded a spin-off of Genentech called VaxGen where the world’s first efficacy trials were completed in the United States, Canada, Holland and Thailand. In 2004, Dr. Francis retired from VaxGen to establish a not-for-profit foundation, Global Solutions for Infectious Diseases, dedicated to developing vaccines for the less developed parts of the world. In 2009, the first successful HIV vaccine trial was reported. That trial used GSID’s vaccine combined in a “prime-boost format” with one from Sanofi. In addition to HIV, Dr. Francis works with international vaccine manufacturers on vaccines for dengue and influenza. He is a frequent consultant for WHO. Dr. Francis is anticipated to serve as an advisor and member of NuVax’s Board of Directors of NuVax.

After completing undergraduate studies at the University of California at Berkeley, Dr. Francis received his M.D. from Northwestern University and his Doctor of Science in Virology from Harvard. In addition, he completed his pediatric training at the University of Southern California Medical Center in Los Angeles and his infectious disease training at Harvard.

About Jaiva Technologies
Jaiva Technologies is a US?based biotechnology company founded by Dr. Umesh Bhatia that is focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel : ) 206.310.5323

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

SEMDA Announces Expanded 2011 Conference

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: SEMDA

Premier Regional Gathering for the Medical Device Industry

ATLANTA, GA–(Marketwire – December 7, 2010) – The Southeastern Medical Device Association’s (SEMDA) 5th annual conference will take place on March 29-30, 2011, adding a half day to the popular medical device event. Recognized as the premier gathering for the Southeast medical device industry, the conference balances presentations by medical device companies to investors with educational programs and networking opportunities.

Specifically designed to meet the needs of medical device industry professionals, the expanded format will allow additional time for educational and panel presentations, as well as one-on-one meetings.

Another addition for 2011 is a Gala Dinner, which will be held on March 29 at the Georgia Tech Hotel and Conference Center. The annual SpotLight Awards, which recognize individuals and companies that have made substantial contributions to the growth of the Southeastern medical device industry, will be presented during the dinner.

This year’s conference will be held at the Georgia Tech Global Learning Center, a midtown Atlanta conference facility that offers more room for presentations and meetings, complemented by state-of-the-art technology capabilities.

Other highlights will include:

  • Keynote presentations from industry leaders
  • Presentations from some of the region’s top existing and emerging medical device companies
  • Workshops on a variety of topics including critical business issues affecting those within the industry
  • Panel discussions by VCs and business development professionals, as well as a CEO Roundtable
  • Numerous industry networking opportunities

For more information about the conference, sponsorship opportunities, presenting company application or registration, visit www.semdaconference.com.

About SEMDA
The Southeastern Medical Device Association (SEMDA) is a non-profit association that supports and promotes the medical device companies in the Southeast. Created in 2004, the association provides a unique resource and networking opportunity for medical device companies, entrepreneurs, inventors, physicians, and investors interested in accelerating the growth of the medical device industry in the Southeast. For more information, visit www.semda.net

Media Contact:
Lyn Hood
Crackerjack Marketing
678-974-2623
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Scottsdale Healthcare Goes Live on STAT DOCTORS eHealth Service as an Employee Health/Wellness Benefit

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Stat Health Services Inc.

STAT DOCTORS to Provide Scottsdale Healthcare Employees With High Quality, Affordable and Convenient Care for Common, Minor Medical Conditions

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – Stat Health Services Inc. and Scottsdale Healthcare announced today that they are offering Stat Health’s innovative STAT DOCTORS™ eHealth service as a supplemental health and wellness benefit for Scottsdale Healthcare’s employees and their covered dependents. 

Scottsdale Healthcare is the city of Scottsdale’s largest employer, operating three hospitals, a cancer center and several ambulatory care facilities with approximately 10,000 covered lives included in its employee medical plan. The agreement is Stat Health Services’ first contract with a major employer.

Like a virtual house call, STAT DOCTORS offers online on-demand care from a physician for many non-emergency minor illnesses or conditions. Effective today, Scottsdale Healthcare is launching the new employee benefit, just in time for the cold and flu season.

“With STAT DOCTORS our health plan participants will have the convenience of online access to board certified emergency physicians for care of common minor medical conditions, any time of the day or night. We believe this will be a popular benefit that our employees will take advantage of when they need care,” says Carol Henderson, senior vice president/chief talent officer for Scottsdale Healthcare.

55 percent of the 114 million visits to an emergency room are for non-emergencies1. STAT DOCTORS leverages the Internet, advanced and proprietary technologies — including secure single sign-on, electronic health records (EHRs), ePrescribing and video conferencing — to bring patients a modern day virtual house call for treating minor medical emergencies.

By offering STAT DOCTORS, employers may benefit from increased employee satisfaction and retention, reduced employee absenteeism and decreased costs. Hospital employers such as Scottsdale Healthcare are also expected to benefit from their employees utilizing the STAT DOCTORS eHealth service for urgent care needs instead of hospital emergency rooms.

“In the past, patients had no choice but to either delay treatment or waste precious time and money waiting in emergency rooms or urgent care centers, exposed to seasonal viruses,” explains Alan C. Roga, M.D., Chairman and CEO of Stat Health. “Our STAT DOCTORS service solves this problem by using advanced technologies to provide convenient access to quality health care, 24 hours a day, 7 days a week.”

1 “Addressing the Problem of Low Acuity Non-Emergent ER Visits,” Mercer Human Resources Consulting, January 2006.

About Scottsdale Healthcare
Scottsdale Healthcare is the community-based, nonprofit parent organization of the Scottsdale Healthcare Osborn Medical Center, Scottsdale Healthcare Shea Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. A leader in medical innovation, talent and technology, Scottsdale Healthcare was founded in 1962 and is based in Scottsdale, Arizona. For more information, visit www.shc.org.

About Stat Health Services Inc.
Stat Health Services Inc. is an eHealth services company. Its STAT DOCTORS™ service provides members convenient and affordable online access to emergency medicine physicians for the diagnosis and treatment of urgent common minor medical conditions. STAT DOCTORS™ brings patients a modern day virtual house call. By providing such features as a secure single sign-on, a virtual waiting room, online medical consultations (eVisits), electronic health records (EHRs), and electronic prescribing (ePrescribing), STAT DOCTORS™ delivers a personalized, secure and superior health care experience. Stat Health’s network of emergency medicine physicians includes top board certified physicians who share a passion for delivering high quality health care, efficiently and effectively, by using the Internet and advanced technologies to treat today’s connected patients. Stat Health is headquartered in Scottsdale, Arizona. For more information, visit www.STATDOCTORS.com.

Media Contacts:
Keith Jones
Scottsdale Healthcare
[email protected]
480-882-4412

Jodi Amendola
Amendola Communications for Stat Health Services Inc.
[email protected]
480-664-8412 ext. 11

Filed Under: Medical And Healthcare

Mitchell International Closes Purchase of Ingenix Property & Casualty Medical Bill Review Business

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Mitchell International

Smooth Leadership and Technology Transition Ensures Successful Integration of Customer Medical Bill Review Operations Into SmartAdvisorTM Medical Bill Review Platform

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty (P&C) claims and Collision Repair industries, today announced the successful close of its purchase of Ingenix’s P&C medical bill review (MBR) business. The purchase places Mitchell Workers’ Compensation Solutions (WCS) business and its SmartAdvisor™ medical bill review platform in a market leadership position, enabling the company to deliver to the insurance and managed care related industries advanced technology solutions with a proven track record of streamlining medical claims operations and improving cost containment.

“Since the intent to purchase the Ingenix MBR business was announced this October 20, Mitchell has experienced broad market acceptance and customer buy-in, the result of a carefully planned business and technology transition strategy that is being deployed within the context of Mitchell’s stable position and long-term experience in the P&C marketplace,” said Nina Smith-Garmon, senior vice president and general manager of the Mitchell Workers’ Compensation Solutions Division.

Smith-Garmon added, “The positive feedback we have received at the recent National Workers’ Compensation and Disability Conference® & Expo indicates that Ingenix P&C MBR customers anticipate a smooth, successful transition to Mitchell and the SmartAdvisor medical bill review technology platform. We will continue to enhance our solution for all our customers by adding to our already-extensive Preferred Provider Organization (PPO) networks and compliance expertise via strategic partnerships and acquisitions.”

Mitchell SmartAdvisor is a comprehensive bill review solution for workers’ compensation that leads the industry in its unique combination of performance software, client services, and best-in-class partnerships. Available through licensed or software-as-a service model, SmartAdvisor’s unique capabilities include customizable workflow modeling, Capstone® business decision rules engine, data analytics and reporting tools, Claims Examiner Portal for fast, secured, real-time access to bill data, and a proven technology platform that delivers on average 50-70% straight-through processing for improved efficiencies and lower costs. Visit www.mitchell.com/smartadvisor for more information or contact Mitchell Workers’ Compensation Solutions directly at 1-800-421-6705 to schedule a demo of the SmartAdvisor bill review system.

About Mitchell International, Inc.
Mitchell International (www.mitchell.com) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction.

About Mitchell Workers’ Compensation Solutions Division
Mitchell Workers’ Compensation Solutions (WCS), a division of Mitchell International, is a leading provider of workers’ compensation cost containment technologies and services. Insurance payers and other clients rely on Mitchell WCS’s best-of-breed medical bill review platform, the SmartAdvisor Software Suite, to improve their medical cost savings results. For more information, please visit www.mitchell.com/smartadvisor.

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

St. Clair Hospital Replaces Scheduling System With Versus RTLS

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Versus Technology, Inc.

TRAVERSE CITY, MI–(Marketwire – December 7, 2010) – St. Clair Hospital Outpatient Surgery Center in Pittsburgh, PA has selected the Versus Advantages Real-time Locating System (RTLS) from Versus Technology, Inc. (Versus) (PINKSHEETS: VSTI) to improve nurse-to-patient assignment and continue automated nurse call cancellation functionality throughout the 34,000 sq. ft. same-day surgical center. The center anticipates an increase in patient volume and looked to RTLS automation to enhance workflow processes.

Versus has provided location information, call cancellation and patient flow to St. Clair for many years. This was primarily to automate a separate system (part nurse call, part scheduling) provided by a nurse call vendor that no longer fully supports the product. The Outpatient Surgery Center genuinely relied on this system for displaying patient and nurse location, assigning nurses to patients and patient readiness. However, the system required manual data entry and is no longer supported.

Working with Intelligent Electronic Systems, Inc. (IES), the local Pittsburgh GE Telligence dealer, Versus designed a new solution for St. Clair which utilizes much of their existing RTLS network, retains well-liked features from their old system and automates several additional features to improve patient care and efficiency. The most notable of these features is Versus’ new Schedule View, which offers caregivers a consolidated view of scheduled appointments and other applicable data. It can be sorted by provider or date, allowing users to filter information relevant to their own responsibilities. This view is an extension of Versus’ Enterprise View, which provides real-time, Glance-and-Go™ clinical information on Floorplans, List Views, Wait Views, etc.

Versus automates nurse-to-patient assignments based on a nurse’s physical presence in the patient room. However, St. Clair’s process required assignment of nurses to patients the night before based on the patient’s acuity and the nurse’s expertise or skill level. The current day’s appointments and assignments are then displayed in a single view. St. Clair’s current system was not equipped to address their pre-staffing requirement, so Versus developed and delivered this capability. Versus receives an inbound HL7 message from St. Clair’s Account Manager Patient Financial Management system allowed current scheduling procedures to be maintained while extending necessary features for nurse pre-assignment and automated nurse notification upon patient arrival.

Additionally, St. Clair’s staff will transition from relying on nurse call lights to determine patient readiness to the web-based Versus Advantages solution. This allows all staff, including those in other departments like radiology or surgery, to determine patient readiness and room availability. Staff will continue to benefit from real-time locating of patients, staff and equipment, as well as wait time alerts and the traditional automated nurse registry and call cancellation that results from Versus’ integration to any nurse call system.

Versus is working closely with St. Clair’s HIS staff (contracted Allscripts employees) and IES to finalize the workflow process that will drive their Enterprise interfaces and communication configurations to pagers.

About St. Clair Hospital
St. Clair Hospital is an independent, acute care facility that provides advanced, high quality health care to more than 400,000 residents of southwestern Pennsylvania. With 525 physicians and more than 2,000 employees, St. Clair is the largest employer in Pittsburgh’s South Hills. Providing virtually every health care service that residents might need throughout their lives, the Hospital combines advanced technologies with exceptional medical expertise to ensure that the community’s health needs are met. For more information, please visit www.stclair.org.

About IES
IES is a life safety sales and service company. They provide Fire Alarm Systems, Nurse Call Systems, CCTV/Security Systems, Access Control Systems, and Fire Alarm Testing/Service Agreements. IES has been chosen by GE Healthcare above all others as their preferred healthcare communication systems company in Southwestern Pennsylvania.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which “bespeak caution,” and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Media Contact:
Versus Technology, Inc.
Stephanie Bertschy
Director of Marketing
877.983.7787
Email Contact

Investor/Analyst Contact:
Versus Technology, Inc.
Joseph Winowiecki
Chief Financial Officer
231.946.5868
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

StepStoneMed Announces Web-Based Virtual Patient Cases — Transforming Medical Education

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: StepStoneMed

Medical Educators Endorse the Virtual Patient Approach as a Highly Effective, Innovative Way to Bridge the Learning Gap Between Textbook and Patient Bedside

HOUSTON, TX–(Marketwire – December 7, 2010) – StepStoneMed™, the emerging leader in innovative solutions for medical education, today announced a new and innovative virtual patient module, Classic Cardiac Codes©. Designed to teach the latest advancements in Advanced Cardiac Life Support (ACLS), Classic Cardiac Codes is a series of web-based interactive lessons designed to teach clinical medicine to students and physicians. The module features ten virtual-patient encounters specifically created to advance learning and retention of some of the most urgent conditions faced by healthcare professionals, regardless of their area of specialization. Traditional resources in medical education and CME are text-based and often dry and boring. StepStoneMed lessons feature memorable, well-developed characters designed to personify the medical conditions they each represent. Learners are guided by the “StepStones,” a navigational progress bar and electronic flashcard system, designed to teach and reinforce the correct sequence of evidence-based medical management decisions. Each case ends with a review of the appropriate protocols, standards of care, and additional resources for the learner. Preliminary studies have demonstrated that medical students using StepStoneMed test at significantly higher levels of mastery and retain their knowledge longer than students depending on traditional methods alone.

Medicine is best learned at the bedside, where book-based facts about diseases, symptoms, and appropriate interventions are translated into patient-based knowledge. Unfortunately, exposure to patients with a variety of conditions is severely limited during traditional medical education. The result is insecure young doctors, inefficient patient care, and escalating costs for diagnostic testing. StepStoneMed has been designed specifically to address this limitation, using the proven educational psychology principles and the latest e-learning technologies.

“This novel approach to medical education incorporates the best of how students, residents and practicing physicians learn. It is interactive, accurate, and simulates the complex way that doctors learn to make decisions in emergency situations. This is a great way to learn how to navigate emergency situations, or to practice these scenarios from time to time to keep these critical skills up to date,” said Mary L. Brandt, MD, Professor and Vice Chair, Michael E. DeBakey Department of Surgery, Baylor College of Medicine.

According to one of StepStoneMed’s founders, David Eagleman, PhD, Department of Neuroscience, Baylor College of Medicine, “This is the future of learning. As neuroscience demonstrates, we learn best when we’re presented with active decision-making, emotional salience, and memorable narrative. These patients — and the lessons they teach — are impossible to forget.”

Caroline Popper, MD, MPH, President, BCM Technologies, Inc., said, “StepStoneMed combines great medical education with innovation in information technology. The confluence of Healthcare and Technology is a major market trend, and BCM Technologies is very excited to work with terrific Baylor entrepreneurs in this company.”

“StepStoneMed bridges the gap from books to bedside with our virtual patients, cleverly designed to personify disease in a memorable way. Our structured guidance through correct diagnosis and intervention protocols ensures effective learning for every medical specialty,” said Cynthia Sheridan, Chief Executive Officer, StepStoneMed. “This new module of cases has been proven to dramatically increase med students’ understanding and long term retention of information.”

StepStoneMed’s interactive learning module, Classic Cardiac Codes, is available today. The module is cost-effective and priced specifically for medical students. For a limited time, students can get two of the cases at no charge by using their medical school email address when they register at www.stepstonemed.com. StepStoneMed modules are also available for academic institutions on a departmental or campus-wide basis.

About StepStoneMed

StepStoneMed was created by a medical student at Baylor College of Medicine, under the mentorship of Professors of Surgery and Neuroscience. Their application is the only virtual patient case tool that offers structured, evidence-based learning in the form of case modules for all the medical specialties. StepStoneMed provides a memorable connection between patient and disease, is readily available to every student over the web, and contains the most current protocols and standards of care.

StepStoneMed is led by a team of seasoned professionals with a unique blend of experience in medicine, medical education, e-learning, software commercialization and serious game design. For more information, visit www.stepstonemed.com.

Media Contact:

Ruth Davidson
StepStoneMed, Inc.
713-795-0105
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Santa’s on His Way… Santa Claus Isn’t Just Bringing Toys This Holiday Season, He’s Also Bringing Happiness to Kids and Families That Are Stricken…

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Hair Fairies

LOS ANGELES, CA–(Marketwire – December 7, 2010) – Announced today, Santa Claus and some very special helpers will be visiting Hair Fairies salons (www.hairfairies.com) nationwide. Santa will be on site every Saturday in December through Christmas to deliver cheer, take photos, listen to wish lists and hand out special treats. The holiday season is upon us and nobody wants it ruined by having to deal with head lice. So, if these bugs happen to find their way into your home, what better way to get rid of them then at one of Hair Fairies unique salons, with the added benefit of meeting jolly ol’ St. Nick. The friendly technicians will work their magic with special techniques and 100% natural, non-toxic products. They will also be discounting many of their all natural Nit-Zapping™ head lice treatment products and up to 50% off your final treatment.

“The holiday season is an important time of year and we want families to be able to enjoy it the best way possible with fun, laughter, and free of lice!” stated Maria Botham, Founder and President of the Hair Fairies brand. “This is also a fun way to give back to the community.”

Hair Fairies, The Head Lice Helpers, the country’s leading head lice brand, has been helping millions of families that are stricken with head lice since 1999. To learn more about Hair Fairies salons and locations, their natural products and to order online, visit www.hairfairies.com. Even if you do not have head lice stop by and visit Santa and learn how you can prevent an outbreak in the future! 

HoHoHo… Happy Holidays from the Hair Fairies staff. 

For more information on the festivities you can
contact one of their salons at their toll free number,
Hair Fairies
1-877-285-0069

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Allied Healthcare International Inc. Reports Fiscal 2010 Fourth Quarter and Year-End Results

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Allied Healthcare International Inc.

Fiscal 2010 Revenues Increased 8.0%, at Constant Exchange Rates; Fiscal 2010 Operating Income Increased 7.7%, at Constant Exchange Rates & Excluding Acquisition Costs

NEW YORK, NY–(Marketwire – December 7, 2010) – Allied Healthcare International Inc. (NASDAQ: AHCI), a leading provider of flexible healthcare staffing services in the
United Kingdom, today issued financial results for its fiscal 2010 fourth
quarter and year-ended September 30, 2010.

To provide investors with a better understanding of the Company’s
performance and because of fluctuations in foreign exchange rates, Allied
is discussing its revenues, gross profit, selling, general & administrative
(SG&A) expenses and operating income at constant exchange rates, which are
calculated using the comparable prior period weighted average exchange
rates. In addition, as the Company’s revenues and gross profit from our
principal operations are denominated in pounds sterling but reported in
United States dollars, an analysis, which is contained in the Historical
Revenues and Gross Profit table at the end of this press release, is
included of the last eight quarters’ revenues and gross profit in pounds
sterling to enable investors to fully understand the underlying trends over
these periods without the effects of currency exchange rates.

Fiscal Fourth Quarter Results

              Three Months Ended
                 September 30,         Three Months Ended September 30,
            -----------------------  -------------------------------------
                                %                                     %
              2010     2009   Change   2010     %      2009     %   Change
            -------- -------- ------ -------  -----  -------- ----- ------
                    Revenues                     Gross Profit
            ------------------------ -------------------------------------

(Amounts in
 thousands)
Homecare    $64,244  $ 58,388  10.0% $19,934   31.0% $ 17,893  30.6%  11.4%
Nursing
 Homes        4,998     6,568 -23.9%   1,641   32.8%    2,070  31.5% -20.7%
Hospitals     5,120     4,889   4.7%   1,326   25.9%    1,233  25.2%   7.5%
            -------  -------- -----  -------         --------        -----
Total, at
 constant
 exchange
 rates       74,362    69,845   6.5%  22,901   30.8%   21,196  30.3%   8.0%
Effect of
 foreign
 exchange    (3,945)        -  -5.6%  (1,189)               -         -5.6%
            -------  -------- -----  -------         --------        -----
Total, as
 reported   $70,417  $ 69,845   0.8% $21,712         $ 21,196          2.4%
            =======  ======== =====  -------         --------        -----


                                                     SG&A
                                     -------------------------------------
SG&A, at
 constant
 exchange
 rates &
 excluding
 acquisition
 costs                               $19,033         $ 17,010         11.9%
Acquisition
 costs, at
 constant
 exchange
 rates                                   157                -          0.9%
                                     -------         --------        -----
SG&A, at
 constant
 exchange
 rates                                19,190           17,010         12.8%
Effect of
 foreign
 exchange                               (946)               -         -5.6%
                                     -------         --------        -----
Total SG&A,
 as reported                         $18,244         $ 17,010          7.3%
                                     -------         --------        -----


                                               Operating Income
                                     -------------------------------------
Operating
 income, at
 constant
 exchange
 rates &
 excluding
 acquisition
 cost                                $ 3,868         $  4,186         -7.6%
Acquisition
 costs, at
 constant
 exchange
 rates                                  (157)               -         -3.8%
                                     -------         --------        -----
Operating
 income, at
 constant
 exchange
 rates                                 3,711            4,186        -11.3%
Effect of
 foreign
 exchange                               (243)               -         -5.8%
                                     -------         --------        -----
Operating
 income, as
 reported                            $ 3,468         $  4,186        -17.2%
                                     =======         ========        =====


                                       Net Income Attributable to Allied
                                     -------------------------------------
                                              Basic           Basic
                                               and             and
                                             Diluted         Diluted
                                               EPS             EPS
                                     -------------------------------------
Income from continuing
 operations attributable
 to Allied, excluding
 acquisition costs                   $ 2,858  $0.07  $  2,937 $0.07
Acquisition Costs                       (146) -0.01         -     -
                                     -------  -----  -------- -----
Income from continuing
 operations attributable
 to Allied                           $ 2,712  $0.06  $  2,937 $0.07
                                     =======  =====  ======== =====

For the fourth quarter of fiscal 2010, total revenue increased 6.5%, to
$74.4 million, compared with $69.8 million reported during the same period
in fiscal 2009. Allied’s Homecare revenue grew 10.0% to $64.2 million. The
acquisition completed in our third fiscal quarter contributed 7.5%, or $4.4
million, to the increase in Homecare revenues. Nursing Homes revenue
declined 23.9% to $5.0 million and Hospitals revenue increased 4.7% to $5.1
million. After the unfavorable impact of currency exchange of $3.9 million,
revenue increased 0.8% year over year to the reported $70.4 million.

Total gross profit for the fourth fiscal quarter increased 8.0% to $22.9
million, from $21.2 million for the comparable quarter in fiscal 2009.
Homecare gross profit grew 11.4% to $19.9 million. The acquisition
completed in our third fiscal quarter contributed 7.6%, or $1.4 million, to
the increase in Homecare gross profit. Nursing Homes gross profit declined
20.7% to $1.7 million and Hospitals gross profit increased 7.5% to $1.3
million. Gross profit as a percentage of revenue was 30.8%, compared with
30.3% for the comparable prior-year period. Foreign exchange decreased
gross profit by $1.2 million to the reported $21.7 million for the 2010
fourth fiscal quarter.

SG&A, excluding acquisition costs, for the fourth fiscal quarter was $19.0
million (25.6% of revenues), an increase of 11.9%, from $17.0 million
(24.4% of revenues) reported last year. The acquisition completed in our
third fiscal quarter contributed 6.4%, or $1.0 million, to the increase in
SG&A. The Company also incurred acquisition costs of $0.1 million.
Foreign exchange decreased costs by $0.9 million to the reported $18.2
million for the 2010 fourth fiscal quarter.

Operating income, before acquisition costs, for the fourth quarter of
fiscal 2010 decreased by 7.6% to $3.9 million from $4.2 million a year ago.
Acquisition costs decreased operating income by $0.1 million. Foreign
exchange decreased operating income by $0.3 million to the reported $3.5
million for the 2010 fourth fiscal quarter.

Income from continuing operations attributable to Allied, excluding
acquisition costs, for the fourth quarter of fiscal 2010 was $2.9 million,
or $0.07 per diluted share. Income from continuing operations attributable
to Allied for the fourth quarter of fiscal 2010 was $2.7 million, or $0.06
per diluted share, compared with $2.9 million, $0.07 per diluted share,
reported during the 2009 fourth fiscal quarter.

Fiscal 2010 Full Year Results

            Year Ended September 30,       Year Ended September 30,
            ------------------------ -------------------------------------
                                %                                     %
              2010     2009   Change   2010     %      2009     %   Change
            -------- -------- ------ -------  -----  -------- ----- ------
                    Revenue                      Gross Profit
            ------------------------ -------------------------------------

(Amounts in
 thousands)
Homecare    $231,718 $203,885  13.7% $71,314   30.8% $ 63,176  31.0%  12.9%
Nursing
 Homes        18,469   25,863 -28.6%   5,971   32.3%    8,097  31.3% -26.3%
Hospitals     19,571   20,062  -2.4%   4,618   23.6%    5,075  25.3%  -9.0%
            -------- -------- -----  -------         --------       ------
Total, at
 constant
 exchange
 rates       269,758  249,810   8.0%  81,903   30.4%   76,348  30.6%   7.3%
Effect of
 foreign
 exchange      1,321        -   0.5%     402                -          0.5%
            -------- -------- -----  -------         --------       ------
Total, as
 reported   $271,079 $249,810   8.5% $82,305         $ 76,348          7.8%
            ======== ======== =====  -------         --------       ------


                                                    SG&A
                                     -------------------------------------
SG&A, at
 constant
 exchange
 rates &
 excluding
 acquisition
 costs                               $67,776         $ 63,234          7.2%
Acquisition
 costs, at
 constant
 exchange
 rates                                   752                -          1.2%
                                     -------         --------        -----
SG&A, at
 constant
 exchange
 rates                                68,528           63,234          8.4%
Effect of
 foreign
 exchange                                318                -          0.5%
                                     -------         --------        -----
Total SG&A,
 as reported                         $68,846         $ 63,234          8.9%
                                     -------         --------        -----


                                                 Operating Income
                                     -------------------------------------
Operating
 income, at
 constant
 exchange
 rates &
 excluding
 acquisition
 cost                                $14,127         $ 13,114          7.7%
Acquisition
 costs, at
 constant
 exchange
 rates                                  (752)               -         -5.7%
                                     -------         --------        -----
Operating
 income, at
 constant
 exchange
 rates                                13,375           13,114          2.0%
Effect of
 foreign
 exchange                                 84                -          0.6%
                                     -------         --------        -----
Operating
 income, as
 reported                            $13,459         $ 13,114          2.6%
                                     =======         ========        =====


                                       Net Income Attributable to Allied
                                     -------------------------------------
                                              Basic            Basic
                                               and              and
                                             Diluted          Diluted
                                               EPS              EPS
                                     -------------------------------------
Income from continuing
 operations attributable to
 Allied, excluding
 acquisition cost                    $10,624  $0.24  $  9,936 $0.22

Acquisition costs                       (756) -0.02         -     -
                                     -------  -----  -------- -----
Income from continuing
 operations attributable to
 Allied                              $ 9,868  $0.22  $  9,936 $0.22
                                     =======  =====  ======== =====

For the year ended September 30, 2010 total revenue increased 8.0%, to
$269.8 million, compared with $249.8 million for the same period in fiscal
2009. Allied’s Homecare revenue grew 13.7% to $231.7 million. The
acquisition completed in the third quarter of fiscal 2010 contributed 3.2%,
or $6.5 million, to the increase in Homecare revenues. Nursing Homes
revenue declined 28.6% to $18.5 million and Hospitals revenue declined 2.4%
to $19.6 million. After the favorable impact of currency exchange of $1.3
million, revenue increased 8.5% year over year to the reported $271.1
million for fiscal 2010.

Total gross profit for the year ended September 30, 2010 increased 7.3% to
$81.9 million, from $76.3 million for the comparable period in fiscal 2009.
Homecare gross profit grew 12.9% to $71.3 million. The acquisition
completed in our third fiscal quarter contributed 3.1%, or $2.0 million, to
the increase in Homecare gross profit. Nursing Homes gross profit declined
26.3% to $6.0 million and Hospitals gross profit declined 9.0% to $4.6
million. Gross profit as a percentage of revenue was 30.4%, compared with
30.6% for the comparable prior-year period. Foreign exchange increased
gross profit by $0.4 million to the reported $82.3 million for fiscal 2010.

SG&A, excluding acquisition costs, for the year ended September 30, 2010
was $67.8 million (25.1% of revenues), an increase of 7.2%, from $63.2
million (25.3% of revenues) reported last year. The acquisition completed
in our third fiscal quarter contributed 2.4%, or $1.5 million, to the
increase in SG&A. We also incurred acquisition costs of $0.7 million.
Foreign exchange increased costs by $0.3 million to the reported $68.8
million for fiscal 2010.

Operating income, before acquisition costs, for the year ended September
30, 2010 increased by 7.7% to $14.1 million from $13.1 million a year ago.
Acquisition costs decreased operating income by $0.7 million. Foreign
exchange increased operating income by $0.1 million to the reported $13.5
million for fiscal 2010.

Income from continuing operations attributable to Allied, excluding
acquisition costs, for the year ended September 30, 2010 was $10.6 million,
or $0.24 per diluted share. Income from continuing operations attributable
to Allied for the year ended September 30, 2010 was $9.9 million, or $0.22
per diluted share, compared with $9.9 million, $0.22 per diluted share,
reported during fiscal 2009.

At September 30, 2010 and September 30, 2009, Allied cash balance was $39.0
million (£24.7 million) and $35.3 million (£22.2 million), respectively,
represent an underlying increase in the cash balance of $3.7 million (£2.5
million).

For the year ended September 30, 2010, depreciation and amortization was
$4.4 million (£2.8 million), capital expenditures were $2.8 million (£1.8
million). Days Sales Outstanding was 26 days at September 30, 2010 (43 days
including unbilled account receivables), and 25 days at September 30, 2009
(40 days including unbilled account receivables).

Management Discussion

Sandy Young, Chief Executive Officer of Allied, commented, “Allied’s
financial performance during the fourth quarter reflects tightening in the
U.K. government’s spending and challenging macroeconomic factors. The
acquisition of Homecare business in Ireland contributed $4.4 million to
Allied’s top line during the quarter, resulting in 10% growth of our
Homecare revenue compared to the fourth quarter a year ago. Excluding the
acquisition, our Homecare revenue grew 2.5% year over year, with an 11.5%
increase in continuing care.

“In order to reduce the U.K. government’s fiscal deficit, following its
Comprehensive Spending Review, HM Treasury announced in October 2010 its
plans to achieve a significant reduction in public spending. While the U.K.
government has stated that it will increase spending in the National Health
Service over the next four years to support healthcare, we note the
increase will be partially offset as the NHS have increased obligations and
cost of treatments going forward due to the growing population and demand
for better healthcare. However, the Comprehensive Spending Review will
also allocate £2 billion a year of additional funding by 2014-15 to support
social care. Combined with a program of reform and efficiency savings,
such as greater use of personal budgets, the U.K. government believes this
should mean local authorities should be able to improve outcomes and should
not need to reduce eligibility for services.

“The Comprehensive Spending Review also announced significant cuts in
funding to local authorities, the main providers of social care, and other
public bodies, which are a key source of revenue to Allied. Individual
local authorities will decide which of their back office costs and front
line services to allocate savings to.

“Based on the current and anticipated changes in the U.K. government’s
policies, we believe that it is possible that demand will be flat on a
consecutive basis for the near term. However, due to Allied’s favorable
position in the industry, strong reputation and innovative business
approach, we expect to return to growth in the mid-term.

“Allied is in a good position to benefit from joint commissioning of health
and social care. For example:

-- Within our homecare revenue, we have over $159 million (£102 million) in
   social care revenue, $57.7 million (£37 million) in continuing care
   revenue and $13.3 million (£8.5 million) in learning disability revenue;
-- We are introducing new Primary Care Trust services this year. They will
   include our night roaming service, our end of life services and other
   specialist health services;
-- We are winning extra care contracts, a potentially new revenue stream;
-- We are looking at new homecare solutions, including
   Telecare/Telehealth; and
-- We are extending the boundaries of the care and supported living we
   provide to include children's services and services for drug and alcohol
   abuse.  Some of these require rental housing to be part of the package.

“Although we anticipate that there will be continuing tension in spending,
we believe that councils and PCTs are likely to:

-- Outsource more than they do at present, particularly in Scotland, Wales
   and Ireland;
-- Have the ability to get incremental savings by directing greater volumes
   to providers of scale like Allied;
-- Keep individuals out of hospital and in their own homes;
-- Favor lower cost homecare over more  expensive residential care;
-- Pursue new and quite entrepreneurial services around the end of life
   pathway; and
-- Still need to provide for the increasing numbers of elderly each year.

“So today, Allied can claim to be one of the leading providers of health
and social care in the U.K., and we continue to expand our market
footprint. During the fourth quarter and in subsequent months we won a
number of domiciliary care framework contracts, the two largest being:

-- East Sussex County Council -- Up to 2,000 hours per week for four years,
   which commenced November 2010.
-- Cardiff City Council -- Up to 2,000 hours per week for three years,
   commencing April 2011.

“In addition we have won a community homecare contract with Leeds City
Council and NHS, and a contract for nursing supplied with Welsh Health
Supply. We have also seen a number of positive wins in continuing care from
framework agreements, including Doncaster and an additional opportunity in
Sheffield.

“In a consistent pursuit of improving and expanding our value proposition,
we continued to make investments in our operational infrastructure. To
date, 55 of our branches are live on Coldharbour, and the software rollout
is continuing according to plan. Our customer complaints and risk
management system, which was built in house, is currently under testing and
is planned to go live at the beginning of calendar 2011. Additionally, we
are actively working on several other projects, such as call monitoring,
carer retention and the centralization of our on-call out of hours service.
We also piloted our recruitment screening and compliance department project
in Wales and have received very positive feedback. Our recruitment pipeline
tracker is undergoing design changes for full rollout to the business in
the near future.

“In summary, Allied is well positioned to capitalize on the growing elderly
population, shift from residential to homecare services and the move
towards joint commissioning of health and social care,” concluded Mr.
Young.

Dr. Jeffrey Peris, Chairman of Allied, commented, “The Board remains
confident in the opportunities for growth through management actions on
innovative initiatives. Based on our identified strategies for growth
being successfully implemented, our financial track record over the last
few years, our focus and results in improving operating efficiencies, and
the recruitment and retention of talented people — we continue to strive
to enhance shareholder value.”

Conference Call Information: December 7, 2010 at 10:00 AM Eastern Time /
3:00 PM UK Time

Allied will host a call and webcast today at 10:00 AM Eastern Time / 3:00
PM UK Time, to discuss its financial results. To join the call, please dial
(877) 407-8031 for domestic participants and (201) 689-8031 for
international participants. Participants may also access a live webcast of
the conference call through the “Investors” section of Allied Healthcare’s
Website: www.alliedhealthcare.com. A telephone replay will be available for
two weeks following the call by dialing (877) 660-6853 for domestic
participants and (201) 612-7415 for international participants. When
prompted, please enter account number 286 and conference ID number 360782.
A webcast replay will also be available and archived on the Company’s
website for ninety days.

Reconciliation of GAAP and Non-GAAP Data

In addition to disclosing results of operations that are determined in
accordance with generally accepted accounting principles (“GAAP”), this
press release also discloses non-GAAP results of operations that exclude or
include certain charges. These non-GAAP measures adjust for foreign
exchange effects and acquisition costs. Management believes that the
presentation of these non-GAAP measures provides useful information to
investors regarding the Company’s results of operations, as these non-GAAP
measures allow investors to better evaluate ongoing business performance.
Investors should consider non-GAAP measures in addition to, and not as a
substitute for, financial measures prepared in accordance with GAAP. A
reconciliation of the non-GAAP measures disclosed in this press release
with the most comparable GAAP measures are included in the financial tables
included in this press release.

ABOUT ALLIED HEALTHCARE INTERNATIONAL INC.

Allied Healthcare International Inc. is a leading provider of flexible
healthcare staffing services in the United Kingdom. Allied operates a
community-based network of approximately 115 branches with the capacity to
provide carers (known as home health aides in the U.S.), nurses, and
specialized medical personnel to locations covering approximately 90% of
the U.K. population. Allied meets the needs of private patients, community
care, nursing and care homes, and hospitals. For more news and information
please visit: www.alliedhealthcare.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release may be forward-looking
statements. These forward-looking statements are based on current
expectations and projections about future events. Actual results could
differ materially from those discussed in, or implied by, these
forward-looking statements. Factors that could cause actual results to
differ from those implied by the forward-looking statements include:
general economic and market conditions; the effect of the change in the
U.K. government and the impact of proposed changes in recent policy making
related to health and social care that may reduce revenue and
profitability; the impact of the HM Treasury Comprehensive Spending Review
2010 setting out the U.K. government’s plans to reduce spending; Allied’s
ability to continue to recruit and retain flexible healthcare staff;
Allied’s ability to enter into contracts with local government social
services departments, NHS Trusts, hospitals, other healthcare facility
clients and private clients on terms attractive to Allied; the general
level of demand and spending for healthcare and social care; dependence on
the proper functioning of Allied’s information systems; the effect of
existing or future government regulation of the healthcare and social care
industry, and Allied’s ability to comply with these regulations; the impact
of medical malpractice and other claims asserted against Allied; the effect
of regulatory change that may apply to Allied and that may increase costs
and reduce revenues and profitability; the effect of existing or future
government regulation in relation to employment and agency workers’ rights
and benefits, including changes to National Insurance rates and pension
provision; Allied’s ability to use net operating loss carry forwards to
offset net income; the effect that fluctuations in foreign currency
exchange rates may have on our dollar-denominated results of operations;
and the impairment of goodwill, of which Allied has a substantial amount on
the balance sheet, may have the effect of decreasing earnings or increasing
losses. Other factors that could cause actual results to differ from those
implied by the
forward-looking statements in this press release include those described in
Allied’s most recently filed SEC documents, such as its most recent annual
report on Form 10-K, all quarterly reports on Form 10-Q and any current
reports on Form 8-K filed since the date of the last Form 10-K. Allied
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events, or
otherwise.

ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)


                                         Year Ended  Year Ended  Year Ended
                                         September   September   September
                                          30, 2010    30, 2009    30, 2008
                                         ----------  ----------  ---------
Revenues:
    Net patient services                 $  271,079  $  249,810  $ 298,577
                                         ----------  ----------  ---------

Cost of revenues:
    Patient services                        188,774     173,462    208,192
                                         ----------  ----------  ---------

          Gross profit                       82,305      76,348     90,385

Selling, general and administrative
 expenses                                    68,846      63,234     77,655
                                         ----------  ----------  ---------

          Operating income                   13,459      13,114     12,730

Interest income                                 361         537        935
Interest expense                                (30)       (110)      (542)
Foreign exchange loss                          (210)       (197)      (586)
                                         ----------  ----------  ---------

          Income before income taxes
           and discontinued operations       13,580      13,344     12,537

Provision for income taxes                    3,524       3,408      3,751
                                         ----------  ----------  ---------

          Income from continuing
           operations                        10,056       9,936      8,786
                                         ----------  ----------  ---------

Discontinued operations:
Income from discontinued operations,
 net of taxes                                     -         367          -
                                         ----------  ----------  ---------

Net income                                   10,056      10,303      8,786

Less:  Net income attributable to
 noncontrolling interest                       (188)          -          -
                                         ----------  ----------  ---------

Net income attributable to Allied
 Healthcare International Inc.           $    9,868  $   10,303  $   8,786
                                         ==========  ==========  =========

Amounts attributable to Allied
 Healthcare International Inc.:
          Income from continuing
           operations, net of tax        $    9,868  $    9,936  $   8,786
          Discontinued operations,
           net of tax                             -         367          -
                                         ----------  ----------  ---------
          Net income                     $    9,868  $   10,303  $   8,786
                                         ==========  ==========  =========

Basic earnings per share - attributable
 to Allied Healthcare International Inc.
 common shareholders
          Income from continuing
           operations                    $     0.22  $     0.22  $    0.20
          Income from discontinued
           operations                             -        0.01          -
                                         ----------  ----------  ---------
Net income attributable to Allied
 Healthcare International Inc. common
 shareholders                            $     0.22  $     0.23  $    0.20
                                         ==========  ==========  =========

Diluted earnings per share - attributable
 to Allied Healthcare International Inc.
 common shareholders
          Income from continuing
           operations                    $     0.22  $     0.22  $    0.19
          Income from discontinued
           operations                             -        0.01          -
                                         ----------  ----------  ---------
Net income attributable to Allied
 Healthcare International Inc. common
 shareholders                            $     0.22  $     0.23  $    0.19
                                         ==========  ==========  =========

Weighted average number of common
 shares outstanding:
          Basic                              44,796      44,986     44,986
                                         ==========  ==========  =========
          Diluted                            45,009      45,011     45,078
                                         ==========  ==========  =========





ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

                                              September 30,  September 30,
                                                  2010           2009
                                              -------------  -------------
                          ASSETS

Current assets:
  Cash and cash equivalents                   $      39,031  $      35,273
  Accounts receivable, less allowance for
   doubtful accounts of $732 and $839,
   respectively                                      20,092         19,594
  Unbilled accounts receivable                       13,393         11,572
  Deferred income taxes                                 552            389
  Prepaid expenses and other assets                   1,943          1,188
                                              -------------  -------------
         Total current assets                        75,011         68,016

Property and equipment, net                           8,924          7,756
Goodwill                                            102,945         95,649
Other intangible assets, net                          3,501          1,646
                                              -------------  -------------
         Total assets                         $     190,381  $     173,067
                                              =============  =============

       LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Accounts payable                            $       1,581  $       1,186
  Current maturities of debt and capital leases         614              -
  Accrued expenses, inclusive of payroll and
   related expenses                                  25,897         24,304
  Taxes payable                                       2,310            201
                                              -------------  -------------
         Total current liabilities                   30,402         25,691

Long-term debt and capital leases, net of
 current maturities                                     389              -
Deferred income taxes                                 1,534            103
Other long-term liabilities                             308              -
                                              -------------  -------------
         Total liabilities                           32,633         25,794
                                              -------------  -------------

Commitments and contingencies

Noncontrolling interest                               4,358              -
                                              -------------  -------------

Shareholders' equity:
  Preferred stock, $.01 par value; authorized
   10,000 shares, issued and outstanding - none           -              -
  Common stock, $.01 par value; authorized
   80,000 shares, issued 45,721 and 45,571
   shares, respectively                                 457            456
  Additional paid-in capital                        242,478        241,555
  Accumulated other comprehensive loss              (15,267)       (14,418)
  Accumulated deficit                               (68,158)       (78,026)
                                              -------------  -------------
                                                    159,510        149,567
  Less cost of treasury stock (2,150 and 585
   shares, respectively)                             (6,120)        (2,294)
                                              -------------  -------------
         Total shareholders' equity                 153,390        147,273
                                              -------------  -------------
         Total liabilities and shareholders'
          equity                              $     190,381  $     173,067
                                              =============  =============





ALLIED HEALTHCARE INTERNATIONAL INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

                                        Year Ended  Year Ended  Year Ended
                                        September   September   September
                                         30, 2010    30, 2009    30, 2008
                                        ----------  ----------  ----------
Cash flows from operating activities:
  Net income                            $   10,056  $   10,303  $    8,786
  Adjustments to reconcile net income
   to net cash provided by operating
   activities:
    Income from discontinued operations          -        (367)          -
    Depreciation and amortization            3,108       2,590       3,231
    Amortization of intangible assets        1,324       1,252       1,634
    Foreign exchange (gain) loss               (43)          7           -
    Increase (decrease) in provision for
     allowance for doubtful accounts            30         360        (167)
    Loss on sale of fixed assets                31          20         166
    Stock based compensation                   636         537         812
    Deferred income taxes                       61         117          88
  Changes in operating assets and
   liabilities, excluding
   the effect of businesses acquired
   and sold:
    Decrease (increase) in accounts
     receivable                                 82      (4,281)      1,579
    (Increase) decrease in prepaid
     expenses and other assets              (1,544)      2,318      (3,488)
    Increase (decrease) in accounts
     payable and other liabilities           2,260       2,867      (3,779)
                                        ----------  ----------  ----------

      Net cash provided by continuing
       operations                           16,001      15,723       8,862
      Net cash used in discontinued
       operations                                -           -        (561)
                                        ----------  ----------  ----------
      Net cash provided by operating
       activities                           16,001      15,723       8,301
                                        ----------  ----------  ----------

Cash flows from investing activities:
  Capital expenditures                      (2,768)     (2,850)     (3,344)
  Acquisition of controlling interest,
   net of cash acquired                     (5,680)          -           -
  Proceeds from sale of business held in
   escrow and designated for debt
   repayment                                     -         116      53,638
  Proceeds from sale of property and
   equipment                                    73           1          50
  Payments on acquisitions payable               -      (1,082)          -
                                        ----------  ----------  ----------

      Net cash (used in) provided by
       investing activities                 (8,375)     (3,815)     50,344
                                        ----------  ----------  ----------

Cash flows from financing activities:
  Repayments of debt and capital lease
   obligations                                (152)          -           -
  Payments under revolving loan, net             -           -     (24,664)
  Borrowings (payments) under invoice
   discounting facility, net                   255           -      (4,458)
  Principal payments on long-term debt           -           -     (23,678)
  Proceeds from sale of interest rate
   swap agreements                               -           -         617
  Treasury shares acquired                  (3,826)          -           -
  Stock options exercised                      288           -           -
                                        ----------  ----------  ----------

      Net cash used in financing
       activities                           (3,435)          -     (52,183)
                                        ----------  ----------  ----------

Effect of exchange rate on cash               (433)     (2,834)       (504)
                                        ----------  ----------  ----------

Increase in cash                             3,758       9,074       5,958

Cash and cash equivalents, beginning of
 year                                       35,273      26,199      20,241
                                        ----------  ----------  ----------

Cash and cash equivalents, end of year  $   39,031  $   35,273  $   26,199
                                        ==========  ==========  ==========

Supplemental cash flow information:
  Cash paid for interest                $       30  $      405  $    1,143
                                        ==========  ==========  ==========

  Cash paid for income taxes, net       $    1,459  $    1,102  $    4,872
                                        ==========  ==========  ==========

Supplemental disclosure of non-cash
 investing and financing activities:
  Capital expenditures included in
   accrued expenses and other long-term
   liabilities                          $      609
                                        ==========

  Details of business acquired in
   purchase transactions:
    Fair value of assets acquired       $   12,319
                                        ==========

    Liabilities assumed or incurred     $    2,715
                                        ==========

    Noncontrolling interest             $    3,888
                                        ==========

    Cash paid for acquisitions          $    5,716
    Cash acquired                               36
                                        ----------

    Net cash paid for acquisitions      $    5,680
                                        ==========





ALLIED HEALTHCARE INTERNATIONAL INC.
HISTORICAL REVENUES AND GROSS PROFIT
(In thousands, except foreign exchange rate)
(Unaudited)


                                             Revenues

                             Q4           Q3           Q2           Q1
                            2010         2010         2010         2010
                        ------------ ------------ ------------ ------------

Homecare                  GBP 39,255   GBP 38,323   GBP 35,860   GBP 35,903
Nursing Homes                  3,048        2,731        2,864        3,261
Hospitals                      3,114        2,933        3,235        3,330
                        ------------ ------------ ------------ ------------
Total                     GBP 45,417   GBP 43,987   GBP 41,959   GBP 42,494
Foreign Exchange rate           1.55         1.49         1.56         1.63
                        ------------ ------------ ------------ ------------
                        $     70,417 $     65,748 $     65,530 $     69,384
                        ============ ============ ============ ============


                                           Gross Profit

                              Q4           Q3           Q2           Q1
                             2010         2010         2010         2010
                        ------------ ------------ ------------ ------------

Homecare                  GBP 12,188   GBP 11,651   GBP 11,083   GBP 11,041
Nursing Homes                  1,002          882          931        1,033
Hospitals                        812          696          755          712
                        ------------ ------------ ------------ ------------
Total                     GBP 14,002   GBP 13,229   GBP 12,769   GBP 12,786
Foreign Exchange rate           1.55         1.49         1.56         1.63
                        ------------ ------------ ------------ ------------
                        $     21,712 $     19,768 $     19,948 $     20,877
                        ============ ============ ============ ============


                                             Revenues

                             Q4           Q3           Q2           Q1
                            2009         2009         2009         2009
                        ------------ ------------ ------------ ------------

Homecare                  GBP 35,763   GBP 34,162   GBP 30,858   GBP 30,620
Nursing Homes                  3,986        3,716        4,159        4,808
Hospitals                      2,956        2,914        3,448        3,612
                        ------------ ------------ ------------ ------------
Total                     GBP 42,705   GBP 40,792   GBP 38,465   GBP 39,040
Foreign Exchange rate           1.64         1.55         1.44         1.58
                        ------------ ------------ ------------ ------------
                        $     69,845 $     63,103 $     55,334 $     61,528
                        ============ ============ ============ ============


                                           Gross Profit

                             Q4           Q3           Q2           Q1
                            2009         2009         2009         2009
                        ------------ ------------ ------------ ------------

Homecare                  GBP 10,951   GBP 10,525    GBP 9,753    GBP 9,487
Nursing Homes                  1,257        1,187        1,298        1,477
Hospitals                        745          679          874          973
                        ------------ ------------ ------------ ------------
Total                     GBP 12,953   GBP 12,391   GBP 11,925   GBP 11,937
Foreign Exchange rate           1.64         1.55         1.44         1.58
                        ------------ ------------ ------------ ------------
                        $     21,196 $     19,173 $     17,166 $     18,813
                        ============ ============ ============ ============

Allied Healthcare International Inc.
Sandy Young
Chief Executive Officer
Paul Weston
Chief Financial Officer
+44 (0) 17 8581 0600

Or

ICR, LLC
Sherry Bertner
Managing Director
+1 646 277 1200
[email protected]

Filed Under: Facilities And Providers

The Global Awards Announces 2010 Winners; Grand Global Awards Go to Taxi Canada & McCann Healthcare Worldwide Japan

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: New York Festivals

The Global Awards Hosts Award Presentations in New York City and Sydney, Australia

NEW YORK, NY–(Marketwire – December 7, 2010) –   The Global Awards®, honoring the “World’s Best Healthcare Advertising™,” announced its 2010 award winners Monday, December 6th at a cocktail party held at the Eli Klein Gallery in New York. The competition will host two award presentations this year, taking the celebrations globally to New York, USA and Sydney, Australia. This year’s GrandJury® awarded two prestigious Grand Global Awards, one to Taxi Canada, and the second to McCann Healthcare Worldwide Japan, as well as 31 Global Awards and 115 Finalist Certificates. 

The Global Awards presentation in New York began with a cocktail reception and hors d’oeuvres; attendees viewed a print and video showcase of the “World’s Best Healthcare Advertising™.” Global Awards Executive Director Michael Demetriades and Global Awards Advisory Board Chairman & Draft FCB Healthcare Chairman Emeritus Tom Domanico presented the trophies to the 2010 award winners. Mr. Domanico commented on this year’s entries, “Each year I’m more impressed with the quality of the work submitted for judging. It speaks volumes about the talent in the Healthcare industry.”

The GrandJury awarded Taxi, of Toronto Canada, the prestigious Grand Global Award for “Antiquing/Strolling/Reading” for client Viagra, winning in Television Advertisement “Communication to the Consumer/Patient.” The premise of the award-winning commercials — when couples stop having sex, they fill the void with other couple activities that can end up taking over their lives; with the help of Viagra, these couples were able to get back into the bedroom again. 

Taxi’s Chief Creative Officer Steve Mykolyn accepted the award in New York and commented, “It’s great to win a Grand Global Award. This win is doubly great for TAXI and Pfizer because the work being recognized for Viagra had two things going for it; a fantastic insight, plus the power to entertain, even with repeated viewings. Make that three things. The campaign also had a positive impact on sales.”

Creative credits for “Antiquing/Strolling/Reading” include: Darren Clarke, Executive Creative Director; Nathan Montieth, Art Director/Writer; Stefan Wegner, Writer/Art Director; and Eugene Marchio, Agency Producer. In addition to the Grand Global Award, Taxi also received a Global Award for “Antiquing” for client Viagra.

McCann Healthcare Worldwide Japan was awarded the coveted Grand Global Award for “It’s Easy” for client Saizen (easy pod) Merck Serono, winning in New Product Launch “Communication to the Healthcare Professional.” The award-winning video illustrates a simple delivery device to administer human growth hormone and features a young girl dancing as she evolves into a woman. Creative credits include: Hajime Nakazawa, Creative Director & Copywriter; Yasutoshi Yamamoto, (Aoyama Creative Studio) Agency Producer; as well as Dee Drive’s Director Wataru Takeishi and Producer Yuko Niwa.

The United States was awarded 10 Global Awards: American Academy of Orthopaedic Surgeons for “Wounded in Action: An Art Exhibition of Orthopaedic Advancements”; Blue Shield of California for “Shield Helps”; CAHG for “Takeda Unbranded Convention Booth” for client Takeda Pharmaceuticals; Crowley Webb and Associates for “Risk Files Poster Campaign” for client Praxis; DeSantis Breindel for “Improving the Health and Health Care of All Americans: A Film About the Robert Wood Johnson Foundation” for client The Robert Wood Johnson Foundation; GSW Worldwide for “When the Body Attacks Itself Campaign” and “When the Body Attacks Itself Photography” for client Kalbitor; PALIO and ZEMOGA for “The Health Tweeder” for client The Health Tweeder. And Seiden was awarded two Global Awards, one for “The Book of Brave” for client Shire Pharmaceuticals, and a second for “Working Harder” for client Visiting Nurse Service of New York.

The 2010 Global Awards GrandJury recognized winners from 17 countries around the world. The United Kingdom received 5 Global Awards: Langland took the lead and was awarded 4 Global Awards receiving trophies for “Kogenate Self Infusion Mailer” for client Kogenate; “Real Danger” for client Pfizer; “Stalevo Dose Tool” for client Stalevo; and “Let’s Work” for Boehringer Ingelheim Oncology. In addition, Random42 Medical Animation was awarded the Global Award for “A Biotechnology Pioneer” for client Amgen Oncology; and RTC Europe was honored for “Siemens Global POS System” for Siemens Audiologische Technik GmbH.

In addition to Taxi Canada receiving both the Grand Global Award and Global Award for client Viagra, LXB Canada was also awarded a Global Award for “Sydney” for client Synagis.

Belgium, Germany, India, Italy, Spain, Sweden, and Switzerland each were honored with one Global Award. Norvell Jefferson Productions Belgium was honored with the Global Award for “The Making of Protein Therapies” for client Genzyme; Young & Rubicam GmbH Germany was awarded the Global Award for “Stairs” for BFF (Counseling for sexually abused or threatened women); McCann Healthcare Mumbai, India was awarded the Global Award for “Marriage/Study/Drive/Fly/Pleasure/Mother” for client Epilex Chromo; Sudler & Hennessey Italy garnered a Global Award for “From Science to Life” for client MIO, i.e. Milano International Oncology; HC BCN Spain was honored with a Global Award for “Bubbles” for client Aerored; Animech Sweden was acknowledged for “The Unknown Mr. Parkinson” for client EPDA; and Euro RSCG Zürich, Switzerland was recognized for “Quick Sex” for Swiss Health Department.

A Global Awards ceremony will also be held on Wednesday, December 8th in Sydney, Australia presented by The Global Awards and Bravo!, a group of Australian healthcare professionals, with representation from healthcare agencies, and the Communications Council of Australia. The evening will begin with a cocktail reception and canapés at Sydney’s Simmer on the Bay, located on historic Walsh Bay. Award winners and their guests will view a showcase of 2010’s winning work, followed by an award ceremony presented by International Awards Group President, Michael O’Rourke. Award Winners will be posted at www.theglobalawards.com following the event.

Judging sessions for this year’s Global Awards were hosted by the following prominent international agencies: McCann Erickson Sydney, Australia; Ogilvy Healthworld London, England; Pharmacom Barcelona, Spain; Topin & Associates Chicago, USA; Trademark DM Melbourne, Australia; and at The Global Awards headquarters in New York, USA. 

Now in its 16th year, The Global Awards receives entries from healthcare corporations, hospitals, advertising agencies, production companies, and design studios that produce communications for medical, pharmaceutical, and healthcare related products. The Global Awards Advisory Board and GrandJury are comprised of a panel of prominent international industry experts, representing the top creative minds in the field of healthcare advertising. 

All winning entries are featured at: www.theglobalawards.com, and are promoted by our network of representatives in 75 countries around the world.

All press inquiries are welcome and should be directed to Gayle Mandel: [email protected]. Phone 212 643 4800.

About the Global Awards
Now in their sixteenth year, The Global Awards are recognized as the only awards dedicated to excellence in healthcare communications on an international basis. 

International Awards Group International Awards Group (IAG) organizes advertising and programming competitions for the following brands: AME Awards® for the World’s Most Effective Advertising™; Midas Awards® for the World’s Best Work in Financial Marketing & Advertising™; The Global Awards® for the World’s Best Healthcare Advertising™; New York Festivals®; World’s Best Advertising™; World’s Best Radio Programs™ and World’s Best Television & Films™. Entries to each of the competitions are judged around the world by panels of peers in their respective industries. Founded in 1957, IAG and their brands now have representation in 75 countries. For more information, go to www.InternationalAwardsGroup.com.

Contact:
Gayle Mandel
International Awards Group
260 West 39
th Street, 10th Floor
New York, NY 10018
212 643-4800
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

CONMED Corporation Awarded Multiple Contracts With HealthTrust Purchasing Group

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: CONMED Corporation

UTICA, NY–(Marketwire – December 7, 2010) – CONMED Corporation (NASDAQ: CNMD) announced today that HealthTrust Purchasing Group, LP (HealthTrust), a leading healthcare group purchasing organization, recently awarded three separate, multi-year purchasing agreements with two of CONMED’s business units, Linvatec and Endoscopic Technologies.

CONMED Linvatec’s agreement enables HealthTrust members to purchase CONMED’s advanced endoscopic imaging products featuring state-of-the-art True HD™ technology. Products included in this agreement include the IM4000 autoclavable camera and image capture systems. 

CONMED reached a separate agreement with HealthTrust for its high-quality line of Enteral Feeding systems that feature the Entake™ family of products. In addition, the parties extended an existing agreement for CONMED Endoscopic Technologies’ extensive line of Gastroenterology (GI) products. Key products covered in this agreement include the Beamer™ System CE600, which is a GI specific electrosurgical/argon plasma generator with related accessories, as well as advanced biliary products such as the Gore Viabil® and Flexxus® metal stents.

“HealthTrust is nationally recognized for its membership’s strong commitment to purchasing products that consistently deliver enhanced clinical outcomes,” said Mr. Joseph J. Corasanti, President and CEO of CONMED. “We are extremely pleased that this large, high-quality group purchasing organization has recognized the unique advantages of our imaging, feeding and GI product offerings.”

ABOUT HEALTHTRUST PURCHASING GROUP

HealthTrust Purchasing Group, LP, headquartered in Brentwood, Tenn., is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as 10,600 ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than $17 billion, HealthTrust is committed to obtaining the best price for clinically recommended products, ensuring their timely delivery, and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. The website is www.healthtrustpg.com.

ABOUT CONMED CORPORATION

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of arthroscopy, gastroenterology, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and pulmonology. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations. The website is www.conmed.com.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company’s ability to devise and execute strategies to respond to market conditions

CONTACT:
CONMED Corporation
Robert Shallish
Chief Financial Officer
315-624-3206

FD
Investors:
Brian Ritchie
212-850-5600

Filed Under: Facilities And Providers

MYA Moves Into its AMAZING New Clinic in Bristol!

Posted on December 7, 2010 Written by Annalyn Frame

LEEDS, UNITED KINGDOM–(Marketwire – Dec. 7, 2010) – Cosmetic surgery is booming all over the UK, especially in the thriving West Country. MYA have seen a good level of new enquiries for the Bristol region over the last couple of years and with over five thousand enquiries since the launch of the company, MYA have decided to open a flagship clinic in the area.

John Ryan, Chairman of MYA and key industry figurehead, comments, “We’re really happy to move into our own building. This will really allow us to deliver the quality of care we’re famous for and put the ‘MYA touch’ on the new clinic.”

Amy Lansdown, manager of MYA Bristol said, “We’re really excited to have our new clinic. We’ve settled in nicely and since it’s just off Whiteladies Road, it’s a place that everyone knows about!”

Breast enlargement continues to be the most popular procedure enquired about in Bristol with other procedures following closely behind.

The top five procedure enquiries for Bristol are:

  • Breast Enlargement
  • Fat Removal/Liposuction
  • Nose Re-shaping
  • Tummy Tuck
  • Breast Uplift

With MYA’s successful Advanced Laser Liposuction launch in late October, the company is continually expanding and the new Bristol clinic is a great example of this. The new clinic is in a traditional Victorian-style building, boasting four floors, nine consulting rooms and a spacious reception area. “The new clinic and consulting rooms really allow for a cosy, personal feel when we’re meeting and chatting with our patients. The patients who have visited us in our new clinic absolutely love the traditional exterior and the modern, contemporary décor. It all adds to the truly amazing MYA experience” says Amy.

“We pride ourselves on providing a patient orientated service and we strive to offer the best care possible which includes having modern, comfortable clinics filled with helpful, friendly MYA staff” Says John. “We’re glad to be a part of this historic city’s culture and lifestyle and we hope you come and visit us soon.”

For more information about MYA Cosmetic Surgery visit the website www.mya.co.uk.

Notes to editors:

MYA Profile

MYA (Make Yourself Amazing) Cosmetic Surgery Ltd is a pioneering cosmetic surgery provider brought to you by John Ryan, the former owner of Transform Medical Group. John has over 25 years experience and has returned to cosmetic surgery enlisting the experience of the very best cosmetic surgeons and medical professionals in the industry. MYA pride themselves on their commitment to high quality service and medical supplies and have a comprehensive after-care policy. MYA’s world class expertise, competitive finance and state of the art national consultation centres are designed to ensure that Making Yourself Amazing is a reassuringly unique experience.

Filed Under: Facilities And Providers

Medistem Announces New Management Team

Posted on December 7, 2010 Written by Annalyn Frame

SOURCE: Medistem Inc.

Internationally Renowned Drug Developers Join Adult Stem Cell Company

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Vladimir Bogin as President and Chairman of the Board, Dr. Sergey Sablin as Vice President and Board Member, and Vladimir Zaharchook as Vice Chairman of the Board and Board Member. These changes were brought about as the result of a stock purchase agreement changing majority ownership of the company. 

“Dr. Sablin, who has a track record of excellence in drug discovery and development, is a founder of Selena Pharmaceuticals and a co-founder of Medivation, companies that advanced Dimebon, a Phase III technology that resulted in a deal with Pfizer with an over $200 million in the upfront payment. Dr. Bogin, a licensed physician with training from Brown and Yale, founded the contract research organization (CRO) Cromos Pharma, and has held Director-level positions with Big Pharma. Mr. Zaharchook is a successful businessperson and strategist. I am happy to entrust the future of our company in the hands of these experienced professionals,” said Dr. Neil Riordan, founder and former President and Chairman of Medistem, who resigned along with board member Dr. Roger Nocera as part of the acquisition. Dr. Riordan remains a shareholder and collaborator of Medistem. 

Medistem was founded in 2005 by Dr. Riordan as a developer, licensor, and licensee of adult stem cell therapeutics. To date technologies developed by Medistem have been used in more than 900 patients internationally. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation as part of its filed IND BB-13898 covering the use of Medistem’s “Endometrial Regenerative Cell” (ERC) product in patients at risk of amputation. 

ERC are a novel stem cell population isolated from menstrual blood that the company has demonstrated is capable of generating heart, brain, lung, liver, pancreatic, bone, muscle, blood vessel and cartilage tissue. Advantages of ERC include: a) lack of need for donor matching, allowing for “off the shelf” use; b) ability to be injected intravenously; and c) economical production in large scale.

“Dr. Riordan has pioneered the development of practical stem cell based products for treatments of debilitating conditions ranging from Multiple Sclerosis, to Duchenne Muscular Dystrophy, to Heart Failure. The intellectual property portfolio for these products, which are the basis of Medistem’s US-based developmental efforts, provide a deep pipeline of therapeutic candidates,” said Dr. Bogin.

“In contrast to companies who perform research for the sake of research, Medistem’s technologies are actually benefitting patients today, unfortunately only outside of the US. I was attracted to Medistem’s desire to make these treatments available to patients through the tried and tested FDA regulatory route,” said Mr. Zaharchook.

“The fact that Medistem’s ERC cells can be shipped to any facility in the US and administered without need for complex cell processing or injection procedures makes this stem cell product very attractive from a commercialization perspective,” said Dr. Sablin.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact:
Dr. Vladimir Bogin
President and Chairman
Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
858 349 3617
858 642 0027
www.medisteminc.com

id=”nav_links”>

Filed Under: Medical And Healthcare

TeamStaff, Inc. to Present at the Third Annual LD MICRO Investor Conference

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: TeamStaff Inc.

SOMERSET, NJ–(Marketwire – December 6, 2010) – TeamStaff, Inc. (NASDAQ: TSTF), a leading logistics and healthcare services provider to the Federal Government and Department of Defense announced today that its President and Chief Executive Officer, Mr. Zach Parker, will deliver a presentation to investors at the Third Annual LD MICRO Conference on Thursday, December 9, 2010 at 3:00pm PST. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, California. A copy of the presentation will be made available in the Investor Relations section of the TeamStaff website (http://teamstaff.com/investor-relations) and also furnished as an exhibit to a Current Report on Form 8-K to be filed by the Company with the SEC.

“I’m pleased to present the TeamStaff story at this year’s LD MICRO investor conference as we believe we have laid the proper foundation to facilitate growth especially into adjacent markets with new customers, like the DoD. I am thankful to participate in this investor conference and I am looking forward to meeting with attendees who specifically have an interest in microcap companies,” said Zach Parker, Chief Executive Officer of TeamStaff.

“We are very pleased to have TeamStaff present at our third annual event,” said Chris Lahiji, President of LD MICRO. “I take pride in having an event that showcases companies of all sizes, in all industries. TeamStaff is a great addition to our roster this year.”

For more information on the conference or to register for the event, please visit http://www.ldmicro.com or call (408) 457-1042.

About TeamStaff, Inc.

TeamStaff serves clients and their employees throughout the United States as a full-service provider of logistics and healthcare support services. TeamStaff specializes in providing high quality healthcare, logistics, and technical services to Federal agencies and the Department of Defense. For more information, visit the TeamStaff corporate web site at www.teamstaff.com or the TeamStaff Government Solutions web site at www.teamstaffgs.com.

This press release contains “forward-looking statements” as defined by the federal securities laws and involve numerous risks and uncertainties. TeamStaff’s actual results could differ materially from those described in such forward-looking statements as a result of such risks and uncertainties. For a discussion of such risks and uncertainties, see “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities Exchange Commission. The information in this release should be considered accurate only as of the date of the release. 

CONTACTS:

Zachary C. Parker,
President and Chief Executive Officer
John E. Kahn,
Chief Financial Officer
TeamStaff, Inc.
1 Executive Drive
Somerset, NJ 08873
866-352-5304

Donald C. Weinberger/Diana Bittner (media)
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500
[email protected]
[email protected]

Filed Under: Medical And Healthcare

Free Guide From Metro Home Health Care Now Available

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: Metro Home Health Care

DEARBORN, MI–(Marketwire – December 6, 2010) – This year, more than 170,000 Michigan residents receive home-delivered health care from home health care providers, who make over 5 million home visits each year.

Many patients and their families prefer that their loved ones recuperate and/or receive rehab services for surgery, an injury or an acute illness in the comfort and familiar surroundings of their own homes. Trained clinicians, nurses, and therapists are able to provide the same level of attentive, compassionate and personalized in-home care as can be found outside.

Choosing a provider can often be a daunting and frustrating task. To aid the public, Dearborn-based Metro Home Health Care, a leading home health care provider in Michigan, is offering at no cost a Home Health Care Guide that provides basic information for people seeking a home health care agency.

The free booklet may be downloaded from the Metro Home Health Care website, www.metrohomehealthcare.com.

“We think the booklet offers specific things to look for in selecting a home health care agency, and what questions to ask before you make a decision,” said Dr. Agustin V. Arbulu, CEO of Metro Home Health Care. “Our mission has always been to provide best care available to the sick, the elderly or those recovering from surgery in their homes.”

Today’s home care professionals, volunteers, and modern medicine make it possible for people to stay in their homes longer and enjoy an improved quality of life.

Home health care has grown far beyond basic or simple professional nursing and home care aide services. Modern home care agencies like Metro Home Health Care offer a comprehensive scope of services including skilled nursing, physical, occupational, speech therapies, medical social work services, specialty wound care nursing, dietary education, and personal care.

“Metro Home Health Care always has the goal of independence in mind when caring for our neighbors,” said Arbulu.

Home care services are paid for by public and private sources, or directly by patients and their families. Medicare and state-run Medicaid are significant payers and often pay 100 percent of home health services for patients who qualify for such services. Third-party payers include commercial insurance, managed care organizations, and workers’ compensation. Despite deep cuts in government funding, home care continues to be the preferred means of receiving quality health care services for millions of Americans.

With offices in five cities covering 10 counties, Metro Home Health Care provides comprehensive in-home and supportive services for the entire Michigan lower peninsula to acute and chronically ill patients and their families. For more information, please call 313-336-6303 or 800-462-5632, or visit www.metrohomehealthcare.com.

CONTACT:
Barrett Kalellis
Shazaaam! Public Relations
248-366-0388
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Resurrection Health Care Preferred Doctors Earn 42 out of 44 Possible Stars in Blue Cross Blue Shield 2010 Blue Star Report

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: Resurrection Health Care

CHICAGO, IL–(Marketwire – December 6, 2010) – Physicians in three out of four medical groups of Resurrection Health Care Preferred (RHCP) have earned 11 blue stars — a perfect score — in the 2010 Blue Star Report. The report is a ranking of HMO contracting medical group physicians that have documented high levels of performance in providing patient care from Blue Cross Blue Shield of Illinois (BCBSIL). The Resurrection Health Care Preferred groups earning 11 stars are: Saint Joseph Health Preferred, Saint Mary and Elizabeth Health Preferred and Saint Francis Health Preferred. One group, Resurrection Health Preferred, earned 9 out of 11 stars.

Of the 96 Chicagoland medical groups surveyed, only eight received all 11 blue stars, three of which were part of Resurrection Health Care Preferred. All of the Resurrection Health Care Preferred medical groups received the Blue Ribbon designation — awarded for high patient satisfaction. All of the patients who had RHCP doctors rated their overall satisfaction with their doctor at above 91%.

The medical group’s doctors earn a blue star every time they meet or exceed the target care goal in each of the eleven reporting categories, including asthma care, breast cancer screenings, cardiovascular disease, childhood immunizations, controlling high blood pressure, colorectal screenings, diabetes care, influenza vaccinations, mental health follow-up, cervical cancer screenings and patient safety.

For more information about making Resurrection Health Care Preferred your choice for all your health care needs, call 773-572-8300 and ask for Member Services or visit us at http://www.reshealth.org/findadoctor/why_rhcp.cfm

Resurrection Health Care is the largest Catholic health care system in Chicago with over 100 sites of care. http://www.reshealth.org/

Follow us on Twitter: http://twitter.com/RHC_Outpatient
Visit our YouTube channel: http://www.youtube.com/user/ResurrectionHealth
Join us on Facebook: http://www.facebook.com/pages/Resurrection-Health Care/73879323438?ref=ts  

CONTACT:
Kristy Lockhart
Resurrection Health Care
773-951-5282

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

IT&E International Named Top Veteran-Owned Small Business Contract Staff Supplier by Amgen Supplier Diversity Program

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: IT & E International, Inc.

THOUSAND OAKS, CA and POTTSTOWN, PA–(Marketwire – December 6, 2010) –  Amgen Inc. (NASDAQ: AMGN) http://www.amgen.com awarded IT&E International http://www.iteinternational.com/ top honors as Veteran-Owned Small Business Contract Staff Supplier in its Supplier Diversity Program.

According to Audrey Porter, IT&E International Vice President, “A special flag-raising ceremony at Amgen’s Thousand Oaks, California headquarters hosted by the Supplier Diversity program was attended by Rocky Chavez, California Secretary of Veteran Affairs, Debbie Gregory Co-Chair of the Veteran and Military Business Owners Association, Ryan Funderburg of IT& E International, and senior Amgen leadership.

“We are extremely grateful to Amgen for this recognition,” continued Ms. Porter, “and appreciate the opportunities to help the company make significant strides in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses,” she said.

About Amgen’s Supplier Diversity Program

Amgen has established a Supplier Diversity Program to ensure that small businesses are not excluded from participating in the supply of goods and/or services required by Amgen. Amgen is committed to identifying and awarding contracts to small, disadvantaged, women-owned businesses consistent with Amgen’s requirements. Amgen strives to identify, develop, and utilize small, disadvantaged, veteran, disabled veteran, and women-owned business enterprises, as well as Historically Underutilized Business Zones (HUBZone), in our procurement program. Amgen’s intent is to support economic development efforts to the extent that jobs may be provided, entrepreneurship may be advanced, and useful goods and/or services may be procured at competitive prices.

About IT&E International

IT&E International offers global regulatory compliance and validation services throughout the product development lifecycle. Consulting services include regulatory planning, providing skilled personnel for development operations, data management to ensure FDA compliance, and validation of new pharmaceutical manufacturing facilities. IT&E International provides our qualified, technical employees to work at pharmaceutical, biotech and life sciences organizations site under client supervision in FDA regulated areas. The company is headquartered at 1610 Medical Drive, Suite 210Pottstown, PA 19464; tel: (610) 340-2012; fax: (610) 340-2007; www.iteinternational.com

Filed Under: Medical And Healthcare

Integrium Celebrates 12 Years Helping Clients Achieve Clinical Trial Success

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: Integrium

In Over 150 Clinical Trials to Date, Clients Have Consistently Exceeded Patient Enrollment Goals While Reducing Costs

TUSTIN, CA–(Marketwire – December 6, 2010) – In its 12 year history, cardiovascular, dermatology and metabolic CRO Integrium has developed and managed over 150 successful clinical trials for clients, consistently beating patient enrollment goals and reducing costs. Integrium provides a therapeutic focus based on deep experience in cardiovascular, dermatological and metabolic trials of all sizes in regions around the world. On the basis of this experience the company offers a full range of services that combine innovative cutting-edge science and technology with practical clinical operations and involve working hands-on with clients, investigators and vendors to deliver high quality service with a sense of immediacy.

Integrium’s smaller size enables it to be far more nimble, and develop a personal rapport and trust with its clients in a way that “mega CROs” simply cannot. 2011 will mark the beginning of Integrium’s 13th year in this highly competitive market, a year the company will usher in with a large cadre of return clients and a team of passionate employees whose dedication is underscored by some of the lowest employee turnover in the business. Its exceptional performance recently caught the attention of the prestigious British pharmaceutical industry journal Scrip Clinical Research, which included Integrium in a cover story on specialty CROs, citing the launch of its dermatological practice as an example of a niche strategy worth watching.

Key Integrium Milestones/Metrics

  • 12-year anniversary
    • Founded in 1998 by clinical research thought leaders Dr. David H.G. Smith, MD and Dr. Joel M. Neutel, MD. Dr. Smith and Dr. Neutel continue to lead the company today.
    • Established formal alliances with regional partner CROs in Europe, Australia and India, with numerous additional Integrium locations in North America and South Africa
  • 150 successful clinical trials for clients
    • Tightened patient enrollment timelines dramatically and reduced study spend for clients such as Graceway Pharmaceuticals and Resverlogix
    • Consistently differentiated itself by demonstrating a deep understanding of the complexities and nuances of clinical research in its three core focus therapeutic areas: cardiovascular disease, metabolic disease and dermatology
    • Underscoring its success in these trials, 63% of Integrium’s business is with clients for whom it has managed clinical trials before
  • Added Dermatology Clinical Research Group in June 2010
    • Helps Integrium clients design scientifically rigorous yet feasible dermatology studies, leveraging its relationships with reliable, high-quality investigators to help identify and recruit study patients, and effectively manage their studies from start to finish
    • Led by noted dermatology drug development expert Dr. Mary Spellman
  • In a business where qualified, motivated professionals are critical to success and turnover is high, Integrium has some of the lowest turnover in the industry, with over 90% of the team remaining intact

Commentary
Dr. David Smith, MD, Founding Partner and Chief Medical Officer, Integrium: “Patient recruitment, enrollment and retention continue to represent a critical bottleneck in clinical research and drug development. We are proud of the results we’ve achieved with clients like Graceway and Resverlogix to ensure that they have the patient subjects they need to get the highest-quality data to run better, safer trials.”

Eileen McAuley, RN, BS, MPA, Chief Operating Officer, Integrium: “We take our mission statement seriously, focusing on integrity as a core value. This translates into our dedication to personalized service from the start of a client’s clinical trial to its completion, rigorous scientific protocols, and unyieldingly high research standards. We are not striving to be the biggest CRO — just the best.”

Dr. Sharon Levy, MD, Senior Vice President of Product Development, Graceway Pharmaceuticals: “Integrium’s keen understanding of our specific therapy areas allows us to stay focused on our primary trial objectives. For a multi-center Phase 2 trial they helped us enroll and randomize many more patients than we thought possible — and did so with a very small drop-out rate and 19 weeks ahead of schedule.”

Dr. Allan Gordon, MD, Ph.D, Senior Vice President, Clinical Development, Resverlogix: “Integrium understands that trial efficiencies come from the ground up. The services team understood that we required a ‘true’ partnership and that success would come from understanding our needs and the complexities inherent in running a 40-site study — and their results exceeded our expectations. That they reduced our cycle so dramatically — by nearly six months — allowed us to come in under budget and see the site results we hoped for.”

Resources

  • Press release announcing successful trials with Graceway Pharmaceuticals and Resverlogix
  • Press release announcing launch of Dermatology Clinical Research Group
  • Overview of Integrium’s expertise as a cardiovascular, dermatology and metabolic CRO
  • Follow Integrium on LinkedIn

About Integrium, LLC
Integrium is a therapeutically-focused, full-service contract research organization that specializes in dermatology, cardiovascular and metabolic clinical research. It has a strong reputation for delivering high-quality management of global clinical development programs and service to its clients. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology, and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit http://www.integrium.com.

Contact:
Randy Wambold
CHEN PR
781-672-3119
Email Contact

Filed Under: Medical And Healthcare

University of Colorado Hospital Selects InterSystems Ensemble for Enterprise Integration

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: InterSystems

Innovative Hospital Evolves From Legacy Integration Platform to Ensemble Technology

CAMBRIDGE, MA–(Marketwire – December 6, 2010) – InterSystems Corporation, the global leader in software for connected healthcare, today announced that the University of Colorado Hospital (UCH) has chosen the InterSystems Ensemble® rapid integration and development platform for enterprise-wide integration.

InterSystems specializes in advanced integration, database, and business intelligence technologies for breakthrough applications. UCH is recognized as one of the leading hospitals in the nation and is consistently recognized among the top hospitals in the country by U.S. News & World Report. Most recently, UCH has been cited as one of the top 10 academic medical centers in the country based on quality, patient safety and patient satisfaction, according to the 2010 Quality and Accountability Performance Scorecard, released by the University HealthSystems Consortium.

Strategy Change Drives Integration Platform Search

“For years, our strategy had been tied to the best-of-breed concept, which resulted in a very decentralized system with more than 150 unique interfaces,” said Peggy Dalious, UCH Applications Director. “Then, we made the decision to move to the InterSystems CACHÉ-based Epic Systems electronic health record application, which required major alterations to our IT plans.”

“We recognized that the integration engine represented a key piece of our infrastructure before we entered what is going to be a mass application overhaul,” Dalious continued.

The change in strategy came at a time when UCH was increasingly uneasy about its legacy integration platform, noted Dalious. The acquisition of the product’s company by another vendor, followed by the acquisition by yet another vendor, added a layer of complexity to working with the product.

“Our interface engineers had heard about Ensemble and thought it might be the right integration option for UCH,” Dalious said. After extensive research and interaction with multiple Ensemble customers, “we had a strong, sensible case for moving to Ensemble.”

The foundation for the Ensemble transition was developed based on a proof-of-concept project. UCH specified two difficult interfaces that would have to be built via Ensemble for the POC. InterSystems reviewed the interfaces onsite and defined the requirements, with UCH software specialists building the interfaces under the guidance of the InterSystems team.

Moving Forward on Solid Foundation

Following the success of the proof-of-concept, UHC has gone live with approximately 35 Ensemble-based interfaces with a core group of applications including human resources and ERP systems that will not be replaced by the Epic implementation. Plans are to go live in 1Q11 with the Epic ambulatory clinics application with Epic outpatient and inpatient modules and a total of about 85 interfaces rolling out through 3Q11.

“We’re already beginning to see how we can use other Ensemble capabilities once the interface migration from the legacy platform is complete,” Dalious said. “We know that features such as workflow management and business activity monitoring are available in Ensemble and we plan to take advantage of those facilities in the future.”

“Ensemble delivers the advanced technology required for strategic breakthroughs like the one now being realized by UCH,” said Paul Grabscheid, InterSystems Vice President of Strategic Planning. “As the healthcare industry continues to rapidly evolve, we are committed to partnering with our customers who leverage our software to optimize care delivery.”

About InterSystems

InterSystems Corporation is a global software technology leader with headquarters in Cambridge, Massachusetts, and offices in 23 countries. InterSystems provides advanced software technologies for breakthrough applications. InterSystems CACHÉ® is a high performance object database that makes applications faster and more scalable. InterSystems Ensemble® is a seamless platform for integration and the development of connectable applications. InterSystems HealthShare™ is a platform that enables the fastest creation of an Electronic Health Record for regional or national health information exchange. InterSystems DeepSee™ is software that makes it possible to embed real-time business intelligence capabilities in transactional applications.

InterSystems is the world’s #1 vendor of database and integration technologies for healthcare applications. InterSystems products are used by thousands of hospitals and labs worldwide, including all 14 hospitals on the Honor Roll of America’s Best Hospitals as rated by U.S. News and World Report. For more information, visit InterSystems.com.

About University of Colorado Hospital

University of Colorado Hospital is the Rocky Mountain region’s leading academic medical center, and has been recognized as one of the United States’ best hospitals, according to U.S. News & World Report. It is best known as an innovator in patient care and often as one of the first hospitals to bring new medicines to patients’ bedsides. Located at the Anschutz Medical Campus in Aurora, Colo., the hospital’s physicians are affiliated with the University of Colorado School of Medicine, part of the University of Colorado system. For additional information, go to www.uch.edu.

Editorial Contacts
Rita Shoor
Shoor & Company
(803) 699-0710
[email protected]

Maureen Flaherty
InterSystems
(617) 621-0600
[email protected]

Filed Under: Medical And Healthcare

Mitchell International and CoreChoice Execute Comprehensive Services Agreement

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: Mitchell International

Leading Medical Bill Review Software & Services Provider Joins With the Nation’s Fastest Growing “Super Specialty” Network to Provide Comprehensive Radiological Services to 1st and 3rd Party Claims Payors

SAN DIEGO, CA and NEW YORK, NY–(Marketwire – December 6, 2010) – Mitchell International, Inc., a leading provider of information, workflow and performance management solutions to the Property & Casualty claims and Collision Repair industries and CoreChoice, the nation’s fastest growing specialty network devoted entirely to radiological services today announced the execution of a multi-year contract. Claims professionals, via Mitchell DecisionPoint®, the leading medical bill management solution for 1st and 3rd party liability claims handlers, can now access the depth and breadth of the CoreChoice radiology network; which includes highly specialized services such as MRI (Open and Closed), Mammography, Sonogram, X-Ray, Nuclear Medicine services and CT, PET and Bone Scan services. This provides for an enhanced ability for insurers to ensure maximum value delivered to policyholders within their coverage limits via the benefits of pre-negotiated contract rates with CoreChoice facilities.

“CoreChoice is an established leader in the provision of a broad set of high quality radiological services,” said Dave Torrence, Senior Vice President and General Manager, Mitchell International. “Our relationship with CoreChoice is a natural and synergistic extension of the capabilities of both of our organizations to the benefit of our customers, who elect to implement CoreChoice, and — most importantly — to injured parties. We know and understand that specialized procedures, including radiological services are driving costs up nationally and we’re excited about extending our capabilities in offering CoreChoice.”

Mitchell is pleased to provide additional benefits for its customers through this new agreement with CoreChoice, including:

  • The service and quality of care results they demand in their claims handling organizations via the ability to provide injured parties — including those who might not otherwise have convenient access to such an extensive range of top quality radiological services — the benefit of more than 6,000 CoreChoice imaging centers throughout the nation, including Washington D.C. and Puerto Rico;
  • Maximum efficiency and productivity of claim handlers. DecisonPoint provides a “single source solution” enabling claims professionals to save time by reducing the use of a variety of disparate claims handling solutions as well as the high amounts of manual processing often required to access the benefits of specialty medical networks;
  • Elimination of billing negotiations as medical billings from CoreChoice facilities are quickly paid via pre-established contractual rates; and
  • A fully integrated and modern medical bill review technology solution that is compliant with standard HIPAA and ANSI X12 data transmission requirements.

Accessibility to CoreChoice networks via Mitchell’s state-of-the-art bill review offerings provides CoreChoice network members significant expansion opportunities. “There is exponential growth in the use of radiological procedures in healthcare,” said Steven F. Gass, Chief Executive Officer, CoreChoice. “CoreChoice is dedicated to providing injured parties the highest quality radiological services available and our Mitchell relationship offers us significant opportunities to expand our reach to assist injured parties to receive prompt, effective, proper and reasonably priced medical care.”

About Mitchell DecisionPoint

Mitchell DecisionPoint® is the leading medical bill management solution for 1st and 3rd party liability claims handlers reviewing more than 13 million medical bills each year representing more than $11 billion in medical provider billed charges. DecisionPoint is in use by more than 40 top US property casualty insurers including 8 of the 10 largest automobile insurers representing more than 60 percent of direct written premium in the personal auto lines market.

About Mitchell International, Inc.

Mitchell International (Mitchell) is a leading provider of information and workflow solutions to the Property & Casualty claims and Automotive Collision Repair industries. The company’s comprehensive solution portfolio streamlines the entire auto physical damage, bodily injury and workers’ compensation claims processes. Mitchell enables millions of electronic transactions between more than 30,000 business partners each month to enhance partner productivity, profitability, and customer satisfaction. For more information please visit www.mitchell.com

About CoreChoice

CoreChoice combines the talents and expertise of medical, technology, and insurance industry professionals to provide a new level of radiology network service. Our philosophy is to provide the largest radiology specialty network in the United States with fair and equitable pricing as well as a prompt pay mechanism for our participating network facilities. For more information please visit www.corechoice.net.

Filed Under: Medical And Healthcare

PEMF Therapy Now Available at Breakthrough Price for Veterinary Applications

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: BioElectronics Corporation

HealFast® Therapy Quick Relief Loop Announced at the 56th Annual AAEP (American Association of Equine Practitioners) Convention

BALTIMORE, MD–(Marketwire – December 6, 2010) – eMarkets Group LLC, the distributor of HealFast® Therapy, disposable drug-free anti-inflammatory medical devices manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), today announced the introduction of a new Quick Relief Loop. The Quick Relief Loop will be available at the breakthrough price of $15.00 for 100 hours of continuous pain relief therapy. 

The new product is on display this week at the annual convention of the American Association of Equine Practitioners in Baltimore.

“The award-winning BioElectronics team has made cost-reduction engineering improvements that enable the breakthrough new pricing,” said Mary K. Whelan, President of eMarkets Group. “BioElectronics technology was cited by the Wall Street Journal as one of the best innovations of 2009. Now the Quick Relief Loop pricing makes cost-effective, drug-free pain relief available to much larger markets.” 

Whelan explained that the new Quick Relief technology is available in the US only in the veterinary market initially. HealFast Therapy is currently in use in leading equine treatment centers and has been recommended by both equine and small animal veterinarians.

Mac Stein is a physical therapist who has used HealFast Therapy extensively. “I have had very good results using the patch on a variety of acute and chronic conditions. The new lower cost unit will be ideal for problems like strains and tendonitis as well as wounds and abscesses which respond rapidly to the continuous application of PEMF Therapy.” Mac Stein will be available to speak with veterinarians at the AAEP Conference Exhibit Hall, booth 704.

The Company said that earlier PEMF therapy delivery systems required cumbersome devices or repeated office visits. The HealFast Therapy Quick Relief patch joins the HealFast family of PEMF products that are available in a range of shapes and sizes for different veterinary uses and are priced from $89.95 for long lasting units with on/off switches to the new $15.00 unit for 100 hours of continuous treatment.

eMarkets Group, the global veterinary distributor of BioElectronics products, markets and sells the product through veterinarians and therapists and on its web site, http://www.healfasttherapy.com. HealFast Therapy is developed and manufactured by BioElectronics Corporation (PINKSHEETS: BIEL), which has extensive worldwide patents and patents pending.

For more information visit http://www.healfasttherapy.com or call 1-888 9 HEALFAST (1-888-943-2532) or 551-200-5586.

About HealFast Therapy
HealFast Therapy is a wearable patch with an embedded microchip that delivers continuous PEMF therapy for horses, cats and dogs. HealFast Therapy is a wearable, disposable patch with an embedded microchip that delivers continuous PEMF therapy for horses, dogs and cats. The patch is a state-of-the-art safe treatment option for relieving pain, edema and inflammation as well as enhancing repair of various types of wounds. HealFast Therapy is distributed by eMarkets Group, LLC, North Caldwell, NJ.

About BioElectronics Corporation
BioElectronics Corporation is the developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ menstrual cycle pain therapy, and RecoveryRx for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:
Mary K. Whelan
eMarkets Group, LLC
551-200-5586
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Houston to Deploy an Additional 250 Parking Pay Stations From Digital Payment Technologies

Posted on December 6, 2010 Written by Annalyn Frame

SOURCE: Digital Payment Technologies

Attend Webinar on December 8 to Learn How the City Boosted Revenues and Became More Efficient With Multi-Space Parking Pay Stations

VANCOUVER, BC–(Marketwire – December 6, 2010) – Digital Payment Technologies (http://www.digitalpaytech.com) (DPT), a leading supplier of parking technology and solutions, today announced that the city of Houston, Texas, will roll out an additional 250 of the company’s LUKE pay stations, marking a significant expansion of an already successful deployment program. On December 8, DPT will host a webinar with Houston’s director of parking management, Liliana Rambo, CAPP, who will share insights gained from her experience planning and implementing a large-scale parking technology transition that has been favorably met by officials and the public in the fourth largest city in the U.S.

The 250 new LUKE pay stations will be configured similarly to those in the original deployment that began in 2006. They will connect to the city’s back-end parking management systems via Wi-Fi, will accept coins, bills and credit cards, and in the future will be able to accept payment by cellular phone. This brings the total number of DPT pay stations in Houston to 1,000, and marks yet another milestone in a tremendously successful program.

“DPT pay stations enable Houston’s parking management division to meet its objectives of delivering superior service to consumers and optimizing operational efficiency,” said Rambo. “In these difficult economic times, the operational efficiency and increased revenue made possible by these advanced parking systems have enabled the city to continue to fund many important municipal programs.”

Houston’s project was initiated to replace outdated single- and double-head parking meters, improve the parking experience for the public, reduce traffic congestion, increase parking turnover and improve the bottom line. By implementing a comprehensive rollout plan that included a variety of communications strategies with key stakeholders throughout the process, Houston’s Parking Management Division has secured some impressive results, including:

  • 80 percent revenue increase without an increase in parking rates.
  • 33 percent productivity improvement for meter operations staff.
  • 1,000 more paid citations per month, equal to $58,000 in revenues, due to citations being upheld in adjudication. The new technology leaves less room to dispute tickets.

DPT’s December 8th webinar will provide additional details and best practices from this $15.4 million advanced parking project that will be useful to municipal, county and state government departments, as well as private parking operators responsible for parking and enforcement. Free registration is available at: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1

“The City of Houston’s use of multi-space pay stations is a testament to the positive impact that smart parking initiatives can have on a city,” said Alan Menezes, vice president of product management and marketing with Digital Payment Technologies. “There is a great opportunity for cities that still rely upon single-head parking meters to institute a similar parking plan and reap the benefits. Our customizable pay stations, back-end services and support and seamless integration with leading industry partners put DPT in the unique position of offering a complete parking solution composed of best-in-class components. Furthermore, DPT has significant experience helping large and small municipalities ensure a smooth transition as they embrace multi-space parking.”

Houston/DPT Webinar Details:
Date:
Wednesday, December 8, 2010
Time: 2:00 p.m. EST / 11:00 a.m. PST
Cost: Free
Register: http://event.on24.com/r.htm?e=265402&s=1&k=8C1A49910D44B77405A4E608E0F0843D&partnerref=dpt1 

About Digital Payment Technologies
Digital Payment Technologies (DPT) is an innovative leader in the design, manufacture, and distribution of electronic parking meters, management software, and online services for the parking industry. DPT products provide complete financial tracking, control, and reporting on parking revenue collected by cities, municipalities, universities, parking management companies, private operators, and national parks, from customer payment through to bank deposit. In 2007, DPT was named Emerging Company of the Year by the British Columbia Technology Industry Association, and has been included on multiple Deloitte Technology Fast 50 and Fast 500 lists as one of the fastest growing high technology companies in North America. For more information visit: http://www.digitalpaytech.com

Media Contact:
Chris Warfield
Sterling Communications for Digital Payment Technologies
206-388-5758
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Leaders Build Momentum for Creation of National Immunization Registry

Posted on December 6, 2010 Written by Annalyn Frame

OTTAWA, ONTARIO–(Marketwire – Dec. 6, 2010) – As Canada looks to the renewal of its Health Accord in 2014, public health leaders are hopeful room can be found for the creation of a national immunization registry, says Debra Lynkowski, Chief Executive Officer, Canadian Public Health Association (CPHA).

“Unfortunately, our typically Canadian response to broader immunization issues has resulted in a patchwork of approaches across the country,” said Lynkowski. “Now, as we approach the renewal of the Health Accord in 2014, is the time for a harmonized, national immunization registry.”

While we recognize additional funding may seem an improbable request of governments in the current fiscal environment, a national immunization strategy that includes at its core a national registry, one supported by all provinces and territories, would ensure Canadians are equitably protected against vaccine-preventable illnesses, regardless of where they live, their age or their socio-economic status.

“All Canadians should have equal access to immunizations for vaccine-preventable diseases. Where you live should have no bearing on access to immunization programs,” said Lynkowski.

Improvements stemming from a national immunization strategy would include harmonization of childhood immunization schedules across the country, aligned introduction of new vaccines, and equal access to vaccines across all provinces and territories. The systematic collection of immunization data in a national immunization registry will modernize the way jurisdictions communicate patients’ immunization histories and help to ensure coverage rates are high enough throughout the country to best protect Canadians.

A national strategy would also promote better opportunities for research, vaccine promotion and improved education of health care providers and the general public, said Lynkowski. Currently, Canada lacks a harmonized cross-country routine immunization schedule.

“Simply put, it is better to prevent disease and illness than to have to treat it,” said Lynkowski.

These recommendations are a result of unprecedented and ongoing dialogue with government leaders, industry and public health and health care stakeholders.

Founded in 1910, the Canadian Public Health Association (CPHA) is the independent voice for public health in Canada with links to the international community. As the only Canadian non-governmental organization focused exclusively on public health, CPHA is uniquely positioned to advise decision-makers about public health system reform and to guide initiatives to help safeguard the personal and community health of Canadians and people around the world. With a diverse membership representing more than 25 professions, a track record of success, a collaborative approach and national reach, CPHA is Canada’s Public Health Leader.

Background

CPHA has been working actively with stakeholders to improve the environment for a national immunization strategy that would protect Canadians against vaccine preventable diseases. To facilitate an ongoing dialogue, CPHA organized a roundtable discussion in 2009 with stakeholders and has since participated in various information-sharing activities organized by leading national organizations.

In addition, to ensure timely response to last year’s H1N1 pandemic, the CPHA, in collaboration with the Public Health Agency of Canada, the Canadian Medical Association, College of Family Physicians of Canada and the National Specialty Society for Community Medicine developed “PANDEMIC H1N1: Fast facts for front-line clinicians.”

In response to a significant demand for information in addition to what was available from the Government of Canada, CPHA established the Canadian H1N1 Information Clearinghouse as an additional, non-governmental source of reliable information for Canadians.

As secretariat for the Canadian Coalition for Immunization Awareness and Promotion, CPHA facilitates and coordinates the activities of the Coalition to minimize duplication and ensure that Canadians receive consistent immunization messages.

A backgrounder is available at the following address: http://media3.marketwire.com/docs/cpha-eng.pdf

Filed Under: Medical And Healthcare

Des chefs de file favorisent la création d’un registre national d’immunisation

Posted on December 6, 2010 Written by Annalyn Frame

OTTAWA, ONTARIO–(Marketwire – 6 déc. 2010) – Alors que le Canada songe au renouvellement de son Accord sur les soins de santé en 2014, les principaux intervenants en santé publique sont optimistes quant à la mise sur pied d’un registre national d’immunisation, déclare Debra Lynkowski, présidente-directrice générale de l’Association canadienne de santé publique (ACSP).

« Notre réponse typiquement canadienne aux problèmes d’immunisation plus vastes a malheureusement entraîné des approches diverses au pays », affirme Debra Lynkowski. « Maintenant, alors qu’on approche du renouvellement de l’Accord sur les soins de santé, en 2014, le moment est venu de mettre sur pied un registre national d’immunisation harmonisé. »

Nous reconnaissons qu’une demande de financement supplémentaire auprès des gouvernements peut sembler invraisemblable dans le présent contexte fiscal, mais une stratégie nationale d’immunisation basée sur un registre national, soutenu par toutes les provinces et les territoires, assurerait une protection équitable des Canadiens contre les maladies évitables par la vaccination, et ce, peu importe leur lieu de résidence, leur âge ou leur statut socio-économique.

« Tous les Canadiens devraient avoir un accès égal à l’immunisation contre les maladies évitables par la vaccination. Le lieu de résidence ne devrait pas avoir d’incidence quant à l’accès aux programmes d’immunisation », soutient Debra Lynkowski.

Les améliorations découlant d’une stratégie nationale d’immunisation comprendraient une harmonisation des calendriers de vaccination pour les enfants partout au pays, un alignement de l’introduction des nouveaux vaccins et une égalité d’accès aux vaccins dans toutes les provinces et territoires. La collecte méthodique de données relatives à l’immunisation dans un registre national d’immunisation modernisera la façon dont les autorités transmettent les dossiers d’immunisation des patients et aidera à assurer des taux de couverture suffisamment élevés partout au pays afin de mieux protéger les Canadiens.

Debra Lynkowski souligne qu’une stratégie nationale promouvrait aussi de meilleures possibilités de recherche, la promotion de vaccins, ainsi qu’une meilleure éducation des fournisseurs de soins de santé et du public. À l’heure actuelle, le Canada n’a pas de calendrier harmonisé de vaccination systématique pancanadienne.

« En bref, il vaut mieux prévenir les maladies que d’avoir à les traiter », conclut Debra Lynkowski.

Ces recommandations sont le résultat d’un dialogue continu sans précédent que tiennent les dirigeants du gouvernement et les principaux intervenants de l’industrie et des secteurs de la santé publique et des soins de santé.

Fondée en 1910, l’Association canadienne de santé publique (ACSP) est le porte-parole de la santé publique au Canada. L’indépendance de l’ACSP, ses liens avec la communauté internationale et le fait qu’elle soit la seule organisation non gouvernementale canadienne à se consacrer exclusivement à la santé publique la placent en position idéale pour conseiller les décideurs à propos de la réforme du réseau de santé publique et pour orienter les initiatives visant à protéger la santé individuelle et collective au Canada et dans le monde. Grâce à son effectif diversifié représentant plus de 25 professions, son efficacité démontrée, son approche de collaboration et son envergure nationale, l’ACSP est le chef de file canadien en santé publique. 

Contexte

L’ACSP travaille activement avec les principaux intervenants de l’industrie pour créer un contexte favorable à une stratégie nationale d’immunisation qui protégerait les Canadiens contre les maladies évitables par la vaccination. Pour faciliter un dialogue continu, l’ACSP a organisé une table ronde en 2009 avec les principaux intervenants et a depuis participé à diverses activités d’échange d’information organisées par d’importants organismes nationaux. 

En outre, pour assurer une réponse dans les meilleurs délais à la pandémie H1N1 de l’année dernière, l’ACSP, en collaboration avec l’Agence de la santé publique du Canada, l’Association médicale canadienne, le Collège des médecins de famille du Canada et la Société nationale de spécialistes pour la médecine communautaire, a mis au point l’outil « GRIPPE PANDÉMIQUE H1N1 — Aide-mémoire à l’intention des cliniciens de première ligne ».

En réponse à l’importante demande de renseignements en plus des renseignements déjà offerts par le gouvernement du Canada, l’ACSP a fondé des centres d’échange d’information canadiens sur la grippe H1N1 comme autre source non gouvernementale de renseignements fiables pour les Canadiens.

En tant que secrétariat pour la Coalition canadienne pour la sensibilisation et la promotion de la vaccination, l’ACSP fait office de facilitateur et de coordonnateur d’activités de la Coalition pour réduire au minimum les chevauchements et s’assurer que les Canadiens reçoivent des messages cohérents concernant l’immunisation.

Un document d’information est disponible à l’adresse suivante : http://media3.marketwire.com/docs/cpha-fre.pdf

Filed Under: Medical And Healthcare

Shuangshi AHP Co. (HIRU) Expands Sales Area

Posted on December 3, 2010 Written by Annalyn Frame

NANCHANG, CHINA–(Marketwire – Dec. 3, 2010) – Hiru Corporation (PINK SHEETS:HIRU) (www.hirucorporation.com) subsidiary Shuangshi AHP Co. dispatched company representatives to evaluate the agricultural developments and increase company sales in the regions of Ganzhou, Yichun and Jian.

Shuangshi’s assistant general manager and sales manager met with several potential customers in the aforementioned regions to discuss the potential of Shuangshi products on the local markets, as the company works on gaining more exposure with Chinese farmers for their vaccination needs.

The representatives also negotiated with two new agricultural clients, each client reporting annual sales of approximately $30 million USD. Following these negotiations, Shuangshi AHP representatives supplied the customers with new HIRU products for testing and evaluation by the clients. Shuangshi AHP anticipates to gain more new clients as the company’s top quality animal vaccination products gain exposure in the market.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hiru Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Hiru Corporation cautions you that any forward-looking information provided by or on behalf Hiru Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hiru Corporation’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hiru Corporation’s control. In addition to those discussed in Hiru Corporation’s press releases, public filings, and statements by Hiru Corporation’s management, including, but not limited to, Hiru Corporation’s estimate of the sufficiency of its existing capital resources, Hiru Corporation’s ability to raise additional capital to fund future operations, Hiru Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hiru Corporation’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hiru Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Filed Under: Medical And Healthcare

Marathon Health Opens Healthy Living Wellness Center for C&S Wholesale Grocers

Posted on December 3, 2010 Written by Annalyn Frame

SOURCE: Marathon Health

Convenient Access to Care for Employees and Dependents

BURLINGTON, VT–(Marketwire – December 3, 2010) – Marathon Health today announced that C&S Wholesale Grocers, the largest grocery wholesaler in the country, will open an onsite healthcare facility at their headquarters in Keene, N.H. on December 6, 2010.

The C&S Healthy Living Wellness Center, which will be managed by Marathon Health, will serve employees and their families, including dependents over the age of six, within the Brattleboro, VT and Keene, NH area. Available services include acute and primary care, wellness and health promotion, health coaching, disease management, medication dispensing, and the Marathon eHealth Portal technology to support the delivery of care and coaching. The Center staff will include two nurse practitioners, a registered nurse and a medical assistant.

“Marathon Health shares our philosophy about healthcare responsibility and has the tools and programs to help improve the overall health of our workforce,” said Richard Cohen, C&S Chairman and CEO. The worksite healthcare initiative will be offered as part of the company’s Total Rewards health programs that encourage people to be active participants in their own health and healthcare.

“What is most important at Marathon Health is how we inspire people to understand and care about their health — it is the foundation of what we do. We are excited to help C&S enhance the culture of health and responsibility they have established,” said Jerry Ford, Marathon Health CEO.

About C&S Wholesale Grocers

C&S Wholesale Grocers of Keene, NH, is the largest food wholesaler and according to Forbes magazine, the 10th largest privately held company in the United States. The company distributes food to supermarkets, retail stores and military bases across the country.

Currently, C&S serves about 3,900 stores from more than 50 locations in 11 states. Among our customers are many of America’s best known companies, including Stop & Shop, Giant of Carlisle, Giant of Landover, Shaw’s, Great Atlantic & Pacific Tea Co. (A&P), Ralphs, Safeway and Target.

About Marathon Health

Marathon Health of Colchester, VT, offers a proven solution for helping employers reduce the total cost of healthcare. The Marathon Health approach integrates the best practices of onsite primary care, health assessment with risk identification, coaching and advocacy, and disease management for high cost chronic conditions. Marathon Health supports its unique model with an eHealth Portal delivering medical content, interactive diet and fitness tools, a personal health record, and an electronic medical record to manage care. For more information, please visit www.marathon-health.com.

Contact:
Tracey Moran
802-857-0459
Email Contact

Filed Under: Medical And Healthcare

CONMED Corporation Receives Clearance From FDA for Novel Tissue Fusion System

Posted on December 3, 2010 Written by Annalyn Frame

SOURCE: CONMED Corporation

UTICA, NY–(Marketwire – December 3, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the U.S. Food and Drug Administration has given marketing clearance for the Company’s thermal energy based tissue fusion system for use in a wide range of surgical procedures. 

“We look forward to introducing our tissue sealing device, the Altrus® Thermal Tissue Fusion System, to the surgical community,” noted Mr. Joseph J. Corasanti, President and CEO of CONMED. “We believe the current marketplace for energy based instruments approximates $1.5 billion, and while our initial revenue goals for Altrus® in 2011 are modest at $5 – $10 million, we expect Altrus® to be a contributor to our long-term growth prospects.”

Over the last several years, surgeons have expanded the use of energy based instruments to reduce surgical times, improve patient outcomes and decrease procedure costs. Based on CONMED’s original research in the technology, and with the understanding of surgeon needs, CONMED has developed the Altrus® Thermal Tissue Fusion system to advance the performance of energy-based instrumentation. Utilizing thermal energy, the Altrus® System is a multi-functional surgical tool that seals, cuts, grasps, and dissects vessels up to 7mm in size utilizing a closed feedback loop between the energy source and the single-use handpiece to precisely control the desired effect on tissue. Its versatility reduces the need for multiple instruments and instrument changes.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations. 

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company’s ability to devise and execute strategies to respond to market conditions.

CONTACT:
CONMED Corporation
Robert Shallish
Chief Financial Officer
315-624-3206

FD
Investors:
Brian Ritchie
212-850-5600

Filed Under: Medical And Healthcare

Callidus Software Offers Free Webinar: How to Make MBOs Really Work

Posted on December 3, 2010 Written by Annalyn Frame

SOURCE: Callidus Software Inc.

Learn How Philips Healthcare Deployed MBO Programs to Drive Business Execution

PLEASANTON, CA–(Marketwire – December 3, 2010) – Callidus Software (NASDAQ: CALD)

WHO:

G. F. “Will” Williams, senior incentive compensation analyst, Philips Healthcare

WHAT:

Is your workforce delivering the results that you need? Are they truly aligned with your top-tier business objectives? Learn how best-in-class organizations outperform competitors by using Management-by-Objective (MBO) programs to drive business performance.

WHEN:

Thursday, December 9, 2010

11 a.m. Pacific / 1 p.m. Central / 2 p.m. Eastern Time

WHERE:

To register for the event and for additional information go to:
http://www2.callidussoftware.com/Q410-MBO-Webinar.html

If you cannot attend the live event, please register and we will send you the on-demand version when available.

In the webinar, you will learn:

  • Best practices in developing and administering MBOs
  • How to develop MBOs that motivate employees and drive them toward accomplishing top-tier corporate objectives
  • How to enhance employee engagement
  • How to overcome common challenges that can potentially hinder your success

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG) (AMS: PHI), which includes Philips Healthcare, is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of “sense and simplicity”. Headquartered in the Netherlands, Philips employs more than 116,000 employees in more than 60 countries worldwide. With sales of EUR 23 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

About Callidus Software®

Callidus Software (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Callidus customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales effectiveness. Our award-winning Software-as-a-Service (SaaS) applications set the standard for performance management of a company’s sales force and channel partners. Over 2 million employees and channel partners have their performance managed by Callidus Software. For more information, please visit www.callidussoftware.com.

©1997-2010 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, and TrueComp Manager are trademarks, service marks, or registered trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Press Contact:
Cheryl Hall
Callidus Software Inc.
925-251-2259
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Sunshine Heart Successfully Completes $9.5 Million Capital Raising With Close of Non-Renounceable Rights Offer

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Sunshine Heart Inc.

Cash to Continue Rapid Advance of Commercial and Regulatory Programs

SYDNEY, AUSTRALIA–(Marketwire – December 2, 2010) –  Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced the successful completion of its non-renounceable rights issue to existing shareholders, raising a total of A$9.5 million.

88 per cent of entitlements were taken up under the rights issue including the shortfall facility, leaving 44,761,462 shares unsubscribed.

The rights issue follows the Company’s recent successful placement to US institutional investors raising A$3.7 million (announced 16 September 2010), bringing the total proceeds to A$13.2 million before deducting fees and expenses.

Majority Australian shareholders, GBS Venture Partners and CM Capital, both continued their strong support for the Company, taking up their full entitlements and also some of the shortfall, for an aggregate amount of $6.6 million

Sunshine Heart Chief Executive Officer Dave Rosa said, “We are delighted to have such strong support from existing shareholders and welcome new US institutional investors during this exciting and pivotal period for Sunshine Heart.”

The capital will be used to fund the key activities of the Company. The most important of these is to advance the regulatory trials in the US by completing the current 20-patient feasibility trial and six-month patient follow up, then preparing the application for the larger FDA pivotal trial which is the precursor for marketing approval in the USA. The Company expects to have approval for this trial and to start implants during 2011.

The money will also be used to apply for CE Mark approval in 2011 which will allow the C-Pulse heart assist device to be marketed in Europe and parts of Asia.

The Company will continue its development of a new, single unit C-Pulse driver as well as introducing product changes to facilitate minimally invasive implant procedures.

The successful US placement was managed by specialist healthcare investment firm Summer Street Research Partners Inc. The non-renounceable rights issue was managed by RBS Morgans in Australia.

About Sunshine Heart Inc.
Sunshine Heart Inc. (ASX: SHC), a global medical device company focused on innovative technologies for the treatment of moderate heart failure, is commercializing the C-Pulse® Heart Assist System, a minimally invasive, implantable, non-blood contacting, heart assist therapy for the treatment of moderate heart failure. The C-Pulse System is designed to relieve the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart’s pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20-patient U.S. feasibility clinical trial with the C-Pulse System and the study has achieved eighty percent enrolment as of November 2010. Sunshine Heart, Inc. is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia.

About the C-Pulse® Heart Assist System
The C-Pulse Heart Assist System uses proprietary balloon counterpulsation technology to increase the amount of blood pumped by the heart and to reduce the workload on the heart. The C-Pulse System is implanted in the patient’s chest through a sternotomy or through a small incision when performed as a minimally invasively procedure. During the procedure, there is no need to place the patient on a heart-lung machine as the patient’s heart remains beating continuously. 

Once implanted, the C-Pulse cuff is positioned on the outside of the patient’s ascending aorta above the aortic valve. An ECG sense lead is then attached to the heart to determine timing for cuff inflation and deflation in synchronization with the heartbeat. The C-Pulse cuff and lead are connected to a single line that is run through the abdomen to connect to a power driver outside the body. Because the C-Pulse System remains outside the blood system, there is potentially less risk of blood clots and stroke in comparison to other mechanical devices, such as left ventricle assist devices (LVADs).

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company’s filings with the Australian Securities Exchange. The shares of Sunshine Heart have not been registered under the Securities Act of 1933 (US Securities Act) and may not be offered, sold or delivered in the United States, or to, or for the account or benefit of, any US Person, as such term is defined in Regulation S of the US Securities Act. In addition, hedging transactions with regard to the shares may not be conducted unless in accordance with the US Securities Act.

For further information, please contact:
Dave Rosa
Chief Executive Officer
+1 952 345 4200
[email protected]

Rowena Hubble
Company Secretary
+61 2 8424 7700
[email protected]

Andrew Geddes
CoActive Health Communications
+ 61 2 9555 4453 or 0408677734
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

HIMSS and ASC X12 Collaborate on Education & Training

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: ASC X12

CHICAGO, IL–(Marketwire – December 2, 2010) – Based on mutual interest in the use of effective and productive electronic data interchange standards in the health care industry, the Healthcare Information and Management Systems (HIMSS) and the Accredited Standards Committee X12 (ASC X12) signed a Memorandum of Understanding formalizing their decision to collaborate on activities and offerings that improve or enhance the implementation of EDI standards in the health care industry.

“ASC X12 and HIMSS have established a cooperative relationship, taking advantage of each organization’s strengths. We look forward to many productive joint initiatives,” said Cathy Sheppard, Chair, ASC X12.

The two organizations intend to collaborate in the development of educational materials, conference presentations, webinars, white papers, articles and reports.

Such cooperative efforts are not new between the organizations, HIMSS and ASC X12 have developed and presented a comprehensive overview of ASC X12 005010 migrations in the Webinar HIPAA 005010 Road to Success — A Prescription for a Healthy and Successful ASC X12 005010 Implementation. HIMSS also published the article ASC X12’s Emerging 5010 Activities, by Cathy Sheppard, in their August 2010 Business Edge online newsletter.

January 1, 2012 is the deadline for health care organizations to be compliant with the ASC X12 005010 transactions mandated by the Health Insurance Reform: Modifications to the Health Insurance Portability and Accountability Act (HIPAA) Electronic Transaction Standards Final Rule (also known as the 005010 Final Rule). ASC X12 and HIMSS are committed to aiding stakeholders in compliance preparation. 

ASC X12N (Insurance) Vice Chair, Bob Poiesz, will serve on an ASC X12 005010 migration panel at the HIMSS11 Annual Conference and Exhibition. The Ninth National Medical Banking Institute, to be held in conjunction with HIMSS11, features national experts and cross-industry leaders from health care, banking, financial systems, government and academia for an interactive dialogue of critical issues and next steps on building the future of medical banking. At the HIMSS Medical Banking Boot Camp ASC X12 will describe 005010 health data transactions mandated by HIPAA and identify the steps a provider will need to take as part of the ASC X12 005010 transition.

“HIMSS and our medical banking and financial systems community welcome the opportunity to work with the Accredited Standards Committee X12 to build awareness and better educate our diverse audiences, on the value of efficient data exchange in health care,” said John Casillas, HIMSS Senior Vice President, Business-Centered Systems. “With this MoU, our organizations can work together to build relationships and develop educational programming that improves the delivery of health care.”

About HIMSS
HIMSS is a cause-based, not-for-profit organization exclusively focused on providing global leadership for the optimal use of information technology (IT) and management systems for the betterment of healthcare. Founded 50 years ago, HIMSS and its related organizations have offices in Chicago, Washington, DC, Brussels, Singapore, Leipzig, and other locations across the United States. HIMSS represents more than 30,000 individual members, of which two thirds work in healthcare provider, governmental and not-for-profit organizations. HIMSS also includes over 470 corporate members and more than 85 not-for-profit organizations that share our mission of transforming healthcare through the effective use of information technology and management systems. HIMSS frames and leads healthcare practices and public policy through its content expertise, professional development, and research initiatives designed to promote information and management systems’ contributions to improving the quality, safety, access, and cost-effectiveness of patient care. To learn more about HIMSS and to find out how to join us and our members in advancing our cause, please visit our website at www.himss.org.

About X12
ASC X12, chartered by the American National Standards Institute more than 30 years ago, develops and maintains EDI and CICA standards along with XML schemas which drive business processes globally. The diverse membership of ASC X12 includes technologists and business process experts, encompassing health care, insurance, transportation, finance, government, supply chain and other industries. For more information, visit the ASC X12 website at www.x12.org

For HIMSS information contact:
Joyce Lofstrom
HIMSS
(312) 915-9237
Email Contact

For ASC X12 information contact:
ASC X12
(703) 970-4480
Email Contact

Filed Under: Facilities And Providers

CMU’s College of Medicine Teams Up With Saginaw Medical Providers

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Central Michigan University

MOUNT PLEASANT, MI–(Marketwire – December 2, 2010) – Following more than two years of exploration, comprehensive study and due diligence, Central Michigan University will establish a relationship with Synergy Medical Education Alliance, Covenant Healthcare and St. Mary’s of Michigan in Saginaw, Mich., through its College of Medicine.

The CMU Board of Trustees, at its Dec. 2 meeting, voted unanimously to establish a new 501(c)(3) Michigan nonprofit corporation, Central Health Advancement Solutions, to serve as the University’s participant in clinical practice entities and medical education relationships.

The boards of St. Mary’s of Michigan and Synergy Medical Education Alliance must approve the agreement. It is anticipated that the required board approvals will be secured by mid-December. Covenant Healthcare’s board has already approved the agreement.

Under the terms of the agreement, if approved, CMU will join in the Synergy Medical Education Alliance partnership and the organization will be renamed CMU Medical Education Partners.

CMU has been engaged in the Saginaw community since the 1970s providing extended and distance learning programs and remains committed to enhancing its engagement through a facility in the Saginaw area to support medical education and clinical practice needs.

In other College of Medicine action, CMU trustees established a Doctor of Medicine degree. The four-year curriculum, with an emphasis on placing doctors in rural settings, will focus on evidence-based practice, patient-centered care, team-based learning and practice, and self-directed lifelong learning.

To view today’s PowerPoint presentation to the board visit http://www.cmich.edu/documents/college_of_medicine/collegeofmedicinepresentation_120210.pdf.

To learn more about CMU’s College of Medicine visit http://www.cmich.edu/med.

For additional news from Central Michigan University, visit the CMU Media Channel at http://www.cmich.edu/mediachannel.

Click here to see all recent news from this company

Filed Under: Facilities And Providers

University of Chicago Medical Center Runs Critical Patient Applications on Oracle’s Sun SPARC Enterprise Servers and Oracle Solaris

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Oracle Corporation

Mission-Critical Servers Deliver Record-Breaking Performance and Scalability

REDWOOD SHORES, CA–(Marketwire – December 2, 2010) – Oracle (NASDAQ: ORCL)

News Facts

  • To provide the best patient care, the University of Chicago Medical Center is running its critical patient care applications on Oracle’s Sun SPARC Enterprise M-Series Servers with Oracle Solaris.
  • The University of Chicago Medical Center (UCMC) is an academic medical center comprised of numerous hospitals, including Bernard A. Mitchell Hospital, Comer Children’s Hospital, Chicago Lying-in Hospital, Duchossois Center for Advanced Medicine and the University of Chicago Pritzker School of Medicine, as well as physician offices in several Chicago locations.
  • UCMC chose Oracle’s Sun SPARC Enterprise M-Series servers running Oracle Solaris for their high level of performance, scalability and availability to run its mission-critical applications, including the Epic Electronic Medical Record (EMR) and Computerized Physician Order Entry (CPOE) systems.
  • More than 6,000 clinical staff rely on the Epic EMR system to deliver 24×7 secure access to all relevant information necessary to provide high-quality patient care, including lab results, orders, documentation on care plans, operating room management and scheduling, reporting and patient portals.
  • With Oracle’s Sun SPARC Enterprise M-Series servers running Oracle Solaris, UCMC has increased performance by 40 percent, decreased maintenance costs and reduced power and cooling by 63 percent in the datacenter.
  • With the new platform, nurses and physicians experience rapid response times, enabling them to provide patient care in a more timely and efficient manner, which is key in hospital and critical-care environments.
  • Part of UCMC’s strategic five-year plan, the SPARC servers provide the capacity to support new initiatives and continued growth, including the deployment of new EMR modules and technology to support a new hospital coming online in 2013.
  • UCMC invested in Oracle’s Sun SPARC Enterprise M-Series servers with Oracle Solaris in March 2010.

Supporting Quote

  • “Oracle’s Sun SPARC Enterprise servers provide us with a secure and reliable platform to run our mission-critical patient care applications and the ability to easily scale to accommodate future growth,” said Michael Sorensen, Executive Director and CTO, IT Services, the University of Chicago Medical Center. “The new platform has delivered dramatic results, including significantly faster response times, which is instrumental in our ability to provide patients with the best care.”

Supporting Resources

  • University of Chicago Medical Center
  • Oracle’s Sun SPARC Enterprise M-Series Servers
  • Oracle Solaris
  • Oracle in Healthcare
  • Follow Oracle Health Sciences on Twitter
  • Join the Oracle Health Sciences Community on Facebook

About Oracle
Oracle (NASDAQ: ORCL) is the world’s most complete, open and integrated business software and hardware systems company. For more information about Oracle, please visit http://www.oracle.com.

Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Contact Info

Nicole Maloney
Oracle
+1.650.506.0806
Email Contact

Susan Vander May
Blanc and Otus for Oracle
+1.415.341.3529
Email Contact

Filed Under: Facilities And Providers

UPDATE: Cardiothoracic Surgeons Group and The Toledo Hospital Recognized Among Nation’s Top Hospitals for Heart Surgery

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: ProMedica Health System

TOLEDO, OH–(Marketwire – December 2, 2010) – Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are now in the nation’s top 12% of hospitals for heart surgery. This is according to a three-star comprehensive rating system, developed by The Society of Thoracic Surgeons (STS), which compares the quality of heart surgery in hospitals across the country. A three-star rating is the highest designation that a hospital can attain for quality and clinical excellence. Cardiothoracic Surgeons for Northwest Ohio was compared to more than 1,000 surgical groups.

Hospitals are scored on performance in the following four categories — patient survival, absence of surgical complications, recommended medications, and optimal surgical technique. The ratings reflect results from isolated heart-bypass operations called coronary artery bypass grafting to newer versions, which include minimally invasive bypass and other complex cardiac procedures.

“I am grateful to my partners and colleagues at The Toledo Hospital who have worked diligently for years to reach this incredible milestone,” said Michael Moront, MD, senior partner, Cardiothoracic Surgeons for Northwest Ohio. “When patients enter our doors, they can feel confident that they will be receiving the very best care from one of the nation’s leading medical groups.”

Consumers can easily see how surgical groups compare with national benchmarks for survival, complications, and other measures by visiting www.consumerhealthreports.org.

About STS
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,000 surgeons, researchers and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus as well as other surgical procedures within the chest. Founded in 1964, the mission of STS is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Its National Adult Cardiac Surgery Database includes more than 4 million surgical records and covers roughly 90% of the more than 1,000 surgical groups in the U.S. that perform cardiac surgery, making it the largest such registry in the world.

About Cardiothoracic Surgeons for Northwest Ohio
Cardiothoracic Surgeons for Northwest Ohio is a member of ProMedica Heart and Vascular Institutes, a collaboration of physicians, technology and specialty services. The group provides a comprehensive scope of leading edge patient care and state-of-the-art surgical procedures, including minimally invasive procedures, bloodless surgery, pediatric cardiac surgery, aortic valve repair and replacement and more. Its team of board-certified physicians, specialists and medical staff make up the largest cardiothoracic surgical program in northwest Ohio.

For more information about cardiac services at ProMedica Health System, visit www.promedica.org

Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are members of ProMedica Health System. ProMedica, a mission-based organization, was formed in 1986 and is a Toledo, Ohio-based, not-for-profit healthcare organization with more than 14,000 employees; 3,000 physicians and more than 306 facilities in Ohio and Michigan. ProMedica serves more than 2.73 million patients annually and includes 11 hospitals; ProMedica Continuum Services with senior, hospice, rehabilitation, and integrative services; ProMedica Physician Group, a network of more than 315 primary care and specialty physicians; and Paramount Health Care, the largest HMO in northwest Ohio. For more information, please visit www.promedica.org.

Contact:
Tedra White
Office: 419-469-3716
Cell: 419-262-0371

Filed Under: Facilities And Providers

SRSsoft to Attain Government Certification for EMR Delivering Productivity-Focused Meaningful Use

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: SRSsoft

MONTVALE, NJ–(Marketwire – December 2, 2010) – SRS, the leader in productivity-enhancing EMR technology and services for high-performance specialty practices, today announced that it will seek certification of its EMR by the Office of the National Coordinator for Health Information Technology (ONC) under the American Recovery and Reinvestment Act (ARRA). Physicians will be able to use the EMR to successfully demonstrate meaningful use and qualify for the government’s incentives. SRS is unique among EMRs in its approach to meaningful use — combining the government’s requirements and desire for data with the acknowledged productivity and efficiency benefits that over 5,000 providers are already experiencing, and for which SRS is valued.

“SRS is unwavering in its adherence to a set of principles that are physician-based and productivity-driven,” says Evan Steele, CEO of SRSsoft. “Our product-development resources are consistently focused on providing physicians with tools that enable them to deliver the highest quality patient care in the most efficient manner. We listen to our customers, and we represent ‘the voice of the physicians,’ which includes advocating for their interests in Washington.

“We have been analyzing the legislation since its passage in February 2009 and continue to evaluate the impact that meeting meaningful use measures will have on physician productivity. In addition, we have challenged the program’s relevance for specialists. Since the release of the Final Rule on meaningful use a few months ago, the landscape has shifted, and several factors have influenced our decision to move forward with certification. Most recently, David Blumenthal’s clarification of the exclusions that can be claimed by many specialists has made participation more inviting. Our clients — primary care and specialists — who are interested in pursuing meaningful use want to have the assurance that the capability will be available to them.”

According to Steele, “The development team at SRS has been working diligently to incorporate the government’s data and communication requirements into our workflow-driven EMR. The uniqueness of the SRS approach to electronic medical records software — Unified Desktop™, open architecture, and browser-based platform — is the key to our ability to deliver productivity-focused meaningful use.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, its robust EMR, SRS CareTracker PM, and SRS PACS increase speed and efficiency, free physicians’ time, boost revenue, slash overhead, and enhance patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

Media Contact
Jeremy Duca
SRSsoft
800.288.8369
Email Contact

Filed Under: Facilities And Providers

Proteonomix, Inc. (PROT) Announces Investor Update and New Company Website

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Proteonomix

MOUNTAINSIDE, NJ–(Marketwire – December 2, 2010) – Proteonomix, Inc. (OTCBB: PROT) (“Proteonomix” or the “Company”) announced today that it has updated its corporate website (http://www.proteonomix.com/) to reflect the dynamic growth and investment opportunity that exists today.

Michael Cohen, CEO stated: “The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancing regenerative stem cell therapies, services, and products through a combination of first to market technologies and innovative clinical trial strategies. Stem cell treatment provides much promise for the treatment of diseases previously regarded as incurable. Through years of research and development, Proteonomix has developed breakthroughs in stem cell therapies for disease and injury, identification biomarkers and reproductive cell/tissue laboratory services.”

“Proteonomix is now actively negotiating strategic partnerships and opportunities for its breakthrough products and technology. We are currently in negotiations to joint venture our patents and intellectual properties with various entities and will be updating the investment community as these milestones are completed,” concluded Mr. Cohen.

About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements: Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact:
Public Relations:
Constellation Asset Management, LLC
415-524-8500

Click here to see all recent news from this company

Filed Under: Facilities And Providers

CRC Health Group, New Life Lodge Drug and Alcohol Addiction Treatment Center Expand Services With Multi-Facility Acquisition

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: CRC Health Group

Additional Five Facilities to Provide Outpatient and In-Home Treatment Services, Options for the One Hundred Thousand-Plus TN Residents Who Need but Do Not Currently Receive Addiction Treatment

BURNS, TN–(Marketwire – December 2, 2010) – New Life Lodge drug and alcohol addiction treatment center, in conjunction with parent company CRC Health Group, the nation’s largest provider of behavioral health and addiction treatment services, today announced the completion of the multi-facility acquisition of Recovery Living Services (RLS) in Tennessee. 

“We are pleased to acquire RLS, which has been providing high quality addiction treatment services for over five years, and to expand the outreach and breadth of services of New Life Lodge,” said Jerry Rhodes, President of the Recovery Division of CRC Health Group. “There are a number of Tennesseans who are dependent on drugs or alcohol and are in desperate need of quality recovery services. We want to help these individuals in their pursuit to reclaim their lives.”

According to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) most recent National Survey on Drug Use and Health, approximately 444,000 (9%) of Tennessee citizens ages 12 or older reported past month use of an illicit drug, with 151,000 citizens reporting dependence or abuse of an illicit drug within the past year. Yet in 2008 (most recent year of data), there were only 9,806 admissions to drug/alcohol treatment centers in Tennessee. Approximately 129,000 Tennessee citizens reported needing but not receiving treatment for illicit drug use.

RLS provides substance abuse treatment for adults and adolescents as well as in-home behavioral health counseling services for at-risk youth. The acquired facilities — located in Downtown Knoxville, West Knoxville, Cookeville, Jamestown and Jacksboro — will continue to provide intensive outpatient program (IOP) services, outpatient opiate (Suboxone-based) detoxification services, and intensive in-home services. In addition, plans are underway to open two additional facilities in Chattanooga and Memphis.

Rebecca Gaskin, LCSW, CAC, MSW, MBA and current Executive Director of New Life Lodge, will oversee the additional facilities. Current CEO of Recovery Living Services, George Massengill, will stay on with CRC Health Group.

“I am very excited to have Recovery Living Services join the New Life Lodge family to serve persons struggling with substance abuse disorders throughout the state of Tennessee,” said Gaskin. “New Life Lodge is committed to providing high quality, effective treatment and RLS has demonstrated the same commitment in outpatient treatment settings throughout the eastern Tennessee area. This partnership will allow New Life Lodge to offer a seamless array of treatment opportunities for individuals to optimize their residential treatment experience and support them as they integrate back into their home environments.”

Gaskin added, “We hope to make our services widely available to those struggling with addiction by expanding our outpatient facilities across the state.”

New Life Lodge has been providing rehabilitation and treatment services for adults and adolescents struggling with alcohol and drug dependency for over 25 years. The treatment center acknowledges that addiction affects the entire family and therefore embraces the family as well as the individual to provide personalized treatment services. Under the supervision of licensed professionals, New Life Lodge has built a nationally recognized reputation and established long-standing relationships within the medical and mental health communities. The program is licensed by the Tennessee Department of Health and the Tennessee Department of Healthcare Facilities, and is CARF-accredited. For more information, visit www.newlifelodge.com.

New Life Lodge is a member of CRC Health Group, the most comprehensive network of specialized behavioral care services in the nation. CRC offers the largest array of personalized treatment options, allowing individuals, families and professionals to choose the most appropriate treatment setting for their behavioral, addiction, weight management and therapeutic education needs. CRC is committed to making its services widely and easily available, while maintaining a passion for delivering advanced treatment. Since 1995, CRC has been helping individuals and families reclaim and enrich their lives.
For more information, visit www.crchealth.com or call (877) 637-6237.

CONTACT:
Kristen Hayes, Communications Director
CRC Health Group
Email Contact
(949) 589-1765

Filed Under: Facilities And Providers

MMRGlobal Enters Into Agreement With MMX Holdings

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: MMRGlobal, Inc.

MMRPro to Be Offered as Part of Manage My ASC Dashboard Technology

LOS ANGELES, CA–(Marketwire – December 2, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) and Texas-based MMX Holdings, LLC, today announced integration of MMRPro into the MMX dashboard-based financial and operating management tool for ambulatory surgical centers (ASCs) (www.managemyasc.com). The Company’s MMRPro electronic document management system for healthcare professionals will be featured on the Manage My ASC dashboard and as a result marketed to thousands of surgery centers located throughout the United States.

The Manage My ASC system was specifically designed to increase productivity and profitability in surgery centers which should help drive sales of MMRPro. As part of the transaction, MMRGlobal became a minority equity holder of MMX Holdings and MMX acquired 750,000 warrants in MMRF at terms and conditions that include purchase prices up to 18 cents per share.

“This transaction demonstrates how MMR can use its equity to create relationships that will allow us to expand our Electronic Medical Record product and service offerings in a coordinated effort to deliver meaningful use to healthcare professionals,” said Robert H. Lorsch, MMRGlobal Chairman and CEO. “It is the most recent example of the Company’s plan to deliver a suite of health information products and services through strategic alliances, partnerships and acquisitions. In addition to MMRPro and the MyMedicalRecords Personal Health Record, these could include one or more Electronic Medical Record products that run on different platforms including the iPad.”

“The opportunity for MMR to sell its services to a targeted market such as surgery centers offers a unique revenue opportunity for the Company,” Lorsch added. “We will continue to explore similar relationships in radiology, hospital systems, veterinary medicine and other specialties.” Lorsch is already a major shareholder and board member of Dancing Paws, a manufacturer of veterinary vitamins, supplements and treats including green bones.

According to John R. Seitz, CEO of Manage My ASC, “The relationship with MMR is one example of how our Manage My ASC Dashboard can streamline the operations of a surgery center and make it operate more effectively and profitably. Surgery centers receive a lot of different types of documents from referring physicians and MMRPro integrated with the dashboard can help manage and consolidate all patient records from any EMR or plain paper-based system employed by the center.”

The relationship with MMX evolved as a result of MMR’s installation of MMRPro at the Spalding Surgical Center of Beverly Hills. Installing MMRPro at Spalding exposed the system to more than 20 physician groups operating at the center at any given time. The Company quickly realized that selling through surgery centers represented a cost-effective way to market MMRPro to physicians. The Manage My ASC Dashboard creates the opportunity to provide a hands-on experience to tens of thousands of physicians referring to or operating at surgery centers when compared to the cost of selling offices of individual healthcare professionals one by one. 

“With over 6,000 in the U.S., ambulatory surgery centers are one of the fastest-growing elements of medical care across the country. Surgery centers will generally support 20 to 30 doctors, each with a patient list of 2,000 or more. The surgery center environment presents a distinctive market for MMR to offer its MMRPro solutions to significant physician populations. We are pleased that MMR is joining other well-known entities, including Kerlan-Jobe, one of the world’s foremost sports medicine destinations,” Seitz added.

MMRPro allows physicians working out of a surgery center to have electronic access to patient documentation, regardless of the system currently used in their offices, and enables the ASC to receive medical records securely from all their treating physicians. The system also cost-effectively digitizes and securely uploads medical records and makes them available to patients in real time while generating stimulus money to referring physicians.

The MMRPro solution is supported by Kodak’s Scan Station 520MDP. Surgery centers may also participate in the MMRPro Stimulus Program. As a result, a surgery center can participate in potentially hundreds of thousands of dollars of recurring upgrade revenue annually coming from the thousands of patients treated at the surgery centers at any given time when contrasted to the number of patients in a typical MMRPro group practice installation. The MMRPro Stimulus Program provides funds to physicians, hospitals and alternative care facilities for patient upgrades to a full-featured MyMedicalRecords Personal Health Record in addition to stimulus monies that may be provided by the federal government.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

About Manage My ASC

Manage My ASC combines timely and focused management reporting, backed-up by our team of industry experts, to deliver management solutions to ASC owners and operators. Our easy to understand on-line dashboard is a powerful management tool and serves as a central reference point for you to view and track your ASC’s activities. Plus, your dashboard is the main meeting point for you and our experts who are there to help you interpret results and take action.

The Manage My ASC solution works for any ASC, regardless of size or geographic location. Manage My ASC customers receive periodic reviews of operation performance, including assessments based on our comprehensive benchmarking database, that lead to specific recommendations to capture improvement opportunities. www.managemyasc.com

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, including future performance, management’s expectations, beliefs, intentions, estimates or projections, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “help,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. . Factors that could cause or contribute to such differences include, but are not limited to, the risk the Company’s products are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices, surgery centers and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company’s marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company’s filings with the Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT:

Michael Selsman
Public Communications Co.
(310) 553-5732
[email protected]

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Premier Diagnostic Health Services Inc. (CNSX:PDH) Announces Its CEO-China Operations Is Travelling to China to Negotiate Contracts With Hospitals

Posted on December 2, 2010 Written by Annalyn Frame

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 2, 2010) – Premier Diagnostic Health Services Inc. (CNSX:PDH) (“PDH”) announces Denis Tusar, CEO – China Operations for PDH, is departing to China, on Saturday, December 4, 2010 to meet with the on-the-ground China Development Team. 

The Team will work under his supervision to negotiate and finalize four to six contracts with qualifying hospitals for the establishment of Centers for Advanced Diagnostics that will utilize PET-CT technology for detection and evaluation of cancer. 

Working from the model established by PDH in collaboration with the No. 3 Armed Police Hospital in Beijing where the first Center has been operating an MRI scanner for three months, PDH will provide and own the PET-CT scanners. The Centers will be operated in collaboration with the hospitals over a 10 – 12 year period with positive revenues expected to be generated from the outset.

PDH is retaining the services of a senior executive from a major Chinese Trading Company to head up the China Development Team. 

About Premier Diagnostic Health Services Inc. (CNSX:PDH)

As leaders in advanced health and education with the international medical community, PDH is rolling out its global strategy of establishing a network of Centres for Advanced Diagnostics in Canada and China. By utilizing MRI and PET-CT, the most advanced medical diagnostic imaging technology available and the production of FDG, the radiopharmaceutical tracer used in oncology PET procedures; PDH is uniquely positioned to deliver continued innovation, growth and profitability.

Filed Under: Facilities And Providers

SullivanCotter Debuts Philadelphia Office

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Sullivan, Cotter and Associates, Inc.

PHILADELPHIA, PA–(Marketwire – December 2, 2010) – Sullivan, Cotter and Associates, Inc., a health care compensation and human resource management consulting firm, has announced the opening of its newest business location in Philadelphia. With offices in the major markets of Atlanta, Boston, Chicago, Detroit, New York, Parsippany, San Francisco and Westport, Philadelphia was a natural additional market for the nationally regarded compensation consulting firm. The new location is at 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.

“We are enthusiastic about our continued growth in the east coast. Our presence in Philadelphia will allow us to meet our commitment to superior client service and accessibility for local health care organizations,” notes SullivanCotter Managing Director, Chris Terranova. “SullivanCotter’s compensation strategies ensure that organizations are in compliance with a myriad of regulatory matters while also being sensitive to the concerns of their boards,” Terranova adds.

Bruce Greenblatt will open the Philadelphia office as a Principal of the Firm. Greenblatt has more than 14 years of consulting experience with particular expertise in executive compensation in the health care industry, as well as the consumer products, manufacturing and communications industries. He has advised the senior management and boards of nonprofit, publicly-traded and private companies on compensation strategy as well as in the design and implementation of executive incentive and other programs.

Sullivan, Cotter and Associates, Inc. specializes in the assessment and development of total compensation and reward programs for executives and physicians in the health care industry. Since 1992, SullivanCotter has worked closely with health care organization executives, boards and compensation committees to devise innovative compensation solutions that attract and retain leadership talent while satisfying not-for-profit missions and regulatory requirements. A leader in independent consulting, benchmarking, trends and analyses, SullivanCotter has also developed the most widely recognized physician and executive compensation surveys in the United States. For more information, visit www.sullivancotter.com or call 888-739-7039 toll-free. In Philadelphia, please call 484-534-2922.

Contact:
Karolyn Raphael
Winger Marketing
312/494-0422
[email protected]

Filed Under: Facilities And Providers

ALDA Pharmaceuticals Corp.: T36(R) Antiseptic Hand Sanitizer Kills "Superbugs" in 15 Seconds

Posted on December 2, 2010 Written by Annalyn Frame

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 2, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company”) announces that new tests have shown that T36® Antiseptic Hand Sanitizer is completely effective against two types of new “superbugs” within 15 seconds. The testing was conducted at BioScience Laboratories in Bozeman, MT against antibiotic-resistant strains of E. coli and Klebsiella. These strains have taken genes from other bacteria that have developed the ability to digest nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. Such genetic “swapping” is common among bacteria and is a major cause of antibiotic resistance.

Dr. Terrance Owen, President & CEO comments, “T36® Antiseptic Hand Sanitizer works in a completely different way than antibiotics. It kills infectious organisms by disrupting their cell walls so the presence of antibiotic-digesting enzymes does not stop it from working. Since these infections are so dangerous, it is important to prevent them from happening in the first place. Proper hygiene, including the use the of hand sanitizers and disinfectants such as T36® Antiseptic Hand Sanitizer and T36® Disinfectant, is a very important step in preventing the spread of potentially incurable diseases.”

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Filed Under: Facilities And Providers

CBLPath and Sonic Healthcare Limited Finalize Acquisition

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: CBLPath

Deal Closes in Conjunction With Naming New CEO

RYE BROOK, NY–(Marketwire – December 2, 2010) – CBLPath today announced that it is now officially part of Sonic Healthcare Limited’s federation of laboratories.

CBLPath will work closely with Sonic’s clinical laboratory divisions to cross sell services to their respective referrer bases. Significant revenue synergies are expected to be realized from the cross sell opportunities in FY2012 and following years. In addition, there are a number of cost synergies which Sonic can offer CBLPath, particularly in the areas of logistics, purchasing and billing.

CBLPath has been operating under the direction of the Office of the CEO comprised of David W. Bryant, President and Chairman of the Board; Dr. Carlos D. Urmacher, Chief Medical Officer; and Joe Sinicropi, Chief Operating Officer. At this time, the Office of the CEO will be disbanded and Mr. Bryant will assume the role of CBLPath’s Chief Executive Officer. Dr. Urmacher will continue in his role as Chief Medical Officer and Mr. Sinicropi in his role as Chief Operating Officer.

The company will continue to operate under the CBLPath name.

About CBLPath
CBLPath is a national specialty lab offering a full convergence of anatomic, molecular and digital pathology services. The company provides a one-stop solution for comprehensive sub-specialized diagnostics, and timely, accurate, patient-centered disease management guidance. Through its Best Practice™ Partnership Program, CBLPath partners with pathologists to help them grow their practices, while giving them the ability to stay independent and “keep medicine local.” The company also provides sub-specialty physicians access to comprehensive, high-quality testing in their local market. Founded in 1988, CBLPath established a reputation for providing timely, highly accurate diagnoses along with extraordinary customer service and a true patient-centered commitment. For more about the company, please visit www.CBLPath.com.

About Sonic Healthcare Limited
Sonic Healthcare is one of the world’s largest medical diagnostics companies, providing laboratory and radiology services to medical practitioners, hospitals, community health services, and their collective patients. Sonic Healthcare Limited is the parent company of the many operating companies around the world comprising the Sonic Healthcare group. It is a public company, listed on the Australian Securities Exchange (ASX), where it is classified as one of Australia’s “Top 100” companies. Sonic Healthcare has its head office at Macquarie Park in Sydney, Australia, in the same building as the main Douglass Hanly Moir Pathology laboratory. In the medical arena, their success is based on the fact that Sonic Healthcare companies are recognized as quality diagnostic practices that have remained true to the ethical principles of the medical profession. For more about the company, please visit www.sonichealthcare.com.

Filed Under: Facilities And Providers

MediMedia Announces Consolidation of Krames and StayWell Custom Communications to Create Industry-Leading Healthcare Communications Firm

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: StayWell Custom Communications

CHATHAM, NJ–(Marketwire – December 2, 2010) – Today, MediMedia announced the consolidation of two of its largest divisions: Krames Patient Education and StayWell Custom Communications. Industry-leaders in their respective fields, the two organizations will join forces to create a combined company that will be the largest provider of interactive and print patient education solutions and consumer health information in the country. The Krames StayWell team will have an unmatched market presence including nearly 80 sales and account executives, more than 80 product developers and designers, nearly 45 interactive solution developers and technology specialists, and 25 dedicated client services professionals. The two companies will combine into one organization effective January 1, 2011, to be called Krames StayWell.

“There is really only one reason we are taking this action, and it is a powerful one,” said MediMedia CEO Steve Simcox. “We believe that by consolidating our extensive technology and content assets, product development expertise, and client services resources, we can drive greater value for our clients.”

The consolidation is designed to build on the combined strengths of both organizations, allowing Krames StayWell to more easily offer seamless access to a wider breadth of products, consultative professional expertise, technology, and content assets. “There is no question that we can serve client needs better together than separately,” said Patrick Clifford, StayWell Company Chairman.

“Our goal is to make it even easier for our clients to do business with us,” said George Parker, President and CEO of Krames, who will serve as CEO of Krames StayWell. “We will be able to provide enterprise-wide and market-specific solutions designed to drive consumer engagement, improve health outcomes, and lower healthcare costs with unmatched ability to integrate print and interactive solutions. Krames StayWell is uniquely positioned to deliver ROI to our clients across all healthcare markets.”

The executive leadership teams of Krames and StayWell Custom Communications will remain intact, and will combine in new roles. “This is a team that has worked together for an extensive period of time, knows each other well, and thrives on the spirit of collaboration and innovation offered by this consolidation,” said Trent Sterling, President and CEO of StayWell Custom Communications, who will serve as President for the new organization. The company will have more than 330 employees located throughout the country. 

Krames StayWell will represent best-in-class health communication solutions across the entire spectrum of consumer engagement. Products from the combined organizations are used by more than 85% of American hospitals, as well as leading health plans, employers, pharmaceutical companies, retail organizations, and thousands of healthcare professionals in multiple care settings.

Krames Patient Education has a long history of creating exceptional patient education solutions, in print and interactive formats, rooted in patient-centric content created in consideration of health literacy design principles. Krames flagship products designed to initiate positive patient health self-management at the point of care include:

  • Krames On-Demand™ — an electronic, print on-demand system featuring more than 5,300 single topic HealthSheet™ articles covering 38 medical specialty areas and spanning 12 languages.
  • Krames Exit-Writer™ — an electronic emergency department discharge instruction program featuring more than 1,400 discharge instruction covering the most common diagnoses addressed in the ER/Urgent care environment plus a prescription writer and medication reconciliation tool.
  • Krames Video Solutions™ — A suite of tools enabling delivery of more than 430 Patient Education videos spanning nine languages via websites, point of care tools, kiosks, CCTV systems and DVDs.
  • Krames Patient Consent™ — An electronic system designed to standardize and streamline the informed consent process. Via the creation of personalized, procedure specific legal forms and companion patient education written in plain language, Krames Patient Consent™ ensures better patient-provider communication improving outcomes while mitigating legal risk.
  • Krames Go-to-Guides™ — A suite of interactive, multimedia disease management workbooks featuring narrated text, embedded video, and quizzes for learning verification designed to match the learning preferences of almost any patient.
  • Krames Print Materials™ — An award-winning library of more than 1,300 booklets, brochures, tear sheets, and other formats featuring Krames signature art-text synergy.

StayWell Custom Communications has a legacy of creating print and interactive health information and health management communications designed to help healthcare organizations engage and motivate consumers, and deliver measurable ROI. The company will contribute a wide range of award-winning solutions to the new organization, ranging across digital, mobile, print, SEO and professional services:

  • Digital — interactive health libraries and health portals offer more than 30,000 interactive content assets, and include the widely used StayWell Solutions Online™ and StayWell Engage™; microsites, video, email, animations, podcasts and symptom checkers;
  • Mobile — text messaging programs, mobile sites, symptom checker for the iPhone, event promotion, contact center solutions and custom applications;
  • Custom Print Solutions — more than 100 million copies each year of award-winning publications and other print communications for community, member, disease management and client-selected audiences;
  • Search Engine Optimization (SEO) — local search, keyword optimization and conversion optimization; and
  • Professional Services — content integration consultation, Return-on-Investment (ROI) measurement, media integration strategy, and consultative strategy support for creating comprehensive multi-media communications solutions that engage consumers and deliver results.

Both organizations have been committed to helping their clients achieve better health outcomes for consumers for decades. Now united, Krames StayWell is uniquely positioned to provide comprehensive, multimedia health information and communication solutions across multiple consumer touch points — delivering the engaging healthcare information patients and consumers want, when they want it and how they want it, and with a focus on generating measurable results for their clients.

About Krames

Krames (a MediMedia Company) is the market leader in patient education and consumer health information solutions. More than 85 percent of American hospitals, as well as leading health plans, employer groups, private practices and pharmaceutical companies use Krames’ solutions to improve quality of care, streamline workflow and lower healthcare costs. Krames also brings health literacy expertise to American Heart Association/ American Stroke Association and American Lung Association patient education through exclusive partnerships with these respected organizations. Founded in 1974, Krames remains at the leading edge of patient education with innovative programs that utilize a comprehensive suite of print, electronic and video content.

For more information, please visit www.krames.com

About StayWell Custom Communications

StayWell Custom Communications (a MediMedia Company) is the leader in custom health content solutions delivered via a variety of sophisticated technology platforms. Our interactive offerings include robust web platforms, online health libraries, e-mail and mobile marketing programs, an extensive range of multimedia tools including video, podcasts and animations, and health management tools and programs. StayWell Custom Communications also offers a comprehensive range of print and print/interactive integrated solutions to meet a broad range of clients’ marketing and communication needs. The company serves hundreds of clients representing several channels in the healthcare industry: hospitals and health systems; health plans; employers; and retail organizations.

For more information, please visit www.staywellcustom.com

About MediMedia

Headquartered in Yardley, PA, with 1,700 employees in offices throughout the U.S., MediMedia changes consumer and professional behaviors through superior engagement, education and end-user preferences. Our health information services group creates, publishes, distributes, and syndicates on and off-line health information to help consumers make informed health decisions on behalf of a variety of sponsors, including providers — both hospitals and physicians, payers, and online media companies. Our health management services group provides population health management services which help consumers lower their health risk, enabling employers to lower their risks, utilization and ultimately their health care expenses. And finally, our professional segment derives its revenues from providing online/off-line professional promotion, engagement, and education services targeted to healthcare professionals and their patients

MediMedia is a Vestar Capital Partners portfolio company.

For more information contact:
Renee Verrastro
973-378-5133

Click here to see all recent news from this company

Filed Under: Facilities And Providers

Dotmatics Expands Into New UK Headquarters

Posted on December 2, 2010 Written by Annalyn Frame

BISHOPS STORTFORD, UNITED KINGDOM–(Marketwire – Dec. 2, 2010) – Dotmatics, a provider of information and data management solutions to the life sciences industry, is pleased to announce that it has moved into new UK headquarters. Situated in the centre of Bishops Stortford, The Old Monastery is a historic building (link) built in the 17th Century.

Stephen Gallagher, Chief Executive Officer of Dotmatics said, “Moving the company to new headquarters marks a new and important milestone for the company. We have seen significant growth in demand for our solutions over the past few years. Expansion into new premises allows us to continue to provide excellent support and development capabilities.”

About Dotmatics

Dotmatics has rapidly emerged as a preferred Informatics supplier to many of the top global Pharma and Biotech organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, browsed, managed and shared within companies. Dotmatics has significant expertise in cheminformatics techniques including chemical databases, SAR analysis, data management and data visualization. A privately-owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.

Recent Corporate Highlights Include:

Fully web based and searchable ELN launched at EUGM.

http://www.dotmatics.com/news.jsp#id94

Dotmatics opens second U.S. office near Boston Mass.

http://www.dotmatics.com/news.jsp#id93

Heptares Therapeutics chooses Dotmatics platform.

http://www.dotmatics.com/news.jsp#id90

Boehringer Ingelheim license Browser and Vortex.

http://www.dotmatics.com/news.jsp#id81

Spanish Giant Almirall choose Dotmatics for Visualisation

http://www.dotmatics.com/news.jsp#id92

Solution Highlights:

Browser – web-based tool for querying, browsing and visualizing biological databases such as IDBS’ ActivityBase™ and any chemical database.

Vortex – world-class visualization and analytics platform for scientific and non-scientific data.

Gateway – securely enables research teams to share information internally and with external partners.

Pinpoint – powerful Oracle chemical cartridge for querying and integrating chemical databases*. Pinpoint represents world-class indexing and search performance at a cost-effective price.

Register – flexible and scalable chemical registration system.

Nucleus – map and import biological and non-biological data files into an Oracle database.

Studies – the new standard in screening data management.

Studies Notebook – a web-based ELN for all disciplines.

*Pinpoint is developed in collaboration with Astex Therapeutics Ltd

Filed Under: Medical And Healthcare

Planta de Taconic en Colonia, Alemania obtiene acreditación AAALAC

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Taconic

Todos los programas Taconic en el mundo hoy tienen acreditación voluntaria

HUDSON, NY–(Marketwire – December 1, 2010) –
Taconic, un proveedor líder de soluciones de ciencias de la vida para investigadores en todo el mundo, anunció que su programa de producción en Colonia, Alemania obtuvo acreditación de la AAALAC International (la Asociación internacional para evaluación y acreditación de cuidados de animales en laboratorio). Con esta acreditación, todos los programas en el mundo hoy están acreditados AAALAC lo que garantiza a los clientes que Taconic cumple con el más alto estándar de la industria en términos de calidad, salud, integridad genética y cuidados para sus modelos animales.

AAALAC International promueve el tratamiento humanitario de animales en ciencias a través de programas con acreditación y evaluación voluntaria. Taconic fue uno de los primeros proveedores acreditados por la AAALAC International en 1969.

“Desde hace más de cuatro décadas, a través de su participación voluntaria en el proceso de acreditación AAALAC, Taconic ha demostrado su compromiso con el tratamiento humanitario y seguro de los animales de investigación vitales para las ciencias biomédicas de nuestros clientes”, dijo Jeffrey J. Lohmiller, DVM, MS, ACLAM, director global de ciencias veterinarias de Taconic. “El obtener la acreditación AAALAC para todos nuestros programas en todo el mundo es un logro que refleja el enfoque firme de Taconic en calidad y responsabilidad”.

El rigoroso proceso de acreditación requiere una revisión estricta por parte de Taconic y una evaluación exhaustiva en el local por parte de los evaluadores de la AAALAC y una revisión del programa integral de uso y cuidados animales del sitio en Colonia. Para mantener su status de acreditación, todos los programas de Taconic se someten a una reevaluación cada tres años de conformidad con los requisitos de la AAALAC.

Según AAALAC International, más de 800 compañías, universidades, hospitales, agencias gubernamentales y otros instituciones de investigación han obtenido esta prestigiosa acreditación.

Acerca de Taconic
Taconic es un proveedor líder de soluciones de ciencias de la vida para investigadores de todo el mundo, ofrece modelos innovadores de animales de laboratorio y servicios científicos que facilitan estudios “in vivo” y fomentan el descubrimiento de fármacos. La vasta gama de soluciones avanzadas de Taconic comprende el diseño, la generación y la producción de modelos personalizados, los repositorios de modelos comerciales, la caracterización de compuestos, la investigación por contrato, la crianza por contrato, el monitoreo genético y las pruebas de salud. Taconic, con sede en el valle del río Hudson en Nueva York, opera siete plantas de reproducción y crianza y tres laboratorios de servicio en Estados Unidos y Europa y mantiene un personal de más de 1.000 especialistas científicos dedicados a la innovación tecnológica. Información adicional acerca de Taconic está disponible en, www.taconic.com.

Filed Under: Medical And Healthcare

Instalação da Taconic em Colônia, Alemanha recebe certificado AAALAC

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Taconic

Todos os programas da Taconic em todo o mundo agora têm credenciamento voluntário

HUDSON, NY–(Marketwire – December 1, 2010) –
A Taconic, provedora líder de soluções em vivo para pesquisadores de ciências da vida de todo o mundo, anunciou hoje que o seu programa de produção em Colônia, Alemanha, recebeu a acreditação AAALAC International (Associação Internacional de Avaliação e Acreditação de Cuidado de Animais em Laboratório). Com esta acreditação, todos os programas Taconic em todo o mundo agora são acreditados AAALAC para garantir para os clientes que a Taconic está em conformidade com os mais altos standards de qualidade, saude, integridade genética e cuidado dos seus modelos animais.

A AAALAC International promove o tratamento humano dos animais na ciência através de acreditações e programas de avaliação voluntários. A Taconic foi uma das primeiras fornecedoras a ser acreditada pela AAALAC International em 1969.

“Há mais de quatro décadas, com o nossa participação voluntária no processo de acreditação da AAALAC, a Taconic demonstra a sua dedicação para com o tratamento seguro e humano dos animais de pesquisa que são vitais para a pesquisa biomédica dos nossos clientes”, disse Jeffrey J. Lohmiller, DVM, MS, ACLAM, Diretor Sênior Global de Ciências Veterinárias da Taconic. “A obtenção da acreditação AAALAC em todos os nossos programas do mundo é uma conquista que demonstra o foco inalterável da Taconic na qualidade e responsabilidade”.

O processo rigoroso de acreditação exigiu uma revisão interna por parte da Taconic e avaliação compreensiva no local pelos avaliadores da AAALAC, que fizeram uma análise de todo o cuidado animal e programa de uso nas instalações na Colônia. Para manter o status de acreditada, todos os programas da Taconic passam por uma reavaliação a cada três anos de acordo com as exigências da AAALAC.

De acordo com a AAALAC International, mais de 800 empresas, universidades, hospitais, agências governamentais e outras instituições de pesquisa receberam esta acreditação tão prestigiada.

Taconic
A Taconic é a provedora líder de soluções de ciências da vida para pesquisadores de todo o mundo, oferecendo modelos inovadores de animais de laboratório e serviços científicos que facilitam os estudos in vivo e o avanço da descoberta de medicamentos. Nas soluções avançadas da Taconic estão incluídas a geração e a produção de modelos de ratos e camundongos geneticamente modificados, reprodução de contrato, repositórios de modelos de prateleira, perfis de compostos, pesquisa de contrato, imagem, monitoramento genético e testes de saúde. Com sede no Hudson River Valley em Nova York, a Taconic opera sete locais de reprodução e três laboratórios de serviço nos EUA e Europa, e tem uma equipe de mais de 1.000 especialistas científicos dedicados à inovação tecnológica. Para mais informações sobre a Taconic, acesse www.taconic.com.

Filed Under: Medical And Healthcare

4,000th Horse Treated Using Vet-Stem Cell Therapy

Posted on December 2, 2010 Written by Annalyn Frame

SOURCE: Vet-Stem

POWAY, CA–(Marketwire – December 1, 2010) – Vet-Stem, the world’s leading Regenerative Veterinary Medicine™ company, is pleased to announce a new milestone of 4,000 horses treated with Vet-Stem Cell therapy.

Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of 4,000 horses. Greater than 75% of horses treated with Vet-Stem Cell therapy for tendon and ligament injuries are able to return to their previous level of performance. What was a new treatment option in 2004 has become the gold standard for performance horses with tendon and ligament injuries.

“We are proud that so many horse owners and veterinarians have placed their trust in Vet-Stem Cell therapy. We feel a great sense of accomplishment knowing that there are thousands of horses and horse owners who have experienced the benefit of stem cell technology. This practical and beneficial application of technology puts stem cell therapy into the present day instead of a future theoretical concept,” said Bob Harman, DVM, MPVM, Founder and CEO of Vet-Stem.

Vet-Stem has also provided stem cells for thousands of dogs with arthritis with a similar success rate. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary medicine. Vet-Stem is now working with small animal veterinarians to develop uses for stem cell therapy for injuries and diseases that currently have few treatment options.

More information about Vet-Stem can be found at www.Vet-Stem.com.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. Vet-Stem has exclusive licenses to over 50 patents including worldwide veterinary rights for use of adipose derived stem cells.

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

WellTek Expands Into the Virtual Event Market

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: WellTek Incorporated

ORLANDO, FL–(Marketwire – December 1, 2010) – WellTek, Inc. (OTCBB: WTKN), a global health, fitness and wellness company, announced today that it plans to expand into the virtual event market, specializing in the healthcare and wellness niche, by launching a new wholly-owned company, WellTek Events, Inc. This next-generation virtual event platform will serve as the foundation in allowing WellTek and other brands to actively reach, engage and influence health and wellness conscious consumers with new and existing brand assets, technologies, products and services.

According to the Virtual Conference and Trade Show Market Study 2010-2015, the worldwide virtual conference and trade show market is forecasted to grow at a compound annual growth rate (CAGR) of 56% between the period of 2010 and 2015 and to generate $18.6 billion in revenues over the period 2010 – 2015. While the virtual event market is still in its infancy, WellTek intends to launch into the virtual event business.

WellTek Events is looking to become the industry leader in producing and delivering powerful virtual events for the healthcare and wellness market — linking exhibitors, attendees, and thought leaders together in a fully immersive and engaging virtual environment. 

Without the costs, hassles and time involved in a physical event, participants navigate through the 3D game-like world booth by booth via an avatar. Advances in technology allow exhibitors to actively reach, engage and influence a highly targeted global audience, create and customize virtual booths, communicate with prospects via video conferencing and live chat, convert leads to customers in real-time with the Ecommerce platform, generate reports and analytics to tract ROI and many more features that ultimately turn prospects into buyers and customers into raving fans.

The integration of virtual events, social networking and social gaming permits attendees to overcome the challenges facing the traditional trade show market, as well as take advantage of the benefits of social media: staying in constant contact, sharing opinions, recommendations and links, getting answers right away and feeling connected to the information they care most about — all while being entertained.

Randy Lubinsky, Chairman and CEO of WellTek, stated, “With over 40 years experience in the medical industry and interacting with physicians, we believe we can leverage our expertise to establish WellTek Events as the premiere company for virtual medical conferences and wellness events.”

In an effort to focus time and capital on WellTek Events, the company has decided to rescind the acquisition of its 51% interest in WellCity, Inc. As part of the rescission, 14,500,000 shares of WellTek common stock will be returned to WellTek and the financial position of both companies will return to that prior to the May 1, 2010 acquisition.

In addition, WellTek has also effectuated a 50 to 1 reverse split as of December 2, 2010 in order to facilitate raising additional growth capital.

About WellTek Incorporated
WellTek is a global health, fitness and wellness company that provides proven solutions to help address some of the world’s most pressing and costly health and wellness challenges. The Company owns and operates WellTek Events, Inc., a fully engaging virtual event platform specializing in the healthcare and wellness market. The Company’s subsidiary, MedX Limited, manufactures, markets and distributes the most advanced medical exercise equipment to the medical and fitness markets. Through its wholly owned subsidiary Pure HealthyBack, Inc., WellTek is redefining healthcare delivery by providing health plans, self-insured employer groups, and consumers with a viable non-surgical, lower cost treatment for patients who are seeking lasting relief from chronic neck and back pain. For more information on the Company, please contact [email protected] or visit www.WellTekinc.com. 

Certain statements contained in this press release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective Company’s Securities and Exchange Commission filings, that may cause actual results to materially differ from projections. Although the Company believes that its expectations are reasonable assumptions within the bounds of its knowledge of its businesses, expectations, representations and operations, there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the Company’s ability to execute properly its business model, to raise additional capital to implement its continuing business model, the ability to attract and retain personnel — including highly qualified executives, management and operational personnel, ability to negotiate favorable future debt facilities and capital raises, and the inherent risk associated with a diversified business to achieve and maintain positive cash flow and net profitability. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will, in fact, occur. 

WellTek, Inc.
[email protected]

Filed Under: Facilities And Providers

PPMIS Launches The Practice Readiness Roadmap

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: PPM Information Solutions

MISSION, KS–(Marketwire – December 1, 2010) – PPM Information Solutions, Inc. (PPMIS) (www.ppmconnect.com) publishes “The Practice Readiness Roadmap — your route to a successful start.” Dedicated to serving the anesthesia community, PPMIS is forging its presence in the medical community and delivering its guide for assisting physicians who are considering starting a practice or moving to a new software vendor or billing service. Download a free copy.

For over a decade, PPMIS has developed first-rate software for medical billing solutions. Formed by anesthesiologists to serve the anesthesia specialty, the company’s goal is providing its clients with industry-leading software products and services. Because PPMIS understands the complexity of billing for anesthesia, its products and services take the everyday complications out of medical billing.

The company’s newest platform, a SaaS model, is medical billing software with flexibility, a full range of reporting options, and strictly enforced exception edits, ensuring claim accuracy that result in prompt reimbursement. The fully integrated Connect platform provides accelerated claims processing, streamlined collections management, and reporting capabilities.

RCM Services, its full-service medical billing service, offers multi-specialty billing, certified coding, SaaS technology, demographic and EMR downloads, payer credentialing, and practice advocacy. Proven metrics ensure the success of the client’s practice. The company believes when the client succeeds, it succeeds. Learn more about PPMIS practice management services.

About PPM Information Solutions, Inc.
PPMIS is a medical billing provider that helps clients recognize revenue faster by submitting clean claims. The company offers both billing software and billing services as its medical billing solutions. This U.S. based company does 100% of its software development at its headquarters in Mission, KS. Its staff is dedicated to delivering the most comprehensive solutions available for medical billing. PPMIS billing solutions and the Practice Readiness Roadmap free practice assessment can be found at www.ppmconnect.com.

Direct inquiries to [email protected], or contact Manolito Jones or Dan Olin at 913-262-2332 to request a product demonstration.

Contact:
Manolito Jones
or Dan Olin
913-262-2332
Email Contact

Click here to see all recent news from this company

Filed Under: Facilities And Providers

TomoTherapy Sponsors American Cancer Society’s Fall 2010 Matching Grant Challenge

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: TomoTherapy

TomoTherapy to Match up to $100,000 in Donations by Dec. 15

MADISON, WI–(Marketwire – December 1, 2010) –  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it is the exclusive sponsor of the American Cancer Society’s Fall 2010 Matching Grant Challenge, a national fundraising campaign that was launched in November.

As sponsor, TomoTherapy will contribute $1 for every $1 donated by the general public, up to $100,000, to support the American Cancer Society’s efforts to help people stay well and get well from cancer, find cures, and fight back against the disease. The Matching Grant Challenge ends on December 15, 2010.

“Every day, TomoTherapy’s innovative radiation therapy solution helps patients fight cancer. With our support of the American Cancer Society, we extend our impact beyond technology,” said Fred Robertson, M.D., TomoTherapy’s CEO. “In matching the generous contributions of individuals, TomoTherapy proudly strengthens the efforts of the American Cancer Society — from funding groundbreaking research to providing resources for patients, their families and caregivers at every step in the cancer experience.”

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Media Contacts:
Kevin O’Malley
Manager, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact

Filed Under: Medical And Healthcare

GammaTech’s Fully Rugged MT10L Clinical Tablet PC Keeps Healthcare Records Secure Inside and Out

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: GammaTech Computer Corporation

Equipped With Intel® Health Mobile Clinical Assistant Solutions Reference Architecture, MT10L Simplifies and Advances the Healthcare Environment

FREMONT, CA–(Marketwire – December 1, 2010) – GammaTech Computer Corp., a major international manufacturer and supplier of innovative notebook and tablet computers, brings its military-grade rugged design and versatile computing to the fast-paced healthcare environment with the MT10L clinical tablet PC. Featuring advanced Intel® Health Mobile Clinical Assistant Solutions reference architecture, a recognized leader in the industry, the MT10L is an ideal mobile solution for healthcare providers searching for an easier way to maintain accurate, timely and instantly accessible records.

“Our MT10L clinical tablet PC is both a simplification and an innovation when it comes to record-keeping for healthcare professionals,” stated Steven Gau, GammaTech president. “Its myriad features allow healthcare workers to make notes in patient-care records at the point of care and document patients’ conditions in real time, ensuring heightened accuracy in documentation. This leads to a reduction in medical errors, enhanced workflow, faster, safer patient care, better transcription efficiencies, better insurance practices and more accurate billing.”

At under three pounds, with a slim, clipboard-style design and molded ergonomic handle, the GammaTech MT10L clinical tablet PC is easy to carry and hold during those long shifts. The 10.4″ high-resolution (1024×768) XGA TFT LCD display features brightness adjustment, eliminating eyestrain, while the resistive touchscreen responds to both fingertips and the included stylus pen. Your shift will never be interrupted by the need to recharge, as hot-swappable twin battery packs provide up to eight hours of life. The fully sealed fan-less design offers ingress protection to guard internal components. In an environment where technology is susceptible to damage from slips and liquids, the MT10L is military-grade in its durability: the fully sealed design ruggedly protects internal components, making the tablet drop-proof, spill-proof, shock-proof, dust-proof, watertight and alcohol and disinfectant wipe resistant (to protect against cross contamination).

Recording patients’ progress as it happens is a snap — literally. The MT10L’s two-megapixel camera with auto-focus enables quicker, more detailed documentation of wounds, surgical sites, range of motion and other conditions, and photos can be saved directly to a patient’s electronic medical record. The MT10L is specifically designed to take advantage of all the features and innovations inherent in Electronic Medical Record advancements. Furthermore, the introduction of this line advances the fiscal incentive programs offered by the Federal government in order to promote electronic healthcare record adoption by clinicians and healthcare facilities. Other features include a docking station, AC power connector, built-in RFID reader and a barcode reader to help reduce prescription errors.

The GammaTech MT10L clinical tablet PC supports both Wi-Fi and Bluetooth technologies and runs on Windows 7 Professional, Vista Business and XP Tablet Edition operating systems.

Availability
The MT10L — along with the entire GammaTech product line — is available to healthcare professionals, hospitals, group purchasing organizations, government entities and universities through authorized GammaTech resellers nationwide. For more information, please visit www.gammatechusa.com.

About GammaTech Computer Corporation
For over two decades, GammaTech Computer Corporation is a leader in the design, manufacturing and sales of rugged and hardened notebook and tablet computers throughout North America. GammaTech promotes its award winning, built-to-order durable mobile computers to businesses, government, healthcare, fire, law enforcement and public safety entities. GammaTech is headquartered in Fremont, California, which provides the final assembly, inventory, service and technical support.

For more information, please visit GammaTech at www.GammaTechUSA.com.

All products/services and trademarks mentioned in this release are the properties of their respective companies.
© 2010 GammaTech Computer Corporation. All rights reserved.

PR Contact:
Rita Lee
Public Communications Worldwide
Email Contact
Tel.: 714-891-3660

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Taconic Facility in Cologne, Germany Receives AAALAC Accreditation

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: Taconic

All Taconic Programs Worldwide Now Have Voluntary Accreditation

HUDSON, NY–(Marketwire – December 1, 2010) – Taconic, a leading provider of in vivo solutions to life science researchers worldwide, announced that its Cologne, Germany production program has earned accreditation from AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International). With this accreditation, all Taconic programs worldwide are now AAALAC accredited thereby assuring customers that Taconic meets the highest industry standard of quality, health, genetic integrity and care for its animal models.

AAALAC International promotes the humane treatment of animals in science through voluntary accreditation and evaluation programs. Taconic was one of the first suppliers to be accredited by AAALAC International in 1969.

“For more than four decades, through our voluntary participation in the AAALAC accreditation process, Taconic has demonstrated its commitment to the safe, humane treatment of the research animals that are vital to our clients’ biomedical research,” said Jeffrey J. Lohmiller, DVM, MS, ACLAM, Global Senior Director, Veterinary Sciences, Taconic. “Attaining AAALAC accreditation across all of our programs worldwide is an achievement that reflects Taconic’s unwavering focus on quality and accountability.” 

The rigorous accreditation process required both a stringent internal review by Taconic and a comprehensive, on-site assessment by AAALAC evaluators, reviewing the Cologne site’s entire animal care and use program. To maintain their accredited status, all Taconic programs undergo re-evaluation every three years as per AAALAC requirements.

According to AAALAC International, more than 800 companies, universities, hospitals, government agencies and other research institutions have earned this prestigious accreditation.

About Taconic
Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative lab animal models and scientific services that facilitate in vivo studies and advance drug discovery. Taconic’s wide range of advanced solutions include custom genetically modified rat and mouse model generation and production, contract breeding, off-the-shelf model repositories, compound profiling, contract research, imaging, genetic monitoring and health testing. Headquartered in New York’s Hudson River Valley, Taconic operates seven breeding facilities and three service laboratories in the U.S. and Europe and maintains a staff of over 1,000 scientific specialists committed to technological innovation. Additional information about Taconic is available at www.taconic.com.

For Taconic media inquiries:
Susan Fogt
Marketing Communications
518.697.3962
[email protected]

Filed Under: Medical And Healthcare

Green Carpet Care From Amano Pioneer Eclipse

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: Amano Pioneer Eclipse

SPARTA, NC–(Marketwire – December 1, 2010) – Amano Pioneer Eclipse® (“APEC”), a worldwide manufacturer of professional floor care products, makes it easy to be green even when cleaning carpets. Their EnviroStar Green® carpet care system is an effective and cost saving method to meet many of today’s green requirements. The system is comprised of four products — a dual purpose extractor & pre-spray cleaner, an extraction rinse, a soil release bonnet buff and an all purpose spotter. 

APEC chemists developed EnviroStar Green from specific raw ingredients that met specific green requirements. The benefits of using the EnviroStar Green system however, go well beyond meeting strict environmental standards. “Our green products are not only earth friendly, they also reduce certain ill effects produced by other conventional systems,” states Jacqueline Van Delft, VP of International Operations at Amano Pioneer Eclipse. “We use raw ingredients that are not classified as skin sensitizers to lower irritancy commonly found in traditional chemistry. This produces a more comfortable and healthier environment for everyone.”

Most traditional cleaning processes leave some residue on the carpet. Not only can this residue trigger allergic reactions in many people, it also affects future maintenance and replacement costs. Acting like glue, residue can quickly attract new dirt to a recently cleaned floor. Commonly known as resoiling, this dirt build-up leads to more frequent cleanings that shorten the life of the carpet.

To minimize residue, Amano Pioneer Eclipse formulated EnviroStar Green products with pH levels less than 10. Compared to some traditional carpet products with levels as high as 11 to 13, a more neutral pH allows more of the chemical to be extracted, is less damaging to carpet fibers and retains existing stain blocking treatments that extend the carpet’s life. 

The EnviroStar Green carpet care system does more than reduce the environmental impact of traditional cleaning. Competitively priced, these products lower downtime and maintenance costs, extend carpet life, reduce cleaning frequency and improve the health and safety of the surrounding environment. And, most of all, they produce results as good as or better than their more harmful counterparts. It’s no wonder that professionals around the world are turning to Amano Pioneer Eclipse for all their carpet care chemicals. For more information on EnviroStar Green Carpet Products and numerous other Amano Pioneer Eclipse floor care systems, please visit www.pioneer-eclipse.com. In the US call 1-800-367-3550. For international inquires call 1-336-372-8080.

About Amano Pioneer Eclipse – since 1978, Amano Pioneer Eclipse has provided building service contractors with mechanical and chemical solutions for cleaning and maintaining all types of flooring.

Contact:
Amano Pioneer Eclipse
www.pioneer-eclipse.com
1-800-367-3550
1-336-372-8080

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Oregon’s Northwest Primary Care Chooses Sage for PACS Medical Imaging

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: Sage

TAMPA, FL–(Marketwire – December 1, 2010) – Sage Healthcare Division, a unit of Sage North America and a major provider of EHR and practice management software and solutions serving approximately 80,000 physicians in North America, today announced that Northwest Primary Care, a 25 physician, physician-owned practice in southeast Portland, has selected Sage to provide the IMPAX PACS (picture archiving and communication system). This new medical imaging system will augment the practice’s existing Sage Intergy practice management and EHR system. 

Sage Healthcare Division offers the IMPAX, a comprehensive PACS, through an arrangement with Agfa HealthCare. The IMPAX solution will allow Northwest Primary Care to more efficiently manage its growing medical imaging services and improve efficiency in reading and reporting on medical imaging studies.

Northwest Primary Care is moving away from film and chose the PACS through Sage to improve patient care and increase quality outcomes, said administrator Michael Whitbeck. “We sought a sophisticated PACS system that will allow our radiologists and physicians to look at the film right from the record, and to allow for more mobility of our radiologists who will be able to view film from anyone, on or off site,” Whitbeck said.

PACS also will reduce the need for redeveloping images related to over and under exposed film, a common problem with film images, said Whitbeck. “We’ll be able to alleviate those issues with PACS, and from that perspective, improve overall quality of care for patients,” he said. 

Northwest Primary Care has four locations throughout southeast Portland, Oregon, and hosts more than 81,000 patient visits per year. In addition to implementing the Agfa HealthCare PACS system through Sage, it has used Sage Intergy EHR for its practice management and electronic health records since 2006. Sage Intergy EHR is fully compatible with the Agfa HealthCare PACS solution, and allows for the viewing of patient images through the EHR. Sage Intergy EHR also can integrate its Radiology Information Systems (RIS) with the Agfa HealthCare solutions.

“Sage remains dedicated to its clients and committed to health centers such as Northwest Primary Care because of the trust they place in our products to improve health outcomes for patients,” said Betty Otter-Nickerson, president of Sage Healthcare Division. “Providing a multitude of solutions, such as an integrated PACS solution to go along with our EHR, shows our dedication to improving practice efficiency and remaining true to our mission of being physician focused and patient centric.”

Sage is a reseller of the Agfa HealthCare PACS and Computed Radiology (CR) solutions and offers installation of the PACS software, along with user support and training.

Sage has provided healthcare software solutions to streamline patient care for nearly 30 years, and is a leading supplier of business management software and services, serving more than 6.2 million small and midsized business customers worldwide.

View Sage Healthcare Division YouTube interviews.

View Sage Healthcare Division information.

About Sage Healthcare Division
Sage Healthcare Division provides integrated electronic health records, EDI applications and practice management systems to approximately 80,000 physicians and thousands of ambulatory care practices throughout North America. These systems enable physicians and practice managers to better manage their practices and improve profitability. Sage Healthcare Division is based in Tampa, Fla., and is a division of Sage North America. For more information, please visit www.sagehealth.com or call (877) 932-6301.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.2 million small and midsize business customers. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,400 people and supports 6.3 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

© 2010 Sage Software, Inc. All rights reserved. Sage, the Sage logos, and the Sage product and service names mentioned herein are registered trademarks or trademarks of Sage Software, Inc. or its affiliated entities. All other trademarks are the property of their respective owners.

Media Contact:

Scott Rupp
Sage North America
813-249-4264
[email protected]

Filed Under: Medical And Healthcare

miCARD(R) Introduces Lifesaving Holiday Gift Card

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: miCARD

The miCARD Gift Card Gives Emergency Medical Personnel Instant Access to a User’s Critical Medical Information, 24/7, Worldwide

SCOTTSDALE, AZ–(Marketwire – December 1, 2010) – The holidays are the perfect time to show loved ones just how much you care. This year give your family and friends the miCARD Gift Card. The only holiday gift card that could save their life in a medical emergency.

At $14.95, the miCARD Gift Card (www.micard.com/migift) is the perfect stocking stuffer to help ensure the health and safety of those you care about most. miCARD’s wallet card gives first responders a readable summary of a loved one’s vital medical information 24/7, worldwide. In less than one minute, miCARD ensures that medical personnel have the essential information they need to make lifesaving decisions from any location. The miCARD Gift Card can be created securely online and is offered as either a printed gift certificate or it can be emailed for those hard-pressed to meet holiday postal deadlines.

“The holiday season reminds us of how much we care about family and friends. Most of us would do anything to ensure their health and safety,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “We wanted to create a holiday gift that offered real value and could actually save lives. Carrying medical information is a proactive step that could both improve your care and save your life.”

Are You Prepared for a Medical Emergency?
1 in 3 Americans will experience a medical emergency this year, yet most of us carry nothing that describes our unique medical background or identifies loved ones to contact in the event of a medical emergency. It’s critically important that individuals of all ages organize and manage their personal medical information in preparation of an unexpected medical event.

miCARD is the only medical information card and online Personal Health Record designed by an emergency physician. miCARD’s wallet card is designed to provide emergency personnel, in the field, a readable summary of a users vital medical information such as: medical conditions, critical medications, emergency contacts, allergies and more. The portable medical card is further supported by an online Personal Health Record containing additional medical information: advance directives, physician contacts, EKG, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

miCARD’s Holiday Gift Card is a low cost solution to the problem of emergency preparedness and care. To order your miCARD Gift Card visit www.micard.com/migift

About miCARD®
miCARD® is a physician-designed, medical information card and online Personal Health Record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information 24/7, worldwide. For more information about miCARD, please visit www.micard.com or contact us at (866) 596.2956.

Contact:
Media Relations
[email protected]
(866) 596.2956

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Cardiothoracic Surgeons Group and The Toledo Hospital Ranked Above Average for Heart Surgery

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: ProMedica Health System

TOLEDO, OH–(Marketwire – December 1, 2010) – Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are now in the nation’s top 12% of hospitals for heart surgery. This is according to a three-star comprehensive rating system, developed by The Society of Thoracic Surgeons (STS), which compares the quality of heart surgery in hospitals across the country. A three-star rating is the highest designation that a hospital can attain for quality and clinical excellence. Cardiothoracic Surgeons for Northwest Ohio was compared to more than 1,000 surgical groups.

Hospitals are scored on performance in the following four categories — patient survival, absence of surgical complications, recommended medications, and optimal surgical technique. The ratings reflect results from isolated heart-bypass operations called coronary artery bypass grafting to newer versions, which include minimally invasive bypass and other complex cardiac procedures.

“I am grateful to my partners and colleagues at The Toledo Hospital who have worked diligently for years to reach this incredible milestone,” said Michael Moront, MD, senior partner, Cardiothoracic Surgeons for Northwest Ohio. “When patients enter our doors, they can feel confident that they will be receiving the very best care from one of the nation’s leading medical groups.”

Consumers can easily see how surgical groups compare with national benchmarks for survival, complications, and other measures by visiting www.consumerhealthreports.org.

About STS
The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,000 surgeons, researchers and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus as well as other surgical procedures within the chest. Founded in 1964, the mission of STS is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Its National Adult Cardiac Surgery Database includes more than 4 million surgical records and covers roughly 90% of the more than 1,000 surgical groups in the U.S. that perform cardiac surgery, making it the largest such registry in the world.

About Cardiothoracic Surgeons for Northwest Ohio
Cardiothoracic Surgeons for Northwest Ohio is a member of ProMedica Heart and Vascular Institutes, a collaboration of physicians, technology and specialty services. The group provides a comprehensive scope of leading edge patient care and state-of-the-art surgical procedures, including minimally invasive procedures, bloodless surgery, pediatric cardiac surgery, aortic valve repair and replacement and more. Its team of board-certified physicians, specialists and medical staff make up the largest cardiothoracic surgical program in northwest Ohio.

For more information about cardiac services at ProMedica Health System, visit www.promedica.org.

Cardiothoracic Surgeons for Northwest Ohio and The Toledo Hospital are members of ProMedica Health System. ProMedica, a mission-based organization, was formed in 1986 and is a Toledo, Ohio-based, not-for-profit healthcare organization with more than 14,000 employees; 3,000 physicians and more than 306 facilities in Ohio and Michigan. ProMedica serves more than 2.73 million patients annually and includes 11 hospitals; ProMedica Continuum Services with senior, hospice, rehabilitation, and integrative services; ProMedica Physician Group, a network of more than 315 primary care and specialty physicians; and Paramount Health Care, the largest HMO in northwest Ohio. For more information, please visit www.promedica.org.

Contact: Tedra White
Office: 419-469-3716
Cell: 419-262-0371

Filed Under: Medical And Healthcare

Patient Tracking a Success During BHEPP Emergency Response Drill

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: Versus Technology, Inc.

TRAVERSE CITY, MI–(Marketwire – December 1, 2010) –  Just ten weeks after Versus Technology, Inc. (Versus) (PINKSHEETS: VSTI) was selected to support the Bethesda Hospitals’ Emergency Preparedness Partnership (BHEPP) Real-time Locating System (RTLS) initiative, the Versus Advantages™ system was recently utilized during the organization’s disaster preparedness drill.

The October 14, 2010 drill was the sixth annual Collaborative Multi-Agency Exercise (CMAX-10) since the BHEPP was formed in 2004, and the first to utilize RTLS for continuity of patient information. Participating organizations included Suburban Hospital, Johns Hopkins Medicine, the National Naval Medical Center (both trauma centers), the U.S. NIH Clinical Center, and the National Library of Medicine. The drill was designed to test the medical readiness and response proficiency supposing a mass casualty in the National Capital Region. Surge capabilities and patient tracking were key components to be tested.

The BHEPP began exploring RTLS options after the inability to track patients during a mass casualty event had been documented as a gap in multiple real disasters. The U.S. Navy produced a video for CMAX-09, in which, Brian Grangnolati, President, Suburban Hospital states, “If you think about what the biggest problem is in any crisis, it’s communication and moving information” as he explains the need for RFID / RTLS. Versus’ RTLS was selected to enhance communication and keep information tied to patients, even as they are moved from facility to facility.

The BHEPP’s goal is to create a sustainable response model that can be replicated in other areas, especially densely populated areas at risk for national disasters or terrorist attacks. “Having real-time information related to the victim’s arrival and location was immensely helpful to the first-time Incident Commander in his decision making,” says Cindy Notobartolo, Division Director ED/Trauma, Safety & Security Services at Suburban Hospital. “Within our patient information system, the patient’s location was tied to triage and treatment data and made available in real-time to all emergency care personnel. The external evaluators were impressed that our tracking ability was 100% throughout the exercise.”

During the drill, as victims arrived at Suburban Hospital triage area, they were decontaminated, triaged and assigned Versus ID badges which were worn clipped to the victim’s clothing. A photo of the victim was also taken to support Lost Person identification and family reunification efforts. Emergency personnel then transported the patient to the appropriate treatment area.

The Versus ID badges, which emit digitized infrared (IR) and radio-frequency identification (RFID) signals, immediately communicated the patient’s location and triage level to care providers and Central Command via the BHEPP’s patient information system. When patients were reassessed, treated or moved to other areas, their locations were updated in real-time. Location of key personnel and equipment was also provided in real-time.

Versus prepared views and rules to support the key RTLS drill functionality as outlined below.

  1. Real-time locating of all patients from decontamination and triage through discharge or hospital admission. 
  2. Rules-based pediatric monitoring, with location-based alerts to help ensure children are secure and monitored at all times. The CMAX-10 drill did not take advantage of the dedicated pediatric area; however, the rules for monitoring and securing pediatric patients are in place and fully functional for future use. 
  3. Real-time locating of critical equipment to decrease time to locate, improve utilization and support sharing across participating facilities. 
  4. Web service integration with National Library of Medicine’s Patient Tracker for badge assignments, triage level and patient demographic information as it became available to the provider.
  5. Real-time locating of key mass casualty incident personnel to improve communication and enhance decision-making capabilities of the Incident Commander. 
  6. Tracking the evacuation of current hospital patients and their arrival at remote partner facilities for expanded surge capacity.

CMAX-10 was a valuable exercise for both the BHEPP and Versus; each organization identified areas for improvement related to expanded use, patient identification, training, information availability, advanced rules for patient transfer and make-ready operations. They look forward to building on this foundational experience to enhance communication and safety during future drills and in the event an actual response is required.

About BHEPP
This partnership is a first-of-its-kind collaboration that links military, federal, local and private mass disaster medical response efforts within the national capital area. Established in 2004, the partnership is now a model for other health care agencies throughout the country.

About Versus Technology, Inc.
Established in 1988, Versus Technology, Inc. specializes in real-time location systems (RTLS) for healthcare. Used for enterprise patient tracking, bed management, asset tracking, and nurse call automation, Versus Advantages™ improves patient flow and documentation of caregiver and patient interactions, while enhancing communication and efficiency. Exclusively endorsed by the American Hospital Association, the Versus Advantages infrared (IR) and Active RFID solution is responsible for clinical-grade location and automation at a number of hospitals, clinics and long-term care facilities worldwide. To learn more about Versus Technology, Inc. (PINKSHEETS: VSTI), our technology and client successes, visit www.versustech.com and take the Advantages Tour.

Safe Harbor Provision
This release may include forward-looking statements which “bespeak caution,” and which are subject to risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. The statements are made only as of the date of this release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

Media Contact:
Versus Technology, Inc.
Stephanie Bertschy
Director of Marketing
877.983.7787
Email Contact

Investor/Analyst Contact:
Versus Technology, Inc.
Joseph Winowiecki
Chief Financial Officer
231.946.5868
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

LumaMed Adds Cancer Imaging Technology From the Wellman Center for Photomedicine

Posted on December 1, 2010 Written by Annalyn Frame

SOURCE: LumaMed

New Technology Could Revolutionize Cancer Surgery

ATLANTA, GA and BOSTON, MA–(Marketwire – December 1, 2010) – LumaMed LLC has entered into an initial agreement with Massachusetts General Hospital to commercialize an imaging system developed at the Wellman Center for Photomedicine that could revolutionize cancer surgery.

The technology is complementary to that previously licensed by LumaMed from Providence Hospital in Oregon for teledermatology imaging, and has the demonstrated ability to provide real-time surgical guidance, enabling a surgeon to “see” cancer margins.

LumaMed’s cancer imaging technology addresses an estimated $1 billion market opportunity for products that improve efficiency and efficacy in cancer removal procedures. Cancer margin delineation is critical in instances where tissue preservation is important, including skin, head and neck, breast, prostate and brain surgeries.

LumaMed is initially focusing on skin cancer, which is the most common of all cancers. Each year, over one million new cases of skin cancer are detected and many require painstaking and expensive Mohs surgery. Once cleared by the FDA, LumaMed plans to market the new devices to Mohs skin cancer surgeons as a visual aid to help eliminate the need for more than one surgical stage, thus improving patient care and creating a substantial economic benefit.

“In combination with a trained physician, we believe LumaMed’s technology could complement histopathological evaluation, help accurately define margins and reduce the occurrence of biopsies,” said Mark A. Samuels, chief executive officer of LumaMed. “The technology agreement with Massachusetts General Hospital will provide us with the additional tools necessary for development and commercialization of our image-guided surgical systems for the real-time evaluation of skin lesions and other cancers.”

LumaMed is combining two powerful approaches for rapid, easy and cost-effective onsite and remote evaluation of suspicious skin lesions using polarization-based spectroscopic imaging technology. Called “Polarization Subtraction Imaging,” PsiScan technology selectively samples the dermal/epidermal junction and papillary dermis, where cancer originates, and enhances image clarity by rejecting surface scatter and light from deeper layers. This results in images with significantly greater clarity and contrast for improved tumor identification and margin delineation. Clarity and contrast is required in skin cancer evaluation to recognize the disruption of the rich texture of the papillary dermis or to detect tumor silhouettes that identify basal cell carcinomas. Such disruption is difficult to discern with existing dermatoscopes or point-and-shoot digital cameras.

About LumaMed, LLC.
LumaMed is developing devices that provide rapid, easy and improved imaging of cancer based on patented “Polarization Subtraction Imaging” (PSI) technology. LumaMed’s revolutionary cancer visualization tools enable real-time imaging of cancer margins during surgery with an accuracy approaching that of conventional pathology. In addition to the initial focus on skin cancer, the approach can be used with other cancers such as prostate, breast, and head and neck cancers. LumaMed products have not been cleared by the FDA for sales in the U.S. and are not presently being offered for sale. For more information, visit www.lumamed.com.

Company contact:
Anju Mathew
VP, Business Development
Email Contact
877-438-5539, ext 105

PR contact:
Lynn Hood
Email Contact
678-974-2623

Filed Under: Medical And Healthcare

Premier Diagnostic Health Services Inc. (CNSX:PDH) Announces the Offering of Two Term Sheets to Raise Funds to Expand Its China Operations

Posted on December 1, 2010 Written by Annalyn Frame

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 1, 2010) – Premier Diagnostic Health Services Inc. (CNSX:PDH) (“PDH”) announces the offering of two non-brokered term sheets to raise a total of $350,000.

The two non-brokered term sheets: “Offering A” and “Offering B” are offered to accredited investors.

  1. Offering A consists of 625,000 Units at $0.40 per Unit, each Unit consisting of one Share and one half Warrant, with a minimum subscription of 125,000 Units for $50,000, for a total Offering of $250,000. One Half Warrant is included with each Unit; a full Warrant entitles the holder to subscribe for a further Share of PDH for $0.60 per Share. Warrants will be non-transferable and will expire on June 30, 2011.
  1. Offering B consists of 250,000 Shares of Premier Diagnostic Health Services Inc. (“PDH”) to raise a total of $100,000. The price per Share is $0.40.

Both “A” and “B” Offerings will expire at 5:00 p.m. on December 20, 2010.

The proceeds from the term sheets will be used to:

  1. Identify a second hospital in the metropolitan area of Beijing, China (in addition to PDH’s already established Center), for the establishment and joint operation of a Center for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into a definitive agreement within three months;
  2. Identify between one and three hospitals in the Pearl River Delta region of Guangdong province, China, particularly in the metropolitan area of Guangzhou, for the establishment and joint operation of Centers for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into definitive agreements within six months; and
  3. General working capital purposes.

The non-brokered private placement offering announced November 3, 2010 was not proceeded with.

About Premier Diagnostics Health Services Inc. (CNSX:PDH)

As leaders in advanced health and education with the international medical community, PDH is rolling out its global strategy of establishing a network of Centres for Advanced Diagnostics in Canada and China. By utilizing MRI and PET-CT, the most advanced medical diagnostic imaging technology available and the production of FDG, the radiopharmaceutical tracer used in oncology PET procedures; PDH is uniquely positioned to deliver continued innovation, growth and profitability.

Filed Under: Medical And Healthcare

CONMED Corporation Establishes $250 Million, Five-Year Revolving Credit Facility

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: CONMED Corporation

UTICA, NY–(Marketwire – November 30, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company has amended its existing senior credit facilities to provide for a five-year, $250 million senior secured revolving credit facility. The term loans currently outstanding will remain in place. A group of ten financial institutions have agreed to participate in the revolving credit facility, with JP Morgan Chase Bank, N.A. as Administrative Agent. The revolving credit facility was arranged by J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (successor by merger to Banc of America Securities LLC) as joint lead arrangers and joint bookrunners.

The amendment increases the revolving line of credit to $250 million and extends its term to November 30, 2015. Interest on drawn amounts is based on a pricing grid determined by the Company’s senior secured debt leverage ratio. At the present leverage ratio, interest cost is equal to LIBOR plus 1.75% and the fee on undrawn commitments is equal to 25 basis points. The agreement also permits a $75 million expansion of the revolver with consent of lenders participating in the expansion.

“We are pleased that our bank lenders have provided this increased credit facility with terms we consider favorable to CONMED,” said Mr. Joseph J. Corasanti, President and Chief Executive Officer. “We do not anticipate that interest expense will be materially affected by the new revolver.”

The new facility will be used to refinance the existing $49 million outstanding on the previous revolving credit facility, eliminate the previous receivable financing facility and for general corporate purposes. It is also intended to provide liquidity should the Company be required to fund the $112 million face amount of 2.5% Senior Subordinated Notes which are puttable on November 15, 2011. 

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made herein constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They are based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

CONTACT:
CONMED Corporation
Robert Shallish
Chief Financial Officer
315-624-3206

FD
Investors:
Brian Ritchie
212-850-5600

Filed Under: Medical And Healthcare

ProAssurance Completes Acquisition of American Physicians Service Group

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: American Physicians Service Group, Inc.

AUSTIN, TX–(Marketwire – November 30, 2010) – ProAssurance Corporation (NYSE: PRA) today completed its previously announced acquisition of American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH). As a result of the merger, APS is now a wholly-owned subsidiary of ProAssurance.

The Chairman and Chief Executive Officer of APS, Ken Shifrin, said, “We’ve found the ideal partner to carry on the physician-focused traditions of APS. We know that ProAssurance will continue to serve our 6,800 insureds with the individual attention that is a part of our mutual corporate cultures. The last decade has resulted in a spectacular 36% average annual increase in APS’ stock price, from $1.50 to $32.50, and I want to thank our shareholders for their trust and for the opportunity to lead the company during this exciting time. I also want to say what an honor it has been to work with the board of directors and employees of APS and to thank them for their loyalty and dedication.”

“We are excited about the opportunities this transaction creates for us,” said ProAssurance’s Chairman and Chief Executive Officer, W. Stancil Starnes. “Not only does it give us significant market presence as the second largest writer of medical professional liability (MPL) insurance in Texas, it also enhances our presence in Oklahoma and Arkansas. We expect to leverage the skill and dedication of APS’ employees to deliver an unmatched level of service and financial strength to policyholders in these three key states. Additionally, we believe our shareholders will see benefits as well, as we expect to grow profitably during a challenging time in our business.”

Under the terms of the merger, each share of APS stock was redeemed for $32.50 in cash. Shareholders whose stock is held by a broker or in direct registration will be paid automatically. Those APS shareholders with stock certificates will receive instructions by mail for surrendering their shares in order to receive payment. Shareholders with questions about the share conversion process may contact American Stock Transfer & Trust at (877) 248-6417.

As a result of this transaction, APS’ common stock will cease to trade on the Nasdaq Stock Market prior to the open of business on December 1, 2010, and will thereafter be delisted.

About APS

APS is an insurance holding company with subsidiaries that provide medical malpractice insurance for physicians and other healthcare providers. APS is headquartered in Austin, Texas. Further information about the company is available on the Internet at www.amph.com.

Filed Under: Medical And Healthcare

Medical Travel Pros Health Options Worldwide (HOW) Presents Free Healthcare Webinar

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: Health Options Worldwide

“Health Care Trends and Employers: New Strategies for a Changing Marketplace”

PRINCETON, NJ–(Marketwire – November 30, 2010) –  To assist companies in managing their healthcare insurance options and show third party administrators (TPA), insurers and physicians how to react appropriately, Health Options Worldwide (HOW), an online vacation surgery resource, is offering a free webinar. Titled “Health Care Trends and Employers: New Strategies for a Changing Marketplace,” the webinar takes place Thursday, December 2nd, at 10 am EST and 4 pm EST. HOW, an international and domestic medical travel and medical tourism agency, will cover the current state of the healthcare marketplace as well as value-based and competitively priced key service to businesses.

Participants can register for 10am EST: https://www3.gotomeeting.com/register/526273158

Participants can register for 4pm EST: https://www3.gotomeeting.com/register/505357078

If participants have any questions or problems registering for the webinar, please contact Chris Peterson at 1-877-234-1345 or via email at: [email protected]. For more information, visit the HOW website at: www.healthoptionsworldwide.com

“Due to rising healthcare costs, companies need new strategies to reduce healthcare spending, improve the quality of care, and educate employees to take a more active role in their healthcare. Employers are afraid of the high costs that come with a self-funded employer solution, but yet they still want to provide health insurance coverage for their employees,” said David Goldstein, president of HOW.

Words like high deductible health plan surgery and voluntary surgery networks will become very popular in the healthcare market. As employee benefits claims and costs continue to rise, employers, TPAs and doctors can benefit from this webinar, says Goldstein. Employers can learn new ways to control risk and encourage employees to become more proactive in managing their healthcare and healthcare spending.

Current healthcare reform stipulations have not reduced claims or costs. Inflation, increased use of services, aging population, changes in provider treatment patterns, medical technology and drug therapy improvements have also influenced the upward healthcare spending trend. “The cost of employer health plans will probably increase within the next six months,” said Goldstein, quoting a survey by Wells Fargo Insurance Services.

Value based healthcare plans and supplemental healthcare solutions are affordable coverage options for businesses that can benefit workers. An increasing number of employers are researching different types of health insurance plans for their employees, knowing they can help them in many different ways.

“HOW leverages the growing trend of consumer-driven health care by connecting patients with physicians that offer high quality, low cost healthcare in the United States as well as internationally,” said Goldstein. He continued by saying that medical tourism will definitely affect the next generation of PPO’s by giving employees more local and regional treatment options with substantial discounts and improved outcomes.

Contact:
David Goldstein
President
Health Options Worldwide
Ph: 1-877-234-1345
www.healthoptionsworldwide.com

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Dr. Steven M. Ornstein Joins Advisory Board of Clinigence

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: Clinigence

ATLANTA,GA–(Marketwire – November 30, 2010) – Clinigence, LLC, a health information technology company focused on the development of clinical business intelligence tools for accountable care organizations (ACOs) and healthcare providers, today announced that Steven M. Ornstein, M.D. has joined the Clinigence Advisory Board overseeing the development of the Clinigence collaborative software-as-a-service (SaaS) platform, helping care providers deliver quality care cost-efficiently.

Dr. Ornstein is a professor at the Department of Family Medicine and Graduate Studies at the Medical University of South Carolina (MUSC) in Charleston. He is also the founder and director of the Practice Partner Research Network (PPRNet) — the nation’s oldest and one of the largest practice-based research networks, operating for over 15 years and covering over 140 practices, 740 care providers and 1.8 million patients in 38 states.

Dr. Ornstein received his BA degree from Dartmouth in 1978 and his MD degree from Duke in 1981. He completed his residency in family practice at MUSC in 1985. He is board certified in family practice and has practiced continuously at MUSC Medical Center since 1985. Dr. Ornstein is a member of the American Academy of Family Physicians. He has led and participated in dozens of research studies on improving the quality of care through prevention, patient engagement and adherence, evidence-based guidelines and the use of information technology. At PPRNet, Dr. Ornstein has pioneered and perfected the translation of research into clinical practice to achieve real, measurable improvements in patient care.

“We are extremely pleased to welcome Dr. Ornstein to our advisory board,” said Kobi Margolin, Clinigence’s CEO. “We believe that his depth of knowledge in the area of translating scientific evidence into real-life improvement in patient outcomes will help us achieve the full potential of our unique and timely clinical business intelligence platform.”

About Clinigence

Clinigence, LLC, in Atlanta, is a health information technology company. Conceived in 2009 and launched in 2010, Clinigence develops, publishes and delivers collaborative software-as-a-service (SaaS) to help healthcare providers derive business value from clinical data and quality patient care. The Clinigence solution is tailored to the emerging needs of healthcare providers due to the shift of the US healthcare system from volume- to value-based purchasing and the growing demand for quality patient care. More information can be found at http://www.clinigence.com or contact Kobi Margolin at [email protected] or +1-678-466-6650.

Kobi Margolin
Email Contact
+1-678-466-6650

Filed Under: Medical And Healthcare

Compass Clinical Consulting Publishes Hospital Benchmarking Guide

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: Compass Clinical Consulting

Using Benchmarks: The Good, The Bad, and The Ugly

CINCINNATI, OH–(Marketwire – November 30, 2010) –  “Using Benchmarks: The Good, The Bad, and The Ugly,” a new guide from Compass Clinical Consulting authored by Shawna O’Neill, RN, MHA; Eric Dam, MHA and Compass Clinical President Cary Gutbezahl, MD, reveals the positives and negatives of hospital benchmarking.

THE BENCHMARKING PROBLEM — ONE-DIMENSIONAL MEASUREMENT

Measurement is the cornerstone of assessing the performance of a hospital department. But, the problem is that benchmarks are one-dimensional, while real work is not. Designing productivity processes using benchmarks can cause problems if not done correctly.

BUILDING A CULTURE OF PRODUCTIVITY

“Using Benchmarks: The Good, The Bad, and The Ugly” shows how hospital leaders and managers can employ benchmarks to build a culture of productivity and provides strategies to:

  • Help struggling managers meet their productivity targets while gaining buy-in from staff members
  • Optimize workforce productivity using realistic benchmarks as guidelines, not mandates
  • Ensure that leaders, managers, and employees “speak the same language” by establishing common definitions of key terms
  • Create appropriate staffing levels to meet department workloads

ADD VALUE AT EVERY STEP

In hospital productivity design, every step within every process change should add value to the patients and the financial stability of the hospital. Whether you choose to approach productivity department by department or house-wide, the strategies in “Using Benchmarks: The Good, The Bad, and The Ugly” will guide your productivity transformation process.

To learn more download “Using Benchmarks: The Good, The Bad, and The Ugly.”

RELATED LINKS:

  • Hospital Productivity Without Fear 
  • Hospital Decisions Today Will Shape Your Hospital’s Future Workforce

About Compass Clinical Consulting
Compass Clinical Consulting helps hospitals reduce the cost of providing safe, quality patient care. Founded in 1979 and based in Cincinnati, OH, Compass has helped hundreds of hospitals and health systems prepare for accreditation, optimize labor cost management, manage clinical resources, and improve patient throughput and physician relations.

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

Remedent Signs Agreement With Small Caps Financial Investment SA (SCF) to Open Glamsmile Studios in Belgium and Italy

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: Remedent, Inc.

DEURLE, BELGIUM–(Marketwire – November 30, 2010) – Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development and the manufacture of oral care and cosmetic dental products signed an agreement with Small Caps Finance SA to open at least two Glamsmile Studios in Brussels, Belgium and Milan, Italy with an option for Rome, Italy as well.

SCF will provide all the necessary financing to a joint venture between both entities, where Remedent/Glamsmile will be the majority owner and provide all the necessary product and support to open the Studios. Glamsmile will operate and manage the Studios under the same formula for success as it does in Europe and Asia. It is anticipated that both Studios will open prior to the conclusion of our year end, namely March 31, 2011.

“The direct retail model of opening Studios in both Asia and Europe has been the reason for our financial turnaround as opposed to our previous wholesale (B2B) model via a distributor. This has led to two consecutive profitable quarters since the beginning of our financial year, April 1, 2010. In addition to western Europe, we will continue with our Glamsmile Studio expansion in Asia as well where we anticipate opening our Shanghai superstore in early 2011. I am very excited about our new venture with SCF for western Europe which will give us further exposure into two new markets, namely Milan and Brussels. The locations for our two new Studios have already been determined and they will be based in the most affluent shopping areas of both major cities. I look forward to the opening of both these two new locations where we expect the financial success to continue as we have experienced with our other Studios located in both Europe and Asia,” said Guy DeVreesse, the CEO of Remedent.

SCF currently has investments in both the pharmaceutical and health care industries. “The Glamsmile concept is unique and we are very excited about introducing beautiful smiles into new markets,” said Mr. Bernardo Ruzziconi, SCF, Chief Executive Officer.

About Remedent.

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com

Forward-Looking Statements

Statements in the press release that are “forward-looking statements” are based on the current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expect”, “intends,” “anticipate,” “anticipates,” “plans,” “projects,” “project,” to be uncertain and forward looking. Actual results could differ materially because of facts such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risks described in Remedent’s filings with the Securities and Exchange Commission, including but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of the press release.

CONTACT:
Stephen Ross
310 922 5685
[email protected]

Filed Under: Medical And Healthcare

MMRGlobal Settles With Lymphoma Research Foundation

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: MMRGlobal, Inc.

LOS ANGELES, CA–(Marketwire – November 30, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) today announced it has signed a settlement agreement with the Lymphoma Research Foundation (LRF), resolving its lawsuit with LRF and giving the Company exclusive control of certain data and tissue samples created during trials of Favrille, Inc.’s FavId™ vaccine. The assets had been the subject of an ownership dispute with LRF. The Company acquired the FavId intellectual property, along with other biotech assets, from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. More than $140 million was spent on the development of the vaccine and other biotech assets and related patents. 

According to Kathleen M. Smith, a principal at Translational Medicine Consulting and a biorepository expert who provided expert testimony in the MMR litigation with LRF, the tissue samples could have values substantially in excess of one million dollars per set. When combined with clinical data and associated intellectual property belonging to MMR, the values could be significantly greater. 

“We will continue to explore licensing opportunities for these biotech assets, patents and other intellectual property with pharmaceutical companies, universities and institutional investors to create future streams of revenue for our shareholders,” said Robert H. Lorsch, MMRGlobal CEO. “I look forward to these assets being put to use to help find additional treatments for Non-Hodgkin’s Lymphoma and other related diseases while generating licensing revenues to help finance the Company’s primary business, namely the development and distribution of its MyMedicalRecords Personal Health Record and MMRPro Electronic Health Record products and services.”

MMR contended that prior to the merger, portions of the Company’s intellectual property were transferred by previous employees and or consultants of Favrille to third parties, including Lymphoma Research Foundation, without the knowledge and consent of Favrille’s Board of Directors or Science Committee. After MMR learned of the transfer, the Company pursued LRF to regain control of the data and tissue samples on behalf of its shareholders.

As part of the settlement agreement, the Lymphoma Research Foundation also settled a complaint filed in Los Angeles Superior Court by The RHL Group, Inc., a creditor of MMRGlobal, against LRF and others involving the transfer of the data, tissue samples and other assets which previously were the property of Favrille. Although The RHL Group case against LRF is settled, the case against the other named defendants is still active.

Over the last two years, MMRGlobal has been working to maximize the value of its biotech assets by perfecting its worldwide patent portfolio, regaining control of its anti-CD20 antibodies and FavId intellectual property including tissue samples, and developing licensing opportunities for the data and materials for use in Non-Hodgkin’s Lymphoma, target validation and other therapeutic research. As part of the settlement agreement, MMRGlobal shall cause the assets or portions of them to be used in further medical research.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, developing and defending its intellectual property rights including those pertaining to the Company’s biotechnology assets, the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and such other additional risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

CONTACT:

Michael Selsman
Public Communications Co.
(310) 553-5732
[email protected]

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

InoLife Technologies, Inc. Announces Plans to Exhibit at the 18th Annual World Congress on Anti-Aging Medicine and Biomedical Technologies Convention…

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: InoLife Technologies Inc.

Company Will Feature and Inform Medical Professionals on the Advantages and Availability of the DNA-Based Plavix Metabolizing Test

RALEIGH, NC–(Marketwire – November 30, 2010) – InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today that it will exhibit at the 18th Annual World Congress on Anti-aging Medicine and Biomedical Technologies, (A4M) convention held at the Mandalay Bay Convention Center in Las Vegas, Nevada on December 9-11.

“This convention provides an excellent opportunity for our Company to expose our products to the medical community as well as the industry press,” stated Gary Berthold, CEO of InoLife Technologies, Inc. “We at InoLife Technologies would like to invite those health-care professionals that are attending the convention to visit booth 240 to discuss opportunities and for demonstrations of the Company’s DNA-based testing products.” 

InoLife will take advantage of this forum to educate physicians and healthcare practitioners on the advantages and availability of the Company’s Plavix metabolizing test. This DNA-based testing procedure can identify how a patient’s genetic inheritance may affect the body’s response to the popular drug commonly used for patients with cardiovascular risks.

The A4M expects approximately 3000 professionals to attend the convention. It is billed to be the largest and most influential conference and expo worldwide on preventative medicine and bio-medical technologies. The A4M organization is comprised of 22,000-plus members that include physicians, health practitioners, scientists, government officials and members of the general public representing over 105 nations. Eighty-five percent (85%) of the organization’s members are physicians (MD, DO,MBBS) followed by 12% that consists of scientists, researchers, and health practitioners, leaving 3% that are government officials, members of the working press and the general public. 

The A4M is dedicated to educating physicians, scientists and health practitioners on biomedical sciences, breaking technologies and anti aging issues. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Filed Under: Medical And Healthcare

Radient Pharmaceuticals Signs Letter of Intent With Latin American Healthcare Distributor

Posted on November 30, 2010 Written by Annalyn Frame

SOURCE: Radient Pharmaceuticals Corporation

TUSTIN, CA–(Marketwire – November 30, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the signing of a Letter of Intent (“LOI”) to form an exclusive distribution agreement and collaborative business development partnership with Colombia-based PROCAPS S.A. PROCAPS is a top tier Latin American healthcare distribution company currently commercializing oncology and other therapeutic products throughout countries in Latin America.

RPC and PROCAPS intend to structure a long-term exclusive distribution partnership to build market share and awareness for RPC’s U.S. FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test in Latin America. The Companies are working on the following terms:

  • RPC and PROCAPS will evaluate strategies to commercialize RPC’s Onko-Sure® IVD cancer test as a medically and economically beneficial cancer test for patients in Colombia and other Latin American healthcare markets.
  • PROCAPS will investigate the market opportunity for full-service distribution of RPC’s Onko-Sure® IVD cancer test kit to clinical reference labs, hospitals and cancer treatment centers in designated territories in Latin America.
  • RPC will grant PROCAPS first rights for distribution of Onko-Sure® in Colombia, Venezuela, Peru, Ecuador, Bolivia, Panama, Guatemala, Dominican Republic, and El Salvador.

In selecting PROCAPS, RPC acknowledges the Company’s expertise in launching new healthcare products in key Latin American markets. PROCAPS has formed successful partnerships with large pharmaceutical companies including Wyeth, Merck, GSK, and Sanofi. Most recently, PROCAPS has become an exclusive distributor of a US-developed oncology therapeutic.

RPC Chairman and CEO Mr. Douglas MacLellan commented, “Cancer knows no borders, and Radient Pharmaceuticals is well positioned to combat this disease by supplying innovative diagnostic tests like Onko-Sure® on both a domestic and global level. Latin America has an escalating cancer challenge similar to other emerging economies and in working with PROCAPS S.A., RPC holds tremendous commercialization potential for the rapidly expanding Latin American healthcare market. We are eager to finalize our partnership with PROCAPS and begin the marketing and sales of Onko-Sure in this region.”

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

ForceLogix Technologies Inc. Announces Filing of Interim Financial Statements and Management’s Discussion and Analysis

Posted on November 29, 2010 Written by Annalyn Frame

SOURCE: ForceLogixTechnologies Inc.

CHICAGO, IL–(Marketwire – November 29, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management’s Discussion and Analysis today for the quarter ended September 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:
Nick Blair
847 327 0306
Email Contact

Click here to see all recent news from this company

Filed Under: Medical And Healthcare

  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Search Our Site

Categories

  • AARP
  • Blue Cross Blue Shield
  • Canadian Health Care System
  • CIGNA HealthCare
  • COVID-19
  • Facilities And Providers
  • FDA
  • Health Clinics
  • Healthcare Companies
  • Healthcare Plan News
  • Humana
  • MedBasics
  • Medical And Healthcare
  • Medical Malpractice
  • Medicare
  • Senior News
  • The SCOOTER Store

Our Partners

Portal of Dallas
Auto News Review
OSS News Review
Holly Bushes
Rose Bushes
SatelliteDish.Net
I Go Cars
Bad School Photos
Canonical Tag
Check A Domain
Idaho Resorts
iWannaBeFamous
Mabank Online
Stockyards
TravelXL

Pages

  • 1199 National Benefit Fund
  • A Little about Drug Preparation and Formulation Development
  • About Us
  • Achieve Your Weight Goals with Advanced Thermogenic with NMN
  • Affordable Health Insurance
  • Anavar: A Deep Dive into Athletic Benefits, Potential Side Effects, and Weight Loss Applications
    • Anavar Cycle: Benefits, Dosages, and Side Effects
      • Anavar Cycle: Benefits, Dosages, and Side Effects
    • Deca Durabolin vs Anavar: Comparing Performance Enhancers
  • B12 Elite Elixir: Vitalizing Your Health and Energy Levels
  • Benefits of Hiring a Senior Caregiving Service
  • Catastrophic Health Insurance
  • Cheap Health Insurance
  • Cheap Health Insurance Plans
  • Child Health Insurance Plans
  • Choosing a Health Insurance Plan
  • Christian Health Insurance
  • Dental Assistants and Their Future
  • Disclaimer
  • Dr. Howard Bellin: Questions about Rhinoplasty
  • Elite Health Online Dual Stack approach: Unlock your weight loss potential
  • Elite Thermogenic Formula: A Game-Changer in Weight Management and Metabolic Health
  • Finding the Right Dentist
  • Get Your Winks in Blink
  • Harnessing the Power of HGH for Vitality and Youthfulness
  • Health Insurance
  • Health Insurance Plans For Family
  • Health Sharing Plans
  • Healthcare and Hospitals: Disinfection is Key
  • High Deductible Health Plans
  • Home Care Employment in Arizona
  • Hormone Replacement Therapy
    • Harmonizing Body and Spirit: Navigating through Hormone Replacement Therapy
    • Hormone Replacement Therapy (HRT) – A Double-Edged Sword
    • Hormone Replacement Therapy (HRT): A Guide to Rebalancing Hormones
    • Hormone Replacement Therapy (HRT): Balancing the Benefits, Side Effects, and Menopausal Relief
    • Hormone Replacement Therapy: Benefits & Considerations
  • Hot ROCS: The Ultimate Solution for Enhanced Energy and Metabolism
  • How A Medical Weight Loss Plan Can Help You Get The Figure You Want
  • How Ketamine Therapy Helps Fight Depression
  • How Orthotic Insoles Improve Your Health
  • Individual Health Insurance Plans
  • Ketamine Uses and Benefits
  • List of Health Insurance Companies
  • Low Income Health Insurance
  • Medical Device CROs: The Role in Research and Development
  • Medical Malpractice
  • Medical Research Consultants
  • Menopause and HRT
  • Mounjaro (Tirzepatide): A Breakthrough in Diabetes and Obesity Management
  • Nicotinamide Adenine Dinucleotide – Unleashing Vital Molecule Power for Optimal health
    • Unlocking the Power of NMN in Our Advanced Thermogenic and NMN Formula
  • Oxytocin Benefits
    • Oxytocin: The Love Hormone Decoded
    • Oxytocin: The Love Hormone’s Role in Bonding and Beyond
  • Oxytocin Benefits and Hormone Therapy
  • Peptides: The Future of Health and Wellness
    • Semax Peptide – A Glimpse into Nootropic Advancements
  • Personal Lubricants for Women – Liven Up Your Life!
  • Phentermine: Benefits, Usage, and Potential Side Effects
  • Privacy Policy
  • Private Health Insurance Plans
  • Rapamycin, the anti-aging marvel and its multidimensional health benefits
    • Rapamycin: The Anti-Aging Wonder Drug
  • Rhesus Negative
  • Self Employed Health Insurance
  • Semaglutide: A Safe and Effective Alternative to Surgical Weight Loss
    • Semaglutide and its Weight Loss Benefits
    • Semaglutide: A Revolutionary Treatment Explored
    • Semaglutide: Bridging Diabetes Treatment and Weight Loss While Managing Side Effects
    • Semaglutide: Revolutionizing Weight Loss and Diabetes Management
    • Semaglutide: Transforming Weight Management and Glycemic Control
  • Short Term Health Insurance Plans
  • Student Health Insurance Plans
  • Temporary Health Insurance
  • Terms of Use
  • Testosterone Replacement Therapy Insights
    • Exploring the HCG Diet: Unveiling a Unique Pathway Towards Weight Management
    • Testosterone for Females: Balancing Health & Wellness
      • Testosterone for Females: Exploration of Hormonal Balance and Health
    • Testosterone Replacement Therapy (TRT): A Comprehensive Guide
    • Unlocking the Pivotal Role of Testosterone in Holistic Wellbeing
  • Testosterone Therapy: Weighing the Benefits, Risks, and Identifying Symptoms
    • The Vital Role of Testosterone in Health & Well-being
  • The Basic Building Blocks For a Sustained, Healthy Diet
  • The Importance of Clinical Study Software
  • The Marvels and Misgivings of Rapamycin: A Glimpse into Anti-aging and Longevity Benefits
  • The Use of Post Cycle Therapy Supplements
  • Timeless Beauty Med Spa: Elevating Skincare in Dallas, Texas
    • Achieve Your Body Goals with Emsculpt Neo: Now Available at Timeless Beauty Med Spa in Dallas, Texas
    • The Ultimate Guide to Facials: A Path to Radiant Skin
  • Travel Health Insurance
  • Ultimate Guide for Anavar Cycles
  • Understanding Metformin: Benefits and Insights
    • Metformin: A Pillar of Hope in Weight Loss Journeys
    • Metformin: The Multifaceted Medication for Modern Health Challenges
  • Understanding Nandrolone: Benefits and Uses
    • Demystifying Nandrolone: Uses, Potential Benefits, and Considerations
    • Nandrolone for Joint Pain: Efficacy, Benefits, and Considerations
    • Nandrolone: From Muscle Building to Therapeutic Uses and Side Effects
  • Unleash your Potential with Nandrolone & Deca Durabolin
  • Unleashing Glutathione’s Power: The Key to Anti-Aging and Health
  • Unlocking Testosterone’s Power: A Comprehensive Guide to Better Health
  • Winstrol – Beyond the World of Bodybuilding
    • Unlocking the Potential of Winstrol: Dosage, Benefits, and Risks

Copyright © 2025 - Privacy Policy - Terms of Use - Disclaimer